Antibody constructs that bind to 4-1BB and tumor-associated antigens and uses thereof
Bispecific antibody constructs targeting 4-1BB and tumor-associated antigens enhance T cell activation near tumors, addressing the limitations of existing 4-1BB therapies by improving efficacy and reducing toxicity.
Patent Information
- Application Number
- JP2021520222
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-10-10
- Filing Date
- 2019-10-10
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2039-10-10
AI Technical Summary
Current 4-1BB targeted therapies for cancer treatment, such as urelumab and utomilumab, are limited by severe liver toxicity at higher doses and lack significant efficacy as monotherapy.
Development of bispecific antibody constructs that bind to both 4-1BB and tumor-associated antigens, enhancing T cell activation and promoting conditional agonism, particularly in the presence of tumor cells expressing moderate to high levels of these antigens.
The antibody constructs effectively activate 4-1BB signaling in immune cells near tumor cells, potentially improving cancer treatment efficacy while minimizing toxicity.
Smart Images

Figure 0007596263000148 
Figure 0007596263000149 
Figure 0007596263000150
Abstract
Description
[Background technology]
[0001] 4-1BB is a member of the TNF receptor superfamily and is expressed on several types of immune cells, including, but not limited to, activated T cells, NK and NKT cells, regulatory T cells, dendritic cells, B cells, and stimulated mast cells. Resting T cells do not express high levels of 4-1BB; it is upregulated after activation by the T cell receptor (TCR). 4-1BB, also known as CD137 or TNFRSF9, is also expressed on non-immune cells, including neuronal populations found in the brain (Bartkowiak and Curran (2015), Front. Oncol. 5:117). 4-1BB is a transmembrane receptor that is activated by binding to its ligand (4-1BBL or CD137L), which is expressed on cells such as macrophages and activated B cells. Once activated, 4-1BB promotes T cell division and survival, enhances the effector function of activated T cells, and generates immunological memory.
[0002] Given its central role in regulating T cell function, 4-1BB and 4-1BB agonists in particular have become attractive targets for the development of cancer immunotherapy. Indeed, numerous clinical trials are examining the efficacy of various 4-1BB-targeted therapies, including anti-4-1BB antibodies alone or in combination with tumor-targeting antibodies, checkpoint inhibitors, or chemotherapy. The majority of these clinical trials are conducted using the anti-4-1BB antibody urelumab. Developed by Bristol-Myers Squibb, urelumab is a human IgG4 antibody currently undergoing multiple phase 1 and phase 2 clinical trials designed to test its efficacy in the treatment of cancer. However, administration of urelumab is limited to a dose of 0.1 mg / kg due to severe liver toxicity at high doses (Segal et al., Clin Cancer Res. 2017 Apr 15;23(8):1929-1936).
[0003] Utomilumab, developed by Pfizer, is a human IgG2 antibody currently undergoing various Phase 1, 2, and 3 clinical trials, also designed to evaluate its efficacy in the treatment of cancer. Although utomilumab does not appear to induce dose-limiting toxicities, early clinical data indicated that its efficacy as monotherapy did not appear to be significant (Makkouk, et al. (2016) European Journal of Cancer 54:112-119 (Non-Patent Document 3)).
[0004] This background information is provided for the purpose of providing known information believed by the applicant to be of possible relevance to the present disclosure. No admission is necessarily made that any of the preceding information is intended, nor should it be construed, to constitute prior art against the claimed invention. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Bartkowiak and Curran(2015),Front.Oncol.5:117 [Non-patent document 2] Segal et al, Clin Cancer Res.2017 Apr 15;23(8):1929-1936 [Non-patent document 3] Makkouk, et al. (2016) European Journal of Cancer 54:112-119 Summary of the Invention
[0006]
[0003] Described herein are bispecific antibody constructs that bind to 4-1BB and a tumor-associated antigen, and uses thereof. One aspect of the present disclosure relates to an antibody construct comprising: a) a first 4-1BB-binding domain that binds to the 4-1BB extracellular domain (4-1BB ECD), and b) a tumor-associated antigen (TAA) antigen-binding domain (TAA antigen-binding domain) that binds to a tumor-associated antigen, wherein the first 4-1BB-binding domain and the TAA antigen-binding domain are linked directly or indirectly to a scaffold.
[0007] Another aspect of the present disclosure relates to an antibody construct or antigen-binding fragment thereof that specifically binds to 4-1BB, comprising a heavy chain variable sequence comprising three CDRs and a light chain variable sequence comprising three CDRs, wherein the heavy chain variable sequence and the light chain variable sequence are selected from the group consisting of variants v28726, v28727, v28728, v28730, v20022, v28700, v28704, v28705, v28706, v28711, v28 Derived from one of: v28696, v28697, v28698, v28701, v28702, v28703, v28707, v20023, v28683, v28684, v28685, v28686, v28687, v28688, v28689, v28690, v28691, v28692, v28694, or v28695.
[0008] Another aspect of the present disclosure relates to pharmaceutical compositions comprising the antibody constructs described herein.
[0009] Another aspect of the present disclosure pertains to one or more nucleic acids encoding the antibody constructs described herein.
[0010] Another aspect of the present disclosure pertains to one or more vectors comprising one or more nucleic acids encoding the antibody constructs described herein.
[0011] Another aspect of the present disclosure pertains to isolated cells comprising one or more nucleic acids encoding the antibody constructs described herein, or one or more vectors comprising one or more nucleic acids.
[0012] Another aspect of the present disclosure relates to a method of preparing an antibody construct described herein, the method comprising culturing an isolated cell described herein under conditions suitable for expressing the antibody construct, and purifying the antibody construct.
[0013] Another aspect of the present disclosure relates to a method of treating a subject having cancer, the method comprising administering to the subject an effective amount of an antibody construct described herein.
[0014] Another aspect of the present disclosure relates to the use of an effective amount of an antibody construct described herein to treat cancer in a subject in need thereof.
[0015] Another aspect of the present disclosure relates to the use of an antibody construct described herein in the preparation of a medicament for treating cancer.
[0016] These and other features of the claimed invention will become more apparent in the following detailed description, which refers to the accompanying drawings. [Brief explanation of the drawings]
[0017] [Figure 1]
[0023] Figure 1 illustrates exemplary antibody formats. A provides a diagram of a naturally occurring antibody format (FSA format), B provides a diagram of a single-arm antibody format (OAA) in which the antigen-binding domain is in Fab format, C provides a diagram of a single-arm antibody format (OAA) in which the antigen-binding domain is in scFv format, D provides a diagram of a bivalent antibody format in which one antigen-binding domain is in scFv format and the other in Fab format (also referred to as hybrid format), and E provides a diagram of a bivalent antibody format in which both antigen-binding domains are in scFv format (also referred to as dual-scFv format). In Figure 1, the Fc portions of the exemplary antibodies are identified in white, while the antigen-binding domains are identified in gray. [Figure 2-1]Figure 2 illustrates a number of additional exemplary formats contemplated for the 4-1BB x TAA antibody constructs described herein. Figure 2A provides an example of a 1 x 1 format, in which the antibody construct comprises one 4-1BB binding domain (shown here as a 4-1BB ligand) and one TAA antigen binding domain (shown here in Fab format). Figure 2B provides an example of a 2 x 1 format, in which the antibody construct comprises two 4-1BB antigen binding domains (both shown here in Fab format) and one TAA antigen binding domain (shown here in scFv format). Figure 2C provides an example of a 2 x 2 format, in which the antibody construct comprises two 4-1BB antigen binding domains (both shown here in Fab format) and two TAA antigen binding domains (both shown here in scFv format). Figure 2D provides another example of a 1 x 1 format, in which the antibody construct comprises one 4-1BB binding domain (shown here in Fab format) and one TAA antigen binding domain (shown here in scFv format). The diagram in Figure 2 is merely exemplary, and it should be understood that although the 4-1BB antigen-binding domains are shown here in Fab format, they may also be in scFv or sdAb format, or if two 4-1BB antigen-binding domains are present, they may be in different formats or may bind to different epitopes of 4-1BB. Similarly, although the TAA antigen-binding domains are shown here in scFv format, they may also be in Fab or sdAb format, or if two TAA antigen-binding domains are present, they may be in different formats or may bind to different TAAs. [Figure 2-2]Figure 2 illustrates a number of additional exemplary formats contemplated for the 4-1BB x TAA antibody constructs described herein. Figure 2E provides another example of a 2 x 1 format, in which the antibody construct comprises two 4-1BB antigen-binding domains (both shown here in Fab format) and one TAA antigen-binding domain (shown here in scFv format) linked to one of the 4-1BB antigen-binding domains. Figure 2F provides another example of a 1 x 1 format, in which the antibody construct comprises one 4-1BB binding domain (shown here in Fab format) and one TAA antigen-binding domain (shown here in scFv format); this type of antibody construct is also referred to as a hybrid format. Figure 2G provides another example of a 1 x 1 format, in which the antibody construct comprises one 4-1BB binding domain (shown here in Fab format) and one TAA antigen-binding domain (shown here in scFv format) linked to the 4-1BB antigen-binding domain. The diagram in Figure 2 is merely exemplary, and it should be understood that although the 4-1BB antigen-binding domains are shown here in Fab format, they may also be in scFv or sdAb format, or if two 4-1BB antigen-binding domains are present, they may be in different formats or may bind to different epitopes of 4-1BB. Similarly, although the TAA antigen-binding domains are shown here in scFv format, they may also be in Fab or sdAb format, or if two TAA antigen-binding domains are present, they may be in different formats or may bind to different TAAs. [Figure 3] 1 illustrates the format of an exemplary 4-1BB x HER2 antibody construct constructed as described in Example 1. [Figure 4-1]Figure 4 shows the ability of different formats of 4-1BB x HER2 antibody constructs and controls to activate 4-1BB in co-culture experiments using 4-1BB-NFkB-luciferase Jurkat reporter cells and SKOV3 or MDA-MB-468 tumor cells. The amount of luminescence induced by antibody constructs v16675 (Figure 4A), v16679 (Figure 4B), v15534 (Figure 4C), v16601 (Figure 4D), v16605 (Figure 4E), and v19353 (Figure 4F) is shown. [Figure 4-2] Figure 4 shows the ability of different formats of 4-1BB x HER2 antibody constructs and controls to activate 4-1BB in co-culture experiments using 4-1BB-NFkB-luciferase Jurkat reporter cells and SKOV3 or MDA-MB-468 tumor cells. The amount of luminescence induced by antibody constructs v1040 (Figure 4G), v16992 (Figure 4H), and v12952 (Figure 4I) is shown. [Figure 5] Figure 1 shows the ability of different formats of 4-1BB x HER2 antibody constructs and controls to activate 4-1BB in primary CD4+ T cell co-culture experiments with and without SKBR3 tumor cells. IL-2 production by T cells was measured by ELISA. [Figure 6] The ability of 4-1BBxHER2 antibody construct v16679, 4-1BB antibody v12592, 4-1BBxHER2 anticalin construct v19353, and negative control antibody v13725 to stimulate IFNγ production in assays in which CD4+, CD8+, or pan T cells were co-cultured with HER2+ SKBR3 cells is compared. [Figure 7] Figure 1 shows the ability of chimeric 4-1BB antibodies to stimulate 4-1BB activity in a 4-1BB-NF-κB reporter gene assay when cross-linked with an anti-Fc antibody. The four columns for each variant correspond to the concentrations of antibody construct tested (from right to left): 2.5 μg / ml, 0.833 μg / ml, 0.277 μg / ml, and 0.092 μg / ml. [Figure 8]Figure 1 shows the constructs used for domain mapping of antibodies that bind to 4-1BB. A shows human, canine, and canine-human chimeric 4-1BB constructs, and B shows full-length transmembrane human 4-1BB and truncated human domain 3 and 4 constructs. [Figure 9-1] Figure 9 shows the ability of chimeric 4-1BB antibodies and controls to bind to human and canine 4-1BB. Figure 9A shows the results for v12592, Figure 9B shows v12593, Figure 9C shows v20022, Figure 9D shows v20023, Figure 9E shows v20025, and Figure 9F shows v20029. [Figure 9-2] Figure 9 shows the ability of chimeric 4-1BB antibodies and controls to bind to human and canine 4-1BB. Figure 9G shows the results for v20032, Figure 9H shows v20036, and Figure 9I shows v20037. [Figure 10] 1 shows the ability of chimeric antibodies to bind to various 4-1BB proteins expressed in 293E6 cells. [Figure 11A] 1 shows the ability of the chimeric antibody to bind to cynomolgus 4-1BB. [Figure 11B] The ability of these chimeric antibodies to bind to mouse 4-1BB is shown. [Figure 12] The sequences of the mouse heavy chain variable domain CDRs of A) 1C8, B) 1G1, and C) 5G8 grafted onto the human framework are shown, as well as the sequences of the mouse light chain variable domain CDRs of D) 1C8, E) 1G1, and F) 5G8 grafted onto the human framework. The sequences are numbered according to Kabat, and CDRs are assigned using the AbM definition and identified with an *. [Figure 13] 1 shows an SPR sensorgram of a representative humanized 4-1BB antibody derived from the mouse 1C8 antibody. [Figure 14] 1 shows an SPR sensorgram of a representative humanized 4-1BB antibody derived from the mouse 1G1 antibody. [Figure 15] 1 shows an SPR sensorgram of a representative humanized 4-1BB antibody derived from the mouse 5G8 antibody. [Figure 16A]Figure 1 shows the ability of the humanized 4-1BB antibody derived from 1C8 to bind to cells expressing 4-1BB as measured by flow cytometry. [Figure 16B] Figure 1 shows the ability of the 1G1-derived humanized 4-1BB antibody to bind to cells expressing 4-1BB as measured by flow cytometry. [Figure 16C] Figure 1 shows the ability of the humanized 4-1BB antibody derived from 5G8 to bind to cells expressing 4-1BB as measured by flow cytometry. [Figure 17] 1 shows a DSC thermogram of a humanized antibody derived from 1C8. [Figure 18] 1 shows a DSC thermogram of a humanized antibody derived from 1G1. [Figure 19] 1 shows a DSC thermogram of a humanized antibody derived from 5G8. [Figure 20] LC-MS profile of a representative purified humanized antibody derived from 1C8 is shown. [Figure 21A] 1 shows the ability of humanized 4-1BB antibodies derived from 1C8 to stimulate 4-1BB activity in a 4-1BB-NF-κB-luc reporter assay. [Figure 21B] 1 shows the ability of humanized 4-1BB antibodies derived from 1G1 to stimulate 4-1BB activity in a 4-1BB-NF-κB-luc reporter assay. [Figure 21C] 1 shows the ability of humanized 4-1BB antibodies derived from 5G8 to stimulate 4-1BB activity in a 4-1BB-NF-κB-luc reporter assay. [Figure 22] 1 illustrates the format of an exemplary 4-1BB×TAA antibody construct prepared as described in Example 17. [Figure 23A] 1 shows the ability of 4-1BB×MSLN antibody constructs v22329 and v22639 to stimulate 4-1BB activity in co-culture experiments using 4-1BB-NF-κB-luciferase Jurkat reporter cells and MSLNhighH226 tumor cells or MSLNlowA549 cells. [Figure 23B]Figure 1 shows the ability of 4-1BB x MSLN antibody constructs v22353 and v22630 to stimulate 4-1BB activity in the same assay. [Figure 24] 1 shows the ability of the 4-1BB×FRα antibody construct v22638 to stimulate 4-1BB activity in a 4-1BB-NF-κB-luciferase Jurkat reporter cell co-culture assay. [Figure 25A] Figure 1 shows the ability of the 4-1BBxNaPi2b construct v22345 to enhance IFNγ production by CD8 cells when co-cultured with tumor cells expressing different levels of NaPi2b. [Figure 25B] Figure 1 shows the ability of the 4-1BBxMSLN construct v22630 to enhance IFNγ production by CD8 cells when co-cultured with various tumor cells expressing MSLN at different levels. [Figure 25C] Figure 1 shows the ability of the 4-1BBxFRα construct v22638 to enhance IFNγ production by CD8 T cells when co-cultured with various tumor cells expressing FRα at different levels. [Figure 25D] Figure 1 shows that the control 4-1BB monospecific antibody v12592 fails to enhance IFNγ production by CD8 T cells when co-cultured with various tumor cells expressing different levels of TAAs. [Figure 26] 1 shows the format of an exemplary 4-1BB×FRα antibody construct prepared as described in Example 20. The scFv configurations illustrated in this figure are for illustrative purposes only, and the scFvs in the construct may be in the VH-VL or VL-VH configurations described in Table 11. [Figure 27] 1 shows the ability of 4-1BB×FRα antibody constructs to bind to 4-1BB-expressing Jurkat cells as measured by flow cytometry. (A) Data for antibody constructs bearing the 4-1BB paratope derived from murine antibody 1C8, (B) derived from murine antibody 2E8, (C) derived from murine antibody 4E6, (D) derived from murine antibody 5G8, (E) derived from murine antibody 6B3, and (F) derived from antibody MOR7480.1. [Figure 28]1 shows the ability of the 4-1BB×FRα antibody construct to bind to FRα expressed on 293E cells as measured by flow cytometry. A shows the ability of v23656, v23657, v23658, v23659, and v23660 to bind to the cells; B shows the ability of v23661, v23662, v23663, v23664, and v23665 to bind to the cells; and C shows the ability of v23651, v17721, and IgG1 to bind to the cells. [Figure 29A] 1 shows the ability of the 4-1BB×FRα antibody construct bearing the FRα paratope 8K22 to stimulate IFNγ production in a CD8+ T cell co-culture assay with FRαhigh IGROV1 or FRαlow A549 cells. [Figure 29B] FIG. 1 shows the ability of the 4-1BB×FRα antibody construct with the FRα paratope 1H06 to stimulate IFNγ production in a CD8+ T cell co-culture assay. [Figure 29C] Figure 1 shows the ability of monospecific 4-1BB antibodies v20022, v20036 or v12592 and monospecific FRα antibody v17721 to stimulate IFNγ production in a CD8+ T cell co-culture assay. [Figure 30-1] Figures 30A and 30B show the UPLC-SEC and Caliper profiles, respectively, of purified parental chimeric 8K22 variant 23820. [Figure 30-2] Figures 30C and 30D show the UPLC-SEC and Caliper profiles, respectively, of a purified representative humanized 8K22 variant 23807. [Figure 31A] BLI sensorgrams of the parent chimeric 8K22 antibody v23820 and two representative humanized 8K22 antibodies v23801 and v23807 in the supernatant are shown. [Figure 31B] BLI sensorgrams of purified parent chimeric 8K22 antibody v23820 and two representative humanized 8K22 antibodies v23801 and v23807 are shown. [Figure 32]A) DSC thermogram of a representative purified humanized 8K22 antibody showing a single transition. B) DSC thermogram of a representative purified humanized 8K22 antibody showing a two-state transition. [Figure 33] A shows the LC / MS profile of a representative purified humanized 8K22 antibody v23801. B shows the LC / MS profile of a representative purified humanized 8K22 antibody v23807. [Figure 34] 1 shows a DSC thermogram of an antibody having an 8K22 binding arm. [Figure 35] A shows the BLI sensorgram of v29675, B shows the BLI sensorgram of v29677, and C shows the BLI sensorgram of v29680. [Figure 36] 1 illustrates a diagram of additional 4-1BB×FRα bispecific antibodies prepared and tested as described in Example 33. [Figure 37] Figure 1 shows the ability of various 4-1BBxFRα bispecific antibodies to stimulate IFNγ production in a primary T cell:tumor cell co-culture assay using IGROV1 cells. [Figure 38A] 1 shows the ability of the 4-1BB×FRα bispecific antibody to activate 4-1BB in an NFκB reporter gene assay using IGROV1 cells. [Figure 38B] 1 shows the ability of the 4-1BB×FRα bispecific antibody to activate 4-1BB in an NFκB reporter gene assay using A431 cells. [Figure 38C] 1 shows the ability of the 4-1BB×FRα bispecific antibody to activate 4-1BB in an NFκB reporter gene assay using HCC827 cells. [Figure 38D] 1 shows the ability of the 4-1BB×FRα bispecific antibody to activate 4-1BB in an NFκB reporter gene assay using OVKATE cells. [Figure 38E] 1 shows the ability of the 4-1BB×FRα bispecific antibody to activate 4-1BB in an NFκB reporter gene assay using OVCAR3 cells. [Figure 38F] 1 shows the ability of the 4-1BB×FRα bispecific antibody to activate 4-1BB in an NFκB reporter gene assay using H661 cells. [Figure 38G] 1 shows the ability of the 4-1BB×FRα bispecific antibody to activate 4-1BB in an NFκB reporter gene assay using H441 cells. [Figure 38H] 1 shows the ability of the 4-1BB×FRα bispecific antibody to activate 4-1BB in an NFκB reporter gene assay using H1975 cells. [Figure 39] A shows the ability of mouse anti-4-1BB paratope 1C8 to bind to cynomolgus monkey 4-1BB, D shows the ability of humanized anti-4-1BB paratope 1C8 to bind to cynomolgus monkey 4-1BB, B shows the ability of mouse anti-4-1BB paratope 1G1 to bind to cynomolgus monkey 4-1BB, E shows the ability of humanized anti-4-1BB paratope 1G1 to bind to cynomolgus monkey 4-1BB, C shows the ability of mouse anti-4-1BB paratope 5G8 to bind to cynomolgus monkey 4-1BB, and F shows the ability of humanized anti-4-1BB paratope 5G8 to bind to cynomolgus monkey 4-1BB. [Figure 40] A shows the sequence of the rabbit heavy chain variable domain CDRs of 8K22 grafted onto the human framework, and B shows the sequence of the rabbit light chain variable domain CDRs of 8K22 grafted onto the human framework. The sequence is numbered according to Kabat, and CDRs are assigned using the AbM definition and are identified with an "*". DETAILED DESCRIPTION OF THE INVENTION
[0018] Detailed Description The present disclosure relates to 4-1BB×TAA antibody constructs that specifically bind to the 4-1BB extracellular domain (ECD) and to a tumor-associated antigen (TAA). In some embodiments, the TAA may be folate receptor-α (FRα), solute carrier family 34 member 2 (SLC34A2 or NaPi2b), HER2, mesothelin (MSLN), or solute carrier family 39 member 6 (SLC39A6 or LIV-1). In some embodiments, the 4-1BB×TAA antibody construct may be capable of conditionally enhancing T cell activity within a tumor. In some embodiments, the 4-1BB×TAA antibody construct may promote conditional agonism of 4-1BB. In some embodiments, the 4-1BB×TAA antibody construct may be more effective at activating 4-1BB on T cells in the presence of TAA-expressing cells, as measured by cytokine production, compared to a monospecific, monovalent anti-4-1BB antibody. In some embodiments, 4-1BBxTAA antibody constructs may be more effective at activating 4-1BB on T cells in the presence of tumor cells that express TAA at moderate to high levels compared to tumor cells that express TAA at low levels. Thus, in related embodiments, 4-1BBxTAA antibody constructs may be used to treat cancer.
[0019] The present disclosure further provides antibody sequences that specifically bind to 4-1BB (anti-4-1BB antibody sequences). These anti-4-1BB antibody sequences may be used to prepare monospecific, bispecific, or multispecific antibody constructs that bind to 4-1BB (4-1BB antibody constructs). These monospecific, bispecific, or multispecific 4-1BB antibody constructs may also be used to treat cancer, either alone or in combination with other anti-cancer therapies.
[0020] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. In the event that there are multiple definitions for terms herein, those in this section prevail. When referring to a URL or other such identifier or address, it is understood that such identifiers may change and particular information on the Internet may change, but that equivalent information may be found by searching the Internet. Reference thereto evidences the availability and public dissemination of such information.
[0021] It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any claimed subject matter. In this application, the use of the singular includes the plural unless specifically stated otherwise.
[0022] In this description, any concentration range, percentage range, ratio range, or integer range should be understood to include any integer within the recited range, as well as fractions thereof (such as tenths and hundredths of integers), where appropriate, unless otherwise indicated. As used herein, "about" means ±1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of the indicated range, value, sequence, or structure, unless otherwise indicated. The terms "a" and "an," as used herein, should be understood to refer to "one or more" of the recited components, unless otherwise specified or indicated by the context. The use of alternatives (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives.
[0023] As used herein, the terms "include," "having," "containing," "comprise," and grammatical variations thereof are used synonymously. These terms are inclusive or open-ended and do not exclude additional, unrecited elements and / or method steps. When used herein in connection with a composition, use, or method, the term "consisting essentially of" indicates that additional elements and / or method steps may be present, but that these additions do not materially affect the manner in which the recited composition, method, or use functions. When used herein in connection with a composition, use, or method, the term "consisting of" excludes the presence of additional elements and / or method steps. A composition, use, or method described herein as including certain elements and / or steps may also consist essentially of those elements and / or steps in certain embodiments, and may consist of those elements and / or steps in other embodiments, whether or not those embodiments are specifically referred to.
[0024] It should also be understood that the positive enumeration of a feature in one embodiment serves as a basis for excluding the feature in a particular embodiment. For example, where a list of alternatives is presented for a given embodiment or claim, it should be understood that one or more alternatives may be deleted from the list, and that the shortened list may form an alternative embodiment, whether or not such alternative embodiment is specifically referenced.
[0025] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, manuals, and papers, are expressly incorporated herein by reference in their entirety for all purposes.
[0026] It is to be understood that the methods and compositions described herein are not limited to the particular methodology, protocols, cell lines, constructs, and reagents described herein, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods and compositions described herein.
[0027] All publications and patents mentioned herein are incorporated by reference in their entirety for the purpose of describing and disclosing, for example, the constructs and methodology described in the publications, which may be used in connection with the methods, compositions, and compounds described herein. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein should be construed as an admission that the inventors described herein are not entitled to antedate such disclosure by virtue of prior invention or for any other reason.
[0028] In this application, amino acid names and atom names (e.g., N, O, C, etc.) are used as defined in the Protein Data Bank (PDB) (www.pdb.org), which is based on the IUPAC Nomenclature and Symbolism for Amino Acids and Peptides (residue names, atom names, etc.), Eur. J. Biochem., 138, 9-37 (1984), together with their corrections in Eur. J. Biochem., 152, 1 (1985). The term "amino acid residue" is intended to denote amino acid residues that are primarily comprised in the group consisting of the 20 naturally occurring amino acids, namely alanine (Ala or A), cysteine (Cys or C), aspartic acid (Asp or D), glutamic acid (Glu or E), phenylalanine (Phe or F), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), lysine (Lys or K), leucine (Leu or L), methionine (Met or M), asparagine (Asn or N), proline (Pro or P), glutamine (Gln or Q), arginine (Arg or R), serine (Ser or S), threonine (Thr or T), valine (Val or V), tryptophan (Trp or W), and tyrosine (Tyr or Y) residues.
[0029] Terms understood by those skilled in the art of antibody technology are given their respective art-acquired meanings unless otherwise expressly defined herein. Antibodies are known to have variable regions, hinge regions, and constant domains. The structure and function of immunoglobulins are reviewed, for example, in Harlow et al., Eds., Antibodies: A Laboratory Manual, Chapter 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, 1988).
[0030] As used herein, the terms "antibody" and "immunoglobulin" are used interchangeably. An "antibody" refers to a polypeptide substantially encoded by one or more immunoglobulin genes, or one or more fragments thereof, that specifically binds to an analyte (antigen). Recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as numerous immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which define immunoglobulin isotypes as IgG, IgM, IgA, IgD, and IgE, respectively. Furthermore, antibodies can belong to one of numerous subtypes; for example, human IgG can belong to the IgG1, IgG2, IgG3, or IgG4 subtypes.
[0031] An exemplary immunoglobulin (antibody) structural unit is composed of two pairs of polypeptide chains, each pair having one immunoglobulin "light" chain (approximately 25 kD) and one immunoglobulin "heavy" chain (approximately 50-70 kD). This type of immunoglobulin or antibody structural unit is considered to be "naturally occurring" or "naturally occurring form." The term "light chain" includes full-length light chains and fragments thereof having sufficient variable domain sequence to confer binding specificity. A full-length light chain contains a variable domain, VL, and a constant domain, CL. The light chain variable domain is present at the amino terminus of the polypeptide. Light chains include kappa chains and lambda chains. The term "heavy chain" includes full-length heavy chains and fragments thereof having sufficient variable domain sequence to confer binding specificity. A full-length heavy chain contains a variable domain, VH, a hinge region, and constant domains, CH1, CH2, and CH3, and optionally a CH4 domain. The VH domain is present at the amino-terminus of the polypeptide, the CH domain is present at the carboxyl-terminus, and the CH3 (or CH4, if present) domain is closest to the carboxy-terminus of the polypeptide. The heavy chain can be of any isotype, including IgG (including IgG1, IgG2, IgG3, and IgG4 subclasses), IgA (including IgA1 and IgA2 subclasses), IgM, IgD, and IgE. The term "variable region" or "variable domain" generally refers to the portion of the light and / or heavy chain of an antibody that is responsible for antigen recognition, and typically includes approximately the amino-terminal 120-130 amino acids of the heavy chain (VH) and the amino-terminal 100-110 amino acids of the light chain (VL).
[0032] The terms "antigen," "immunogen," "antibody target," "target analyte," and similar terms are used herein to refer to a molecule, compound, or complex that is recognized by an antibody, i.e., that can be specifically bound by an antibody. The terms can refer to molecules that can be specifically recognized by an antibody, such as polypeptides, polynucleotides, carbohydrates, lipids, chemical moieties, or combinations thereof (e.g., phosphorylated or glycosylated polypeptides, etc.). One of skill in the art will understand that the terms do not indicate that a molecule will be immunogenic in all circumstances, but merely that it can be targeted by an antibody.
[0033] An "antigen-binding domain" is that portion of an antibody that can specifically bind to an epitope or antigen. The epitope- or antigen-binding function of an antibody can be performed by a fragment of a naturally occurring antibody. Examples of antigen-binding domains include: (i) a Fab fragment, i.e., a monovalent fragment consisting of the VH, VL, CH1, and CL domains; (ii) a F(ab')2 fragment, i.e., a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VH and VL domains of a single antibody arm; (v) an sdAb fragment (Ward et al., (1989) Nature 341:544-546), which comprises a single variable domain; and (vi) an isolated complementarity-determining region (CDR). Exemplary formats of antigen-binding domains described herein include, but are not limited to, Fab, scFv, VHH, or sdAb formats. Furthermore, methods for converting between types of antigen-binding domains are known in the art (see, for example, the method for converting scFv to Fab format described in Zhou et al (2012) Mol Cancer Ther 11:1167-1476). Thus, if an antibody is available in a format that includes an antigen-binding domain that is an scFv, but it is desired that the antibody construct include an antigen-binding domain in Fab format, one of skill in the art can make such a conversion, and vice versa.
[0034] A "Fab fragment" (also called fragment antigen binding, Fab format) contains the constant domain sequence of the light chain (CL) and constant domain 1 (CH1) of the heavy chain, together with the variable domains VL and VH on the light and heavy chains, respectively. The variable domains contain the CDRs, which are involved in antigen binding. Fab' fragments differ from Fab fragments by having a few additional amino acid residues at the C-terminus of the heavy chain CH1 domain, including one or more cysteines from the antibody hinge region.
[0035] A "single-chain Fv" or "scFv" format comprises the VH and VL domains of an antibody in a single polypeptide chain. The scFv polypeptide may optionally further comprise a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding. For a review of scFvs, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
[0036] The "single domain antibody" or "sdAb" format refers to a single immunoglobulin domain. sdAbs may be of camelid origin, for example. Camelid antibodies lack light chains and their antigen-binding site consists of a single domain, termed "VHH." sdAbs contain three CDRs / hypervariable loops that form the antigen-binding site: CDR1, CDR2, and CDR3. sdAbs are fairly stable and can be expressed as fusions with the Fc region of an antibody (see, e.g., Harmsen MM, De Haard HJ (2007) "Properties, production, and applications of camelid single-domain antibody fragments," Appl. Microbiol. Biotechnol. 77(1):13-22).
[0037] An antibody binds to an "epitope" on an antigen. An epitope is a local site on an antigen that is recognized and bound by an antibody. An epitope can include a few amino acids, for example, 5 or 6, or more, for example, 20 or more amino acids. In some cases, an epitope includes non-protein components, for example, from carbohydrates, nucleic acids, or lipids. In some cases, an epitope is a three-dimensional moiety. Thus, for example, if the target is a protein, the epitope can be composed of contiguous amino acids, or amino acids from different parts of the protein that are adjacent due to protein folding (e.g., a discontinuous epitope). The same is true for other types of target molecules that form three-dimensional structures.
[0038] An epitope may be determined by obtaining an X-ray crystal structure of the antibody:antigen complex and determining which residues on the antigen are within a specified distance of residues on the antibody of interest, where the specified distance is 5 Å or less, e.g., 5 Å, 4 Å, 3 Å, 2 Å, 1 Å or less, or any distance in between. In some embodiments, an epitope is defined as a stretch of 8 or more contiguous amino acid residues along the antigen sequence, where at least 50%, 70%, or 85% of the residues are within a specified distance of the antibody or binding protein in the X-ray crystal structure. Mapping of epitopes recognized by antibodies can also be performed as described in detail in "Epitope Mapping Protocols" (Methods in Molecular Biology) ISBN-089603-375-9 (1996) by Glenn E. Morris and in "Epitope Mapping: A Practical Approach" Practical Approach Series, 248 (2001) by Olwyn MRWestwood and Frank C. Hay. For example, X-ray cocrystallography, cryo-electron microscopy, array-based oligopeptide scanning, site-directed mutagenesis mapping, hydrogen-deuterium exchange, and cross-linking mass spectrometry can be used to determine or map epitopes. These methods are well known in the art.
[0039] The term "specifically binds," as used herein, refers to the ability of a binding agent to distinguish between possible partners in an environment in which binding occurs. A binding agent may be, for example, an antibody, an antibody construct, or an antigen-binding domain. A binding agent that interacts with a particular target in the presence of other potential targets is said to "specifically bind" to the target with which it interacts. In some embodiments, specific binding is assessed by detecting or determining the degree of association between the binding agent and its partner; in some embodiments, specific binding is assessed by detecting or determining the degree of dissociation of the binding agent-partner complex; in some embodiments, specific binding is assessed by detecting or determining the ability of the binding agent to compete with an alternative interaction between its partner and another entity. In some embodiments, specific binding is assessed by performing such detection or determination over a range of concentrations. The term "specifically binds," when used herein in reference to an antigen-binding domain, antibody, or antibody construct, means that the antigen-binding domain, antibody, or antibody construct binds to its target antigen with no or minimal binding to other antigens.
[0040] "Complementarity-determining regions" or "CDRs" are amino acid sequences that contribute to antigen-binding specificity and affinity. "Framework" regions (FRs) can help maintain the proper conformation of CDRs to facilitate binding between the antigen-binding region and the antigen. Structurally, framework regions can be located between the CDRs of an antibody. Variable regions typically exhibit the same general structure of relatively conserved framework regions (FRs) connected by three hypervariable regions, also known as CDRs. The CDRs from heavy and light chain variable domains are typically aligned by framework regions, which can enable binding to a specific epitope. From the N-terminus to the C-terminus, both light and heavy chain variable domains typically contain the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The assignment of amino acids to each domain typically follows the definition of the Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), unless otherwise specified. Typically, there are three heavy chain CDRs and three light chain CDRs (or CDR regions) in the variable portion of an immunoglobulin. The three heavy chain CDRs are referred to herein as HCDR1, HCDR2, and HCDR3, while the three light chain CDRs are referred to as LCDR1, LCDR2, and LCDR3. Thus, "CDR" as used herein may refer to all three heavy chain CDRs or all three light chain CDRs (or, where appropriate, both all heavy chain CDRs and all light chain CDRs). CDRs provide the majority of contact residues for binding an antibody to an antigen or epitope. In many cases, three heavy chain CDRs and three light chain CDRs are required for antigen binding. However, in some cases, even a single variable domain can confer antigen-binding specificity. Furthermore, as is known in the art, in some cases, antigen binding can also occur through a combination of at least one or more CDRs, e.g., HCDR3s, selected from the VH and / or VL domains.
[0041] Many different definitions of CDR sequences are commonly used, including those described by Kabat et al. (1983, Sequences of Proteins of Immunological Interest, NIH Publication No. 369-847, Bethesda, MD) and Chothia et al. (1987, J Mol Biol, 196:901-917), as well as the IMGT, AbM (University of Bath) and Contact (MacCallum RM, and Martin ACR and Thornton JM, (1996), Journal of Molecular Biology, 262(5), 732-745) definitions. By way of example, the CDR definitions according to Kabat, Chothia, IMGT, AbM and Contact are provided in Table A below. Thus, as will be readily apparent to one skilled in the art, the exact numbering and arrangement of CDRs may vary based on the numbering system used. However, it should be understood that the disclosure of a VH herein includes disclosure of the associated (unique) heavy chain CDRs (HCDRs) as defined by any known numbering system. Similarly, the disclosure of a VH herein includes disclosure of the associated (unique) heavy chain CDRs (HCDRs) as defined by any known numbering system.
[0042] Table A: General CDR Definitions 1 TIFF0007596263000001.tif76157 1 Either the Kabat or Chothia numbering system may be used for HCDR2, HCDR3 and the light chain CDRs in all definitions except Contact, which uses Chothia numbering. 2Kabat numbering is used. The positions in the Kabat numbering scheme that delimit the ends of the Chothia and IMGT CDR-H1 loops vary depending on the length of the loop, because Kabat places insertions at positions 35A and 35B outside these CDR definitions. However, the IMGT and Chothia CDR-H1 loops can be unambiguously defined using Chothia numbering. CDR-H1 definitions using Chothia numbering: Kabat H31-H35, Chothia H26-H32, AbM H26-H35, IMGT H26-H33, Contact H30-H35.
[0043] Throughout this specification, amino acid residues in VH and VL sequences are numbered according to the Kabat scheme unless otherwise indicated.
[0044] "Chimeric antibody," as used herein, refers to an antibody whose amino acid sequence comprises VH and VL sequences found in a first species and constant domain sequences found in a second species that are different from the first species. In many embodiments, chimeric antibodies have murine VH and VL sequences linked to human constant domain sequences.
[0045] "Humanized" forms of non-human (e.g., rodent) antibodies are antibodies that contain minimal sequence derived from non-human immunoglobulin. Most often, humanized antibodies are human immunoglobulins (recipient antibodies) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit, or non-human primate having the desired specificity, affinity, or capacity. In some cases, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies can contain residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. Generally, humanized antibodies will contain substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable regions correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).
[0046] "CDR-grafted antibody," or "CDR-grafted antibody," as used herein, refers to an antibody whose amino acid sequence comprises heavy and light chain variable region sequences from one species, but in which one or more of the CDR sequences of the VH and / or VL sequences have been replaced with CDR sequences from another species, such as an antibody having murine VH and VL sequences in which one or more of the murine CDRs (e.g., HCDR3) have been replaced with human CDR sequences. Similarly, "CDR-grafted antibody" can also refer to an antibody having human VH and VL regions in which one or more of the human CDRs (e.g., CDR3) have been replaced with murine CDR sequences.
[0047] As used herein, a primary antibody, or antigen-binding portion thereof, "competes" for binding to a target by a secondary antibody, or antigen-binding portion thereof, if binding of the secondary antibody to the target is detectably reduced in the presence of the primary antibody compared to binding of the secondary antibody in the absence of the primary antibody. Alternatively, binding of the primary antibody to the target may, but need not, also be detectably reduced in the presence of the secondary antibody. That is, a secondary antibody may inhibit binding of a primary antibody to a target without the primary antibody inhibiting binding of the secondary antibody to the target. However, antibodies are said to "cross-compete" with each other for binding of their respective epitope(s) if each antibody detectably inhibits binding of the other antibody to its cognate epitope or ligand, either to the same extent, to a greater extent, or to a lesser extent. Both competing and cross-competing antibodies are encompassed by the present disclosure. The term "competing" antibody may apply to a primary or secondary antibody, as can be determined by one of skill in the art. In some cases, the presence of a competing antibody (e.g., a primary antibody) reduces binding of the secondary antibody to the target by at least 10%, e.g., at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or more, e.g., such that binding of the secondary antibody to the target is undetectable in the presence of the primary (competing) antibody.
[0048] Dissociation constant (K D or K d The term "K" as used herein is intended to refer to the equilibrium dissociation constant of a particular ligand-protein interaction. As used herein, a ligand-protein interaction refers to, but is not limited to, a protein-protein interaction or an antibody-antigen interaction. D measures the tendency of two proteins (e.g., AB) complexed with each other to reversibly dissociate into their components (A+B), which is called the “off rate (k off The dissociation and association rates, also called "on-rates (k on )" Therefore, K D is k off / kon and is expressed as molar concentration (M). D The smaller the K, the stronger the binding affinity. D A decrease in K indicates an increase in affinity. D has a K of 1 nM D The affinity is expressed as K A or K a It is sometimes measured as K D or K d The K of the antigen-binding construct D The K value can be determined using methods well established in the art. D One method for determining K is by using surface plasmon resonance (SPR), typically using a biosensor system such as a Biacore® system. Isothermal titration calorimetry (ITC) can be used to determine K D The Octet™ system may also be used to measure the affinity of an antibody for a target antigen.
[0049] As used herein, the term "conditional agonism" is intended to refer to the ability of a 4-1BB x TAA antibody construct to stimulate 4-1BB activity in immune cells, such as T cells or NK cells, primarily when the immune cells are present in the vicinity of TAA-expressing cells. In one embodiment, "conditional agonism" refers to the ability of a 4-1BB x TAA antibody construct to stimulate 4-1BB activity in immune cells only when the immune cells are present in the vicinity of TAA-expressing cells.
[0050] The term "amino acid modification" as used herein includes, but is not limited to, amino acid insertions, deletions, substitutions, chemical modifications, physical modifications, and rearrangements. In some embodiments, the amino acid modification is an amino acid substitution.
[0051] The amino acid residues of immunoglobulin heavy and light chains are determined according to several rules, such as Kabat (Kabat and Wu, 1991; Kabat et al., Sequences of proteins of immunological interest. 5th Edition - US Department of Health and Human Services, NIH publication no. 91-3242, p647 (1991)), IMGT (Lefranc, M.-P., et al. IMGT (registered trademark), the international ImMunoGeneTics information system (registered trademark), Nucl. Acids Res, 37, D1006-D1012 (2009), and Lefranc, M.-P., IMGT, the International ImMunoGeneTics Information System, Cold Spring Harb Protoc. 2011 Jun 1; 2011 (6)), 1JPT (Katja Faelber, Daniel Kirchhofer, Leonard Presta, Robert F Kelley, Yves The VH, CH1, CL, and VL domains may be numbered according to conventions including the EU index (as described in A. Muller, "The 1.85 Å resolution crystal structures of tissue factor in complex with humanized fab d3h44 and of free humanized fab d3h44: revisiting the solvation of antigen combining sites1," Journal of Molecular Biology, Volume 313, Issue 1, Pages 83-97), and EU (according to the EU index as in Kabat, which refers to EU antibody numbering (Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85)). Kabat numbering is used herein for the VH, CH1, CL, and VL domains unless otherwise indicated.EU numbering is used herein for the CH3 and CH2 domains, and hinge region, unless otherwise indicated.
[0052] antibody construct As used herein, an "antibody construct" refers to a polypeptide or set of polypeptides that specifically binds to an epitope or antigen and comprises one or more immunoglobulin structural features. Generally, an antibody construct is a polypeptide or set of polypeptides whose amino acid sequence comprises elements characteristic of an antigen-binding domain (e.g., an antibody light chain or variable region or one or more complementarity-determining regions ("CDRs") thereof, or an antibody heavy chain or variable region or one or more CDRs thereof, optionally in the presence of one or more framework regions). In some embodiments, an antibody construct is or comprises a naturally occurring form of an antibody. In some embodiments, the term "antibody construct" encompasses proteins having a binding domain that is homologous or largely homologous to an immunoglobulin binding domain. In some embodiments, an antibody construct comprises a fragment of a naturally occurring antibody comprising at least one antigen-binding domain. In some embodiments, an antibody construct may further comprise a binding domain other than the antigen-binding domain, e.g., a ligand of a target protein.
[0053] In certain embodiments, an "antibody construct" encompasses a polypeptide having an antigen-binding domain that exhibits at least 99% identity to an immunoglobulin-binding domain. In some embodiments, an "antibody construct" is any polypeptide having an immunoglobulin-binding domain, e.g., a binding domain that exhibits at least 70%, 75%, 80%, 85%, 90%, 95%, or 98% identity to a reference immunoglobulin-binding domain. An "antibody construct" may have an amino acid sequence identical to that of an antibody (or a fragment thereof, e.g., an antigen-binding fragment thereof) found in a natural source. An "antigen-binding fragment" of an antibody includes a fragment of an antibody having an antigen-binding domain with the required specificity. Antigen-binding fragments therefore include antibody fragments, antibody derivatives, functional equivalents, and homologs, humanized antibodies, and include any polypeptide containing an immunoglobulin-binding domain, whether natural or wholly or partially synthetic. Chimeric molecules containing an immunoglobulin-binding domain fused to another polypeptide, or an equivalent, are also included.
[0054] Antibody constructs may be monospecific, bispecific, or multispecific and may bind to at least one different target, antigen, or epitope. Antibody constructs can be prepared in many formats, and exemplary antibody construct formats are described in Figures 1 and 2 and elsewhere throughout this application. The term "antibody construct," as used herein, is meant to encompass monospecific, bispecific, or multispecific antibody constructs. A "monospecific" antibody construct is a type of antibody construct that binds to one target, antigen, or epitope. A monospecific antibody construct may contain one or more antigen-binding domains, each binding to the same epitope. A monospecific antibody construct may be monovalent (i.e., having only one arm or paratope), bivalent (i.e., having two arms or paratopes, both binding to the same epitope), or multivalent (i.e., having multiple arms or paratopes, all binding to the same epitope). A "bispecific" antibody construct is a type of antibody construct that targets two different antigens or epitopes. Generally, a bispecific antibody construct may have two antigen-binding domains, but in some embodiments, a bispecific antibody construct may have three or more antigen-binding domains, provided that no more than three unique epitopes are recognized by any of the antigen-binding domains. The two or more antigen-binding domains of a bispecific antibody construct will bind to two different epitopes, which may be present on the same or different molecular targets. When two different epitopes are present on the same molecular target, the bispecific antibody construct is referred to herein as a "double paratopic" antibody. In some embodiments, the monospecific or bispecific antibody construct is in a naturally occurring form, also referred to herein as a full-length (FSA) format. In other words, in the latter embodiment, the monospecific or bispecific antibody construct has the same format as a naturally occurring IgG, IgA, IgM, IgD, or IgE antibody.
[0055] A multispecific antibody construct may comprise three or more antigen-binding domains, each capable of binding to a different target or epitope. In some embodiments, the multispecific antibody construct comprises a format that is the same as a naturally occurring IgG, IgA, IgM, IgD, or IgE antibody, but further comprises one or more additional antigen-binding domains.
[0056] In some embodiments, antibody constructs may have structural elements characteristic of chimeric or humanized antibodies or may have amino acid sequences derived from chimeric or humanized antibodies, hi some embodiments, antibody constructs may have structural elements characteristic of human antibodies.
[0057] Described herein are antibody constructs capable of binding to the extracellular domain (ECD) of 4-1BB and to tumor-associated antigens (TAA). Also described herein are antibody constructs comprising sequences that specifically bind to the ECD of 4-1BB.
[0058] Antibody constructs binding to 4-1BB and to TAA (4-1BB x TAA antibody constructs) The antibody construct capable of binding to the ECD of 4-1BB and to a TAA comprises a 4-1BB binding domain that binds to the 4-1BB ECD and a TAA antigen binding domain, wherein the 4-1BB binding domain and the TAA antigen binding domain are linked directly or indirectly to a scaffold. Thus, in certain embodiments, the 4-1BB x TAA antibody construct described herein is a bispecific antibody construct that binds to two different targets. In certain other embodiments, the 4-1BB x TAA antibody construct may be a multispecific antibody construct, in which the 4-1BB x TAA antibody construct binds to 4-1BB and to two or more different TAAs. In related embodiments, the scaffold is an Fc construct. In certain embodiments, the scaffold is an Fc construct with modifications that reduce its ability to mediate effector function.
[0059] In some embodiments, the 4-1BBxTAA antibody construct can bind to 4-1BB-expressing cells. In some embodiments, the 4-1BBxTAA antibody construct can bind to a TAA expressed on the surface of a cancer cell. In some embodiments, the 4-1BBxTAA antibody construct can activate 4-1BB signaling in 4-1BB-expressing cells. In some embodiments, the 4-1BBxTAA antibody construct can enhance CD3-stimulated T cell activation.
[0060] 4-1BB binding domain 4-1BB (also known as TNFRSF9 or CD137) is a member of the TNF receptor superfamily. Human 4-1BB is a 255-amino acid protein (mRNA and polypeptide sequences are accession numbers NM_001561 and UniProt Q07011, respectively). The complete human 4-1BB amino acid sequence is provided in SEQ ID NO:79. The sequence shown in SEQ ID NO:1 includes the signal sequence (amino acid residues 1-23), the extracellular domain (ECD, amino acid residues 23-187), the transmembrane region (amino acids 188-213), and the intracellular domain (amino acids 214-255) (Bitra et al. J. Biol. Chem. (2018) 293(26) 9958-9969).
[0061] The 4-1BB receptor is expressed on the cell surface in both monomeric and dimeric forms and may undergo trimerization with 4-1BB ligands, enabling signal transduction. The structure of mammalian 4-1BB proteins consists of four cysteine-rich domains (CRDs) that show homology with other TNFR superfamily members. CRD1 consists of amino acids 24-45, and both mouse and human 4-1BB lack the disulfide found in other TNFR superfamily members. CRD2 and CRD3 extend from amino acids 47-86 and 87-118, respectively, and are the domains that contact 4-1BBL (Bitra et al., supra). CRD4 consists of amino acids 119-159, followed by a short stalk region at amino acid 160 followed by a transmembrane domain at amino acid 187 (see SEQ ID NO:79). CRD1, CRD2, CRD3, and CRD4 are also referred to herein as domains 1, 2, 3, and 4, respectively.
[0062] In one embodiment, the 4-1BB×TAA antibody construct comprises one 4-1BB binding domain. In some embodiments, the 4-1BB×TAA antibody construct may comprise two or more 4-1BB binding domains. In certain embodiments, the 4-1BB×TAA antibody construct comprises two 4-1BB binding domains and a TAA antigen binding domain, wherein the 4-1BB binding domain and the TAA antigen binding domain are directly or indirectly linked to a scaffold. In a related embodiment, the 4-1BB×TAA antibody construct comprises two 4-1BB binding domains and a TAA antigen binding domain, wherein the 4-1BB binding domain and the TAA antigen binding domain are directly or indirectly linked to a scaffold, and at least one of the 4-1BB binding domains is a 4-1BB antigen binding domain. In related embodiments, when the 4-1BB x TAA antibody construct comprises two or more 4-1BB antigen-binding domains, each 4-1BB antigen-binding domain may bind to the same epitope on the ECD of 4-1BB, or they may bind to different epitopes on the ECD of 4-1BB. In other embodiments, the 4-1BB x TAA antibody construct comprises antigen-binding domains, a 4-1BB binding domain and a TAA antigen-binding domain.
[0063] In yet other embodiments, the 4-1BB x TAA antibody construct comprises three or more 4-1BB binding domains that bind to the ECD of 4-1BB. In one embodiment, the three or more 4-1BB binding domains comprise at least one 4-1BB antigen binding domain. In one embodiment, the three or more 4-1BB binding domains comprise at least two 4-1BB antigen binding domains. In the latter embodiment, the two 4-1BB antigen binding domains may bind to the same epitope of 4-1BB, or they may bind to different epitopes of 4-1BB.
[0064] The 4-1BB antigen binding domain may be in scFv, Fab or sdAb format. Thus, in one embodiment, the 4-1BB antigen binding domain of the 4-1BB x TAA antibody construct is in Fab format. In an alternative embodiment, the 4-1BB antigen binding domain is in scFv format. In additional embodiments, the 4-1BB x TAA antibody construct comprises two or more 4-1BB antigen binding domains, and at least one 4-1BB antigen binding domain is in Fab format. In other embodiments where the 4-1BB x TAA comprises two or more 4-1BB antigen binding domains, at least two of the antigen binding domains are in Fab format.
[0065] The 4-1BB x TAA antibody construct comprises a 4-1BB binding domain that binds to the ECD of 4-1BB. In certain embodiments, the 4-1BB x TAA antibody construct comprises a 4-1BB binding domain capable of binding to the ECD of human 4-1BB. Suitable 4-1BB binding domains include naturally occurring molecules such as ligands or 4-1BB-binding fragments thereof. An example of such a molecule is the 4-1BB ligand, also known as TNFSF9 or CD137L (see, e.g., NP_003802.1). Thus, in one embodiment, the antibody construct comprises a 4-1BB binding domain that binds to the 4-1BB ligand and a TAA antigen-binding domain, wherein the 4-1BB binding domain and the TAA antigen-binding domain are linked directly or indirectly to a scaffold.
[0066] As described above, in some embodiments, the 4-1BB x TAA antibody construct comprises a 4-1BB binding domain, which is an antigen-binding domain. The antigen-binding domain can be constructed from the sequence of an antibody that binds to the ECD of 4-1BB. Suitable antibodies include commercially available antibodies known in the art, or antibodies identified and prepared according to methods well known in the art and described herein. The 4-1BB antigen-binding domain can be constructed from a murine, human, humanized, or chimeric anti-4-1BB antibody. In some embodiments, the 4-1BB antigen-binding domain is derived from an anti-4-1BB agonist antibody. An anti-4-1BB agonist antibody can bind to 4-1BB and stimulate 4-1BB signaling activity. 4-1BB signaling activity refers to at least one activity that can be exhibited by 4-1BB in vitro or in vivo. For example, these activities can include stimulating cytokine release from T cells or NK cells, increasing metabolic activity by T cells or NK cells, or enhancing cytotoxic activity by T cells or NK cells.
[0067] Numerous antibodies that bind to human 4-1BB are known in the art, including, but not limited to, uterimab (described in WO2012 / 032433, Pfizer), urelumab (described in WO2004 / 010947 and WO2005 / 035584, BMS), and the antibodies described in WO2018 / 156740 (Macrogenics), US8,337,850 (Pfizer), US2018 / 0258177 (Eutilex), WO2017 / 077085 (Cancer Research Technologies), and WO2006126835 (University of Ulsan). Urelumab and uterimab are exemplary anti-4-1BB agonist antibodies.
[0068] In one embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen-binding domain capable of competing with one of the antibodies described in the previous paragraph for binding to an epitope on the 4-1BB ECD. In one embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen-binding domain capable of competing with utomilumab for binding to an epitope on the 4-1BB ECD. In another embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen-binding domain capable of competing with urelumab for binding to an epitope on the 4-1BB ECD. In yet another embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen-binding domain capable of competing with an anti-4-1BB antibody described in US 8,337,850 for binding to an epitope on the 4-1BB ECD. In still further embodiments, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen-binding domain capable of competing with an anti-4-1BB antibody described in US2018 / 0258177 for binding to an epitope on the 4-1BB ECD. In even further embodiments, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen-binding domain capable of competing with an anti-4-1BB antibody described in WO2018 / 156740 for binding to an epitope on the 4-1BB ECD. In other embodiments, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen-binding domain that binds to the same epitope on the 4-1BB ECD as utomilumab, or urelumab, or any one of the anti-4-1BB antibodies described in US8,337,850, US2018 / 0258177, or WO2018 / 156740.
[0069] In one embodiment, the 4-1BB×TAA antibody construct comprises a 4-1BB antigen binding domain that binds to a 4-1BB ECD other than domain 3 or domain 4. In another embodiment, the 4-1BB×TAA antibody construct comprises a 4-1BB antigen binding domain that binds at least partially to an epitope within amino acid residues 24-85 of the mature 4-1BB protein (SEQ ID NO:79). In one embodiment, the 4-1BB×TAA antibody construct comprises a 4-1BB antigen binding domain that binds to domain 1 of 4-1BB. In another embodiment, the 4-1BB×TAA antibody construct comprises a 4-1BB antigen binding domain that binds to domain 2 of 4-1BB. In one embodiment, the 4-1BB×TAA antibody construct comprises a 4-1BB antigen binding domain that binds to domain 3 of 4-1BB. In one embodiment, the 4-1BB×TAA antibody construct comprises a 4-1BB antigen binding domain that binds to domain 4 of 4-1BB.
[0070] In some embodiments, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain that binds to the ECD of human and cynomolgus monkey 4-1BB.
[0071] In one embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain comprising at least one, two, or all three heavy chain CDRs and / or at least one, two, or all three light chain CDRs of urelumab, utomilumab, or any one of the anti-4-1BB antibodies described in US8,337,850, US2018 / 0258177, or WO2018 / 156740. In an alternative embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain comprising at least one, two, or all three heavy chain CDRs and at least one, two, or all three light chain CDRs of urelumab, utomilumab, or any one of the anti-4-1BB antibodies described in US8,337,850, US2018 / 0258177, or WO2018 / 156740. In other embodiments, the 4-1BB x TAA construct comprises a 4-1BB antigen-binding domain comprising a VH sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH sequence of urelumab, utomilumab, or any one of the anti-4-1BB antibodies described in US8,337,850, US2018 / 0258177, or WO2018 / 156740. The specific VH and VL sequences of MOR7480.1 are one of the antibodies described in US8,337,850 and are provided in Table 15 as SEQ ID NOs:71 and 72, respectively. The CDRs of MOR7480.1 are provided in Table B below. The VH, VL and CDR sequences of the other 4-1BB antigen-binding domains described above can be readily determined by one of skill in the art in light of the disclosures in US8,337,850, US2018 / 0258177, WO2018 / 156740, WO2004 / 010947, WO2005 / 035584, US2018 / 0258177, WO2017 / 077085, or WO2006126835.
[0072] Table B: MOR7480.1 CDR TIFF0007596263000002.tif71139
[0073] Additional VH, VL and CDR sequences of antibodies that bind to 4-1BB are set forth below and in Table 13; these antibodies are identified as 1B2, 1C3, 1C8, 1G1, 2A7, 2E8, 2H9, 3D7, 3H1, 3E7, 3G4, 4B11, 4E6, 4F9, 4G10, 5E2, 5G8, and 6B3. In one embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain comprising VH and VL sequences that are at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH and VL sequences of any one of antibodies 1B2, 1C3, 1C8, 1G1, 2A7, 2E8, 2H9, 3D7, 3H1, 3E7, 3G4, 4B11, 4E6, 4F9, 4G10, 5E2, 5G8, or 6B3 as set forth in Table 13. In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 1B2 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 1B2 listed in Table 13. In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 1C3 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 1C3 listed in Table 13. In one embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 1C8 listed in Table 13 and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 1C8 listed in Table 13.In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 1G1 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 1G1 listed in Table 13. In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 2A7 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 2A7 listed in Table 13. In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 2E8 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 2E8 listed in Table 13. In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 2H9 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 2H9 listed in Table 13. In one embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 3D7 listed in Table 13 and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 3D7 listed in Table 13.In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 3H1 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 3H1 listed in Table 13. In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 3E7 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 3E7 listed in Table 13. In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 3G4 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 3G4 listed in Table 13. In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 4B11 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 4B11 listed in Table 13. In one embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 4E6 listed in Table 13 and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 4E6 listed in Table 13.In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 4F9 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 4F9 listed in Table 13. In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 4G10 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 4G10 listed in Table 13. In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 5E2 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 5E2 listed in Table 13. In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 5G8 listed in Table 13, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 5G8 listed in Table 13. In one embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain comprising a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 6B3 listed in Table 13 and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 6B3 listed in Table 13.
[0074] In one embodiment, the 4-1BBxTAA antibody construct comprises the heavy chain and light chain CDRs of one of the antibodies listed in Table 13. The CDRs of these antibodies can be found in Table 18. In a related embodiment, the 4-1BBxTAA antibody construct comprises the heavy chain and light chain CDRs of any one of antibodies 1C3, 1C8, 1G1, 2E8, 3E7, 4E6, 5G8, or 6B3 described in Table 13.
[0075] In one embodiment, a 4-1BB x TAA antibody construct comprises a 4-1BB antigen-binding domain comprising the humanized VH and VL sequences of any one of antibodies 1B2, 1C3, 1C8, 1G1, 2A7, 2E8, 2H9, 3D7, 3H1, 3E7, 3G4, 4B11, 4E6, 4F9, 4G10, 5E2, 5G8, or 6B3. Several exemplary humanized VH and VL sequences are listed in Table 14 and have been used to construct several 4-1BB antibody constructs comprising humanized VH and VL sequences based on the murine VH and VL sequences of anti-4-1BB antibodies 1C8, 1G1, and 5G8.
[0076] In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen-binding domain comprising a humanized VH sequence and a humanized VL sequence of antibody 1C8. In a related embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28726, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28726. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28727, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28727. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28728, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28728. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28730, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28730.
[0077] In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen-binding domain comprising the humanized VH and VL sequences of antibody 1G1. In a related embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28683, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28683. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28684, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28684. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28685, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28685. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28686, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28686. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28687, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28687. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28688, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28688.In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28689, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28689. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28690, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28690. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28691, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28691. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28692, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28692. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28693, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28693. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28694, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28694.
[0078] In one embodiment, the 4-1BBxTAA antibody construct comprises a 4-1BB antigen binding domain comprising the humanized VH and VL sequences of antibody 5C8. In a related embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28700, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28700. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28704, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28704. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28705, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28705. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28706, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28706. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28711, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28711. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28712 and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28712.In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28713, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28713. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28696, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28696. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28697, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28697. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28698, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28698. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28701, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28701. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28702, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28702.In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28703, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28703. In another embodiment, the 4-1BBxTAA antibody construct comprises a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of v28707, and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of variant 28707.
[0079] In one embodiment, the 4-1BBxTAA antibody construct comprises the heavy chain CDRs and light chain CDRs of any one of humanized antibodies v28726, v28727, v28728, v28730, v28700, v28704, v28705, v28706, v28711, v28712, v28713, v28696, v28697, v28698, v28701, v28702, v28703, v28707, v28683, v28684, v28685, v28686, v28687, v28688, v28689, v28690, v28691, v28692, v28694, and v28695. The CDRs of these antibodies can be found in Table 18.
[0080] In other embodiments, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain and a TAA antigen binding domain, wherein the 4-1BB binding domain and the TAA antigen binding domain are linked directly or indirectly to a scaffold, and the 4-1BB antigen binding domain is selected from the group consisting of v28726, v28727, v28728, v28730, v20022, v28700, v28704, v28705, v28706, v28711, v28712, v287 v28696, v28697, v28698, v28701, v28702, v28703, v28707, v20023, v28683, v28684, v28685, v28686, v28687, v28688, v28689, v28690, v28691, v28692, v28694, and v28695.
[0081] In other embodiments, the 4-1BB x TAA antibody construct comprises a 4-1BB binding domain that can bind to the ECD of human 4-1BB and is cynomolgus monkey cross-reactive. The term "cynomolgus monkey cross-reactive" as used herein is meant to describe a binding domain that can bind to a target from one species (e.g., human or mouse) and also bind to the same target expressed in cynomolgus monkeys. In some embodiments, the antibody construct comprises a 4-1BB binding domain that can bind to the ECD of mouse 4-1BB.
[0082] TAA and TAA antigen-binding domains The 4-1BB x TAA antibody constructs described herein comprise a 4-1BB binding domain that binds to the 4-1BB extracellular domain (4-1BB ECD) and a tumor-associated antigen (TAA) antigen binding domain that binds to a tumor-associated antigen, wherein the 4-1BB binding domain and the TAA antigen binding domain are directly or indirectly linked to a scaffold. In some embodiments, the 4-1BB x TAA antibody construct comprises a first TAA antigen binding domain and a second TAA antigen binding domain that are directly or indirectly linked to a scaffold.
[0083] As used herein, "tumor-associated antigen" or "TAA" refers to an antigen expressed by cancer cells. Tumor-associated antigens may or may not be expressed by normal cells (non-tumor cells). If a TAA is not expressed by normal cells (i.e., if the TAA is unique to tumor cells), the TAA may also be referred to as a "tumor-specific antigen." If the TAA is not unique to tumor cells, it may also be expressed on normal cells under conditions that do not induce a state of immune tolerance to the antigen. Expression of an antigen on a tumor may occur under conditions that allow the immune system to respond to the antigen. A TAA may be an antigen that is normally present at low levels on normal cells but is expressed at high levels on tumor cells. These TAAs of greatest clinical interest are differentially expressed compared to corresponding normal tissues, allowing selective recognition of tumor cells by specific T cells or immunoglobulins. In some embodiments, a TAA may be a membrane-bound antigen or an antigen localized on the surface of tumor cells.
[0084] In one embodiment, the 4-1BB×TAA antibody construct comprises a TAA antigen-binding domain that binds to a TAA expressed at high levels in tumor cells. For example, tumor cells may express a TAA at greater than about 1 million copies per cell. In another embodiment, the 4-1BB×TAA antibody construct comprises at least one TAA antigen-binding domain that binds to a TAA expressed at moderate levels in tumor cells. For example, tumor cells may express a TAA at greater than about 100,000 to about 1 million copies per cell. In one embodiment, the 4-1BB×TAA antibody construct comprises at least one TAA antigen-binding domain that binds to a TAA expressed at low levels in tumor cells. For example, tumor cells may express a TAA at less than about 100,000 copies per cell. In one embodiment, the 4-1BB×TAA antibody construct binds to a TAA expressed at higher levels on tumor cells than on normal cells.
[0085] In some embodiments, the 4-1BBxTAA antibody construct binds to a TAA expressed on breast cancer cells, lung cancer cells, ovarian cancer cells, colon cancer cells, skin cancer cells, bladder cancer cells, lymphoma or leukemia cells, kidney cancer cells, pancreatic cancer cells, gastric cancer cells, esophageal cancer cells, prostate cancer cells, thyroid cancer cells or other non-liver cancer cells.
[0086] The 4-1BB×TAA antibody construct may comprise a variable number of TAA antigen-binding domains. Thus, in certain embodiments, the 4-1BB×TAA antibody construct comprises a 4-1BB binding domain and a TAA antigen-binding domain, wherein the 4-1BB binding domain and the TAA antigen-binding domain are directly or indirectly linked to a scaffold. In other embodiments, the 4-1BB×TAA antibody construct comprises two 4-1BB binding domains and one TAA antigen-binding domain, wherein the 4-1BB binding domain and the TAA antigen-binding domain are directly or indirectly linked to a scaffold. In yet other embodiments, the 4-1BB×TAA antibody construct comprises one or more 4-1BB binding domains and two TAA antigen-binding domains, wherein the 4-1BB binding domain and the TAA antigen-binding domain are directly or indirectly linked to a scaffold. In related embodiments, when the antibody construct comprises two or more TAA antigen binding domains, each TAA antigen binding domain may bind to the same epitope of one TAA, or to different epitopes of the same TAA, or to different TAAs.
[0087] The TAA antigen binding domain may be in scFv, Fab or sdAb format. Thus, in one embodiment, the TAA antigen binding domain of the 4-1BBxTAA antibody construct is in Fab format. In an alternative embodiment, the TAA antigen binding domain is in scFv format. In additional embodiments, the 4-1BBxTAA antibody construct comprises two or more TAA antigen binding domains, and at least one TAA antigen binding domain is in scFv format. In other embodiments where the 4-1BBxTAA comprises two or more TAA antigen binding domains, at least two of the antigen binding domains are in scFv format.
[0088] In one embodiment, the 4-1BB x TAA antibody construct is directed against an antigen specific for carbonic anhydrase IX, alpha-fetoprotein (AFP), alpha-actinin-4, A3, A33 antibody, ALK (anaplastic lymphoma receptor tyrosine kinase), ART-4, B7, B7-H4, Ba733, BAGE, BCMA, BrE3-antigen, CA125, CAMEL, CAP-1, CASP-8 / m, CCL 19, CCL21, CD1, CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD2 3, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD44, CD45, CD46, CD52, CD54, CD55, CD59, CD6 4, CD66a-e, CD67, CD70, CD70L, CD74, CD79a, CD79b, CD80, CD83, CD95, CD123, CD126, CD132, CD133, CD138 , CD147, CD154, CD171, CDC27, CDK-4 / m, CDKN2A, CSF1R, CTLA-4, CXCR4, CXCR7, CXCL12, HIF-1a, colon-specific antigen- p(CSAp), CEA, CEACAM5, CEACAM6, c-Met, DAM, DL3, EGFR, EGFRvIII, EGP-1 (TROP-2), EGP-2, ELF2-M, Ep-CAM, EphA2, fibroblast growth factor (FGF), Flt-1, Flt-3, folate receptor, G250 antigen, GAGE, GD2, gp100, GPC3, GRO-13, HLA-DR, HM1.24, human chorionic gonadotropin (HCG) and its subunits, HER2 / neu, HMGB-1, hypoxia-inducible factor (HIF-1), HSP70-2M, HST-2, Ia, IGF-1R, IFN-gamma, IFN-alpha, IFN-beta, IFN-X, IL-4R, IL-6R, IL-13R, IL13Ralpha2, IL-15R, IL-17R, IL-18R, IL-2, IL-6, IL-8, IL-12, IL-15, I L-17, IL-18, IL-23, IL-25, insulin-like growth factor-1 (IGF-1), KC4-antigen, KS-1-antigen, KS1-4, Le-Y, LDR / FUT, macrophage migration inhibitory factor (MIF), MAGE, MAGE-3, MART-1, MART-2, mCRP, MCP-1, melanoma glycoprotein, mesothelin, MIP-1A, MIP-1B, MIF, MUC1, MUC2, MUC3, MUC4, MUC5ac, MUC1 3, MUC16, MUM-1 / 2, MUM-3, NaPi2B, NCA66, NCA95, NCA90, NY-ESO-1, PAM4 antigen, pancreatic cancer mucin, PD-1, PD-1 receptor, placental growth factor, p53, PLAGL2, prostatic acid phosphatase, PSA, PRAME, PSMA, P1GF, ILGF, ILGF-1R, IL-6, IL-25, RS5, RANTES, ROR1, T101, SAGE, 5100, survivin, mackerel The present invention also includes a TAA antigen binding domain that binds to a TAA selected from, but not limited to, ibin-2B, TAC, TAG-72, tenascin, TRAG-3, TRAIL receptor, TGFβ, TNF-alpha, Tn antigen, Thomsen-Friedenreich antigen, tumor necrosis antigen, VEGFR, ED-B fibronectin, WT-1, 17-1A-antigen, complement factors C3, C3a, C3b, C5a, C5, angiogenesis markers, bcl-2, bcl-6, Kras, oncogene markers, and oncogene products (see, e.g., Sensi et al., Clin Cancer Res 2006, 12:5023-32; Parmiani et al., J Immunol 2007, 178:1975-79; Novellino et al., Cancer Immunol Immunother 2005, 54:187-207).
[0089] In one embodiment, the 4-1BB x TAA antibody construct described herein comprises a 4-1BB binding domain that binds to the 4-1BB extracellular domain (4-1BB ECD) and a TAA antigen binding domain that binds to the folate receptor (FRα), wherein the first 4-1BB binding domain and the TAA antigen binding domain are linked directly or indirectly to a scaffold. In one embodiment, the 4-1BB x TAA antibody construct described herein comprises a 4-1BB binding domain that binds to the 4-1BB extracellular domain (4-1BB ECD) and a tumor-associated antigen (TAA) antigen binding domain that binds to solute carrier family 34 member 2 (SLC34A2, NaPi2b), wherein the first 4-1BB binding domain and the TAA antigen binding domain are linked directly or indirectly to a scaffold. In one embodiment, a 4-1BB x TAA antibody construct described herein comprises a 4-1BB binding domain that binds to the 4-1BB extracellular domain (4-1BB ECD) and a tumor-associated antigen (TAA) antigen binding domain that binds to HER2, wherein the first 4-1BB binding domain and the TAA antigen binding domain are linked directly or indirectly to a scaffold. In one embodiment, a 4-1BB x TAA antibody construct described herein comprises a 4-1BB binding domain that binds to the 4-1BB extracellular domain (4-1BB ECD) and a tumor-associated antigen (TAA) antigen binding domain that binds to mesothelin, wherein the first 4-1BB binding domain and the TAA antigen binding domain are linked directly or indirectly to a scaffold. In one embodiment, the 4-1BB x TAA antibody construct described herein comprises a 4-1BB binding domain that binds to the 4-1BB extracellular domain (4-1BB ECD) and a tumor-associated antigen (TAA) antigen binding domain that binds to solute carrier family 39 member 6 (SLC3A6, LIV-1), wherein the first 4-1BB binding domain and the TAA antigen binding domain are directly or indirectly linked to a scaffold.
[0090] A TAA antigen-binding domain may be constructed from the sequence of a known antibody directed against the TAA. Many such antibodies are known in the art and may be commercially obtained from a number of sources. For example, various antibody-secreting hybridoma lines are available from the American Type Culture Collection (ATCC, Manassas, Va.). In addition, numerous antibodies against various TAAs have been deposited with the ATCC and / or have published variable domain sequences that may be used to prepare the TAA antigen-binding domain of an antibody construct. Those skilled in the art will understand that antibody sequences or antibody-secreting hybridomas against various TAAs may be obtained by a simple search of the ATCC, NCBI, and / or USPTO databases. Alternatively, antibodies that specifically bind to a desired TAA may be generated according to methods known in the art and described elsewhere herein.
[0091] FRα antigen-binding domain In one embodiment, the 4-1BB×TAA antibody construct is a 4-1BB×FRα antibody construct comprising a 4-1BB antigen binding domain and a FRα antigen binding domain, wherein the 4-1BB binding domain and the FRα antigen binding domain are directly or indirectly linked to a scaffold.
[0092] FRα is a member of the folate receptor family that functions to bind folate and transport 5-methyltetrahydrofolate into cells. FRα is also known as folate receptor 1, FOLR, FOLR1, FBP, or MOv18, and is expressed in tumor cells as well as normal cells, either in a soluble form or as a secreted protein anchored to the cell membrane by a glycosylphosphatidylinositol (GPI) linkage. FRα is further described in Cheung et al. (2016) Oncotarget 7:52553-52574. The polypeptide sequence of this protein is described in GenBank accession number AAB05827.1 and UniProt P15328, and is provided herein as SEQ ID NO:80.
[0093] The FRα antigen-binding domain may be derived from anti-FRα antibodies known in the art, including, but not limited to, farletuzumab (Morphotek, described in WO2004 / 003388 and WO2005 / 080431) and mirvetuximab (ImmunoGen, described in WO2011106528). Other anti-FRα antibodies are described in US8,388,972 (Advanced Accelerator Applications), WO2018 / 098277 (Eisai R&D Management Co.), US9,695,237 (Kyowa Hakko Kirin Co.), WO2015 / 196167 (Bioalliance), WO2016 / 079076 (Roche), and WO2018 / 071597 (Sutro).
[0094] In one embodiment, the 4-1BBxTAA antibody construct comprises an FRα antigen-binding domain capable of competing with farletuzumab for binding to an epitope on FRα. In another embodiment, the 4-1BBxTAA antibody construct comprises an FRα antigen-binding domain capable of competing with mirvetuximab for binding to an epitope on FRα. In yet other embodiments, the 4-1BBxTAA antibody construct comprises an FRα antigen-binding domain capable of competing with any one of the anti-FRα antibodies described in US8,388,972, WO2018 / 098277, US9,695,237, WO2015 / 196167, WO2016 / 079076, or WO2018 / 071597 for binding to an epitope on FRα.
[0095] In other embodiments, the 4-1BB×TAA antibody construct comprises an FRα antigen binding domain that binds to the same epitope of FRα as farletuzumab or mirvetuximab, or any one of the FRα antibodies described in US8,388,972, WO2018 / 098277, US9,695,237, WO2015 / 196167, WO2016 / 079076, or WO2018 / 071597.
[0096] In one embodiment, the 4-1BB×TAA antibody construct comprises an FRα antigen binding domain comprising at least one, two, or all three heavy chain CDRs and / or at least one, two, or all three light chain CDRs of farletuzumab, mirvetuximab, or any one of the anti-FRα antibodies described in US8,388,972, WO2018 / 098277, US9,695,237, WO2015 / 196167, WO2016 / 079076, or WO2018 / 071597. In an alternative embodiment, the 4-1BB×TAA antibody construct comprises an FRα antigen-binding domain comprising at least one, two, or all three heavy chain CDRs and at least one, two, or all three light chain CDRs of farletuzumab, mirvetuximab, or any one of the anti-FRα antibodies described in US8,388,972, WO2018 / 098277, US9,695,237, WO2015 / 196167, WO2016 / 079076, or WO2018 / 071597. In other embodiments, the 4-1BBxTAA construct comprises an FRα antigen-binding domain comprising a VH sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH sequence of farletuzumab, mirvetuximab, or any one of the anti-FRα antibodies described in US8,388,972, WO2018 / 098277, US9,695,237, WO2015 / 196167, WO2016 / 079076, or WO2018 / 071597. The specific sequences of the CDRs of mirvetuximab and farletuzumab are set forth in Table C, and the VH and VL sequences of these antibodies are provided in Table 17; others can be readily determined by one of skill in the art in light of the disclosures in US8,388,972, WO2018 / 098277, US9,695,237, WO2015 / 196167, WO2016 / 079076, or WO2018 / 071597.
[0097] Table C: CDR sequences of exemplary anti-FRα antibodies TIFF0007596263000003.tif146149
[0098] Alternatively, the FRα antigen-binding domain may be derived from a novel antibody generated according to methods known in the art.
[0099] The VH and VL sequences of additional anti-FRα antibodies are provided in Table 17. In one embodiment, a 4-1BB×FRα antibody construct comprises an FRα antigen-binding domain having a VH sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VH sequence of antibody 8K22 or 1H06 and a VL sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the VL sequence of antibody 8K22 or 1H06. The CDRs of these antibodies are provided in Table 18. In one embodiment, a 4-1BB×TAA antibody construct comprises the heavy chain CDRs and light chain CDRs of antibody 8K22 or 1H06.
[0100] In one embodiment, the 4-1BB×FRα antibody construct comprises humanized antibodies v28726, v28727, v28728, v28730, v28700, v28704, v28705, v28706, v28711, v28712, v28713, v28696, v28697, v28698, v28701, v28702, v28703, v28714, v28715, v28716, v28717, v28718, v28719, v28729, v28720, v28721, v28722, v28723, v28724, v28725, ... The present invention comprises a 4-1BB antigen-binding domain comprising any one of the CDRs of v28707, v28683, v28684, v28685, v28686, v28687, v28688, v28689, v28690, v28691, v28692, v28694, and v28695, and a FRα antigen-binding domain linked to a scaffold. In one embodiment, the 4-1BB×FRα antibody construct comprises humanized antibodies v28726, v28727, v28728, v28730, v28700, v28704, v28705, v28706, v28711, v28712, v28713, v28696, v28697, v28698, v28701, v28702, v28703, v2870 and a 4-1BB antigen-binding domain comprising any one of the CDRs of v28683, v28684, v28685, v28686, v28687, v28688, v28689, v28690, v28691, v28692, v28694, and v28695, and a FRα antigen-binding domain comprising the CDRs of 8K22 or 1H06.
[0101] SLC34A2 / NaPi2b antigen-binding domain In one embodiment, the 4-1BB×TAA antibody construct is a 4-1BB×NaPi2b antibody construct comprising a 4-1BB antigen binding domain and a NaPi2b antigen binding domain, wherein the 4-1BB binding domain and the NaPi2b antigen binding domain are directly or indirectly linked to a scaffold.
[0102] SLC34A2 is a pH-sensitive sodium-dependent phosphate transporter. This protein, also known as NaPi2b, NAPI-3B, NAPI-IIb, and NPTIIb, is expressed in some normal epithelial cells of the lung, intestine, and mammary gland and functions to transport phosphate ions. NaPi2b has been found to be highly expressed primarily on tumor cells of lung and ovarian cancers (Lin K et al., Clin Cancer Res. 2015 Nov 15;21(22):5139-50). NaPi2b is a multispanning membrane protein with extracellular domains of 14, 129, 57, and 6 amino acids. The polypeptide sequence of this protein is described in NCBI Reference Sequence: NP_001171470.1 and UniProt O95436 and is provided herein as SEQ ID NO: 81.
[0103] The NaPi2b antigen-binding domain may be derived from antibodies known in the art, including, but not limited to, rifastuzumab (Genentech, Seattle Genetics, described in WO2011 / 066503), MX-35 (Ludwig Institute, described in WO2009 / 097128), and the antibody described by Mersana Therapeutics in US2017 / 0266311. Alternatively, the NaPi2b antigen-binding domain may be derived from novel antibodies generated according to methods known in the art and described elsewhere herein.
[0104] In one embodiment, the 4-1BBxTAA antibody construct comprises a NaPi2b antigen-binding domain capable of competing with rifastuzumab for binding to an epitope on NaPi2b. In another embodiment, the 4-1BBxTAA antibody construct comprises a NaPi2b antigen-binding domain capable of competing with MX-35 for binding to an epitope on NaPi2b. In yet other embodiments, the 4-1BBxTAA antibody construct comprises a NaPi2b antigen-binding domain capable of competing with any one of the anti-NaPi2b antibodies described in WO2011 / 066503, WO2009 / 097128, or US2017 / 0266311 for binding to an epitope on NaPi2b.
[0105] In other embodiments, the 4-1BB×TAA antibody construct comprises a NaPi2b antigen binding domain that binds to the same epitope of NaPi2b as rifastuzumab or MX-35, or any one of the anti-NaPi2b antibodies described in WO2011 / 066503, WO2009 / 097128, or US2017 / 0266311.
[0106] In one embodiment, the 4-1BB×TAA antibody construct comprises a NaPi2b antigen binding domain comprising at least one, two, or all three heavy chain CDRs and / or at least one, two, or all three light chain CDRs of rifastuzumab or MX-35, or any one of the anti-NaPi2b antibodies described in WO2011 / 066503, WO2009 / 097128, or US2017 / 0266311. In alternative embodiments, the 4-1BBxTAA antibody construct comprises a NaPi2b antigen binding domain comprising at least one, two, or all three heavy chain CDRs and at least one, two, or all three light chain CDRs of rifastuzumab or MX-35, or any one of the anti-NaPi2b antibodies described in WO2011 / 066503, WO2009 / 097128, or US2017 / 0266311. In other embodiments, the 4-1BBxTAA construct comprises a NaPi2b antigen-binding domain comprising a VH sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH sequence of rifastuzumab or MX-35, or any one of the anti-NaPi2b antibodies described in WO2011 / 066503, WO2009 / 097128, or US2017 / 0266311. The specific sequences of the CDRs of exemplary anti-NaPi2b antibodies are set forth in Table D, and the VH and VL sequences of these antibodies are found in Table 17. Other anti-NaPi2b antibody sequences can be readily determined by one of skill in the art in light of the disclosures of WO2011 / 066503, WO2009 / 097128, or US2017 / 0266311.
[0107] Table D: CDR sequences of exemplary anti-NaPi2b antibodies TIFF0007596263000004.tif146151
[0108] Alternatively, the NaPi2b antigen-binding domain may be derived from a novel antibody generated according to methods known in the art.
[0109] HER2 antigen-binding domain In one embodiment, the 4-1BB×TAA antibody construct is a 4-1BB×HER2 antibody construct comprising a 4-1BB antigen binding domain and a HER2 antigen binding domain, wherein the 4-1BB binding domain and the HER2 antigen binding domain are directly or indirectly linked to a scaffold.
[0110] HER2 (also known as ErbB2) is a receptor protein tyrosine kinase that belongs to the human epidermal growth factor receptor (HER) family, which includes the EGFR, HER2, HER3, and HER4 receptors. The extracellular (ecto) domain of HER2 contains four domains: domain I (ECD1, approximately 1-195 amino acid residues), domain II (ECD2, approximately 196-319 amino acid residues), domain III (ECD3, approximately 320-488 amino acid residues), and domain IV (ECD4, approximately 489-630 amino acid residues) (residue numbering excluding the signal peptide). See Garrett et al. Mol. Cell. 11:495-505 (2003), Cho et al. Nature 421:756-760 (2003), Franklin et al. Cancer Cell 5:317-328 (2004), Tse et al. Cancer Treat Rev. 2012 Apr;38(2):133-42 (2012), or Plowman et al. Proc. Natl. Acad. Sci. 90:1746-1750 (1993). The polypeptide sequence of HER2 is set forth in UniProt P04626 and is included herein as SEQ ID NO:82.
[0111] The HER2 antigen-binding domain may be derived from antibodies known in the art, including, but not limited to, trastuzumab (Genentech, e.g., as described in US Pat. Nos. 5,821,337 and 6,528,624) or pertuzumab (Genentech, US Pat. No. 7,862,217). The online Therapeutic Antibodies Database (Tabs, operated by Craic Computing LLC, tabs.craic.com) has identified many additional anti-HER2 antibodies that provide suitable sequences for preparing the anti-HER2 antigen-binding domain of a 4-1BB x TAA antibody construct.
[0112] In one embodiment, the 4-1BBxTAA antibody construct comprises a HER2 antigen-binding domain capable of competing with trastuzumab for binding to an epitope on HER2. In another embodiment, the 4-1BBxTAA antibody construct comprises a HER2 antigen-binding domain capable of competing with pertuzumab for binding to an epitope on HER2. In yet other embodiments, the 4-1BBxTAA antibody construct comprises a HER2 antigen-binding domain capable of competing with any one of the anti-HER2 antibodies described in US 5,821,337, US 6,528,624, or US 7,862,217 for binding to an epitope on HER2.
[0113] In other embodiments, the 4-1BBxTAA antibody construct comprises a HER2 antigen binding domain that binds to the same epitope of HER2 as trastuzumab or pertuzumab, or any one of the anti-HER2 antibodies described in US 5,821,337, US 6,528,624, or US 7,862,217.
[0114] In one embodiment, the 4-1BBxTAA antibody construct comprises a HER2 antigen binding domain comprising at least one, two, or all three heavy chain CDRs and / or at least one, two, or all three light chain CDRs of trastuzumab or pertuzumab or margetuximab, or any one of the anti-HER2 antibodies described in US 5,821 ,337, US 6,528,624, or US 7,862,217. In an alternative embodiment, the 4-1BBxTAA antibody construct comprises a HER2 antigen binding domain comprising at least one, two, or all three heavy chain CDRs and at least one, two, or all three light chain CDRs of trastuzumab or pertuzumab or margetuximab, or any one of the anti-HER2 antibodies described in US 5,821 ,337, US 6,528,624, or US 7,862,217. In other embodiments, the 4-1BBxTAA construct comprises a HER2 antigen-binding domain comprising a VH sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH sequence of trastuzumab or pertuzumab or margetuximab, or any one of the anti-HER2 antibodies described in US 5,821,337, US 6,528,624, or US 7,862,217. The specific sequences of the CDRs of exemplary anti-HER2 antibodies are set forth in Table E, and the VH and VL sequences of these antibodies are found in Table 17. Other anti-HER2 antibody sequences can be readily determined by one of skill in the art in light of at least the disclosures of WO2011 / 066503, WO2009 / 097128, or US 2017 / 0266311.
[0115] Table E: CDR sequences of exemplary anti-HER2 antibodies TIFF0007596263000005.tif146149
[0116] Alternatively, the HER2 antigen binding domain may be derived from a novel antibody generated according to methods known in the art.
[0117] SLC39A6 / LIV-1 antigen-binding domain In one embodiment, the 4-1BB×TAA antibody construct is a 4-1BB×LIV-1 antibody construct comprising a 4-1BB antigen binding domain and a LIV-1 antigen binding domain, wherein the 4-1BB binding domain and the LIV-1 antigen binding domain are directly or indirectly linked to a scaffold.
[0118] SLC39A6, also known as LIV-1 or ZIP6, belongs to a family of proteins that function as zinc transporters. SLC39A6 is expressed at low levels in normal cells throughout the body, but at high levels in some tumor cells, particularly breast cancer cells (Takatani-Nakase et al., (2016) Biomed Res Clin Prac 1:71-75). The polypeptide sequence of LIV-1 is described in UniProt accession number Q13433 and is included herein as SEQ ID NO:83.
[0119] The LIV-1 antigen-binding domain may be derived from antibodies known in the art, including, but not limited to, those described in WO2012 / 078688 (Seattle Genetics), WO2004 / 067564 (Abbvie), and WO2001 / 055178 (Genentech). Other antibodies that bind to LIV-1 are described in US2008 / 0175839.
[0120] In one embodiment, the 4-1BBxTAA antibody construct comprises a LIV-1 antigen-binding domain capable of competing with any one of the antibodies described in WO2012 / 078688, WO2004 / 067564, WO2001 / 055178, or US2008 / 0175839 for binding to an epitope on LIV-1. In another embodiment, the 4-1BBxTAA antibody construct comprises LIV-1 capable of competing with any one of the anti-LIV-1 antibodies described in WO2012 / 078688, WO2004 / 067564, WO2001 / 055178, or US2008 / 0175839 for binding to an epitope on LIV-1.
[0121] In other embodiments, the 4-1BB×TAA antibody construct comprises a LIV-1 antigen binding domain that binds to the same epitope of LIV-1 as any one of the anti-LIV-1 antibodies described in WO2012 / 078688, WO2004 / 067564, WO2001 / 055178, or US2008 / 0175839.
[0122] In one embodiment, the 4-1BB×TAA antibody construct comprises a LIV-1 antigen binding domain comprising at least one, two, or all three heavy chain CDRs and / or at least one, two, or all three light chain CDRs of any one of the anti-LIV-1 antibodies described in WO2012 / 078688, WO2004 / 067564, WO2001 / 055178, or US2008 / 0175839. In an alternative embodiment, the 4-1BB×TAA antibody construct comprises a LIV-1 antigen binding domain comprising at least one, two, or all three heavy chain CDRs and at least one, two, or all three light chain CDRs of any one of the anti-LIV-1 antibodies described in WO2012 / 078688, WO2004 / 067564, WO2001 / 055178, or US2008 / 0175839. In other embodiments, the 4-1BB×TAA construct comprises a LIV-1 antigen-binding domain comprising a VH sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH sequence of any one of the anti-LIV-1 antibodies described in WO2012 / 078688, WO2004 / 067564, WO2001 / 055178, or US2008 / 0175839. Specific sequences of the CDRs, VH, and VL of exemplary anti-LIV-1 antibodies are described in the disclosures of WO2011 / 066503, WO2009 / 097128, or US2017 / 0266311.
[0123] Alternatively, the LIV-1 antigen-binding domain may be derived from a novel antibody generated according to methods known in the art and described elsewhere herein.
[0124] Mesothelin (MSLN) antigen-binding domain In one embodiment, the 4-1BB×TAA antibody construct is a 4-1BB×MSLN antibody construct comprising a 4-1BB antigen binding domain and an MSLN antigen binding domain, wherein the 4-1BB binding domain and the MSLN antigen binding domain are directly or indirectly linked to a scaffold.
[0125] Mesothelin (MSLN), also known as CAK antigen or prepro-megakaryocyte potentiating factor, is expressed in normal lung mesothelial cells and at lower levels in other normal organs. Mesothelin is expressed at high levels in ovarian and lung cancers. The polypeptide sequence of mesothelin is set forth in UniProt Accession No. Q13421 and is included herein as SEQ ID NO:84.
[0126] The MSLN antigen-binding domain may be derived from anti-MSLN antibodies known in the art, including, but not limited to, anetumab (Bayer, described in WO2009 / 068204), 6A4 / BMS-986148 (BMS, described in WO2009 / 045957), or the anti-MSLN antibody from Mab Designs described in WO2018 / 060480.
[0127] In one embodiment, the 4-1BBxTAA antibody construct comprises an MSLN antigen-binding domain that competes with anetumab for binding to MSLN. In another embodiment, the 4-1BBxTAA antibody construct comprises an MSLN antigen-binding domain that competes with 6A4 / BMS-986148 for binding to MSLN. In yet another embodiment, the 4-1BBxTAA antibody construct comprises an MSLN antigen-binding domain that competes with an anti-MSLN antibody from Mab Designs for binding to MSLN.
[0128] In some embodiments, the 4-1BBxTAA antibody construct comprises an MSLN antigen-binding domain that binds to the same epitope as anetumab for binding to MSLN. In another embodiment, the 4-1BBxTAA antibody construct comprises an MSLN antigen-binding domain that binds to the same epitope as 6A4 / BMS-986148 for binding to MSLN. In yet another embodiment, the 4-1BBxTAA antibody construct comprises an MSLN antigen-binding domain that binds to the same epitope as an anti-MSLN antibody from Mab Designs for binding to MSLN.
[0129] In one embodiment, the 4-1BBxTAA antibody construct comprises an MSLN antigen-binding domain comprising at least one, two, or all three heavy chain CDRs and / or at least one, two, or all three light chain CDRs of any one of the anti-MSLN antibodies described in WO2009 / 068204, WO2009 / 045957, or WO2018 / 060480. In an alternative embodiment, the 4-1BBxTAA antibody construct comprises an MSLN antigen-binding domain comprising at least one, two, or all three heavy chain CDRs and at least one, two, or all three light chain CDRs of any one of the anti-MSLN antibodies described in WO2009 / 068204, WO2009 / 045957, or WO2018 / 060480. In other embodiments, the 4-1BBxTAA construct comprises an MSLN antigen-binding domain comprising a VH sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH sequence of any one of the anti-MSLN antibodies described in WO2009 / 068204, WO2009 / 045957, or WO2018 / 060480. The specific sequences of the CDRs of exemplary anti-MSLN antibodies are set forth in Table F, and the VH and VL sequences of these antibodies are found in Table 17. Other anti-MSLN antibody sequences can be readily determined by one of skill in the art in light of the disclosures of WO2009 / 068204, WO2009 / 045957, or WO2018 / 060480.
[0130] Table F: CDR sequences of exemplary anti-MSLN antibody RG7787 TIFF0007596263000006.tif104137
[0131] scaffold As described herein, a 4-1BB x TAA antibody construct comprises a 4-1BB binding domain that binds to the 4-1BB ECD and a TAA antigen binding domain, wherein the first 4-1BB binding domain and the TAA antigen binding domain are directly or indirectly linked to a scaffold. Direct linkage of the 4-1BB binding domain and the TAA antigen binding domain occurs when each of these domains is directly linked to the scaffold without a linker. Thus, in one embodiment, the 4-1BB binding domain is linked to the scaffold without a linker, and the TAA antigen binding domain is also linked to the scaffold without a linker. Methods for achieving direct linkage are known in the art and include, for example, recombinant DNA techniques and / or chemical conjugation.
[0132] Indirect linkage can be achieved by linking one or both of the 4-1BB binding domain and the TAA antigen binding domain to the scaffold using a linker. Thus, in one embodiment, the 4-1BB binding domain is linked to the scaffold using a linker, and the TAA antigen binding domain is also linked to the scaffold using a linker. In another embodiment, one of the 4-1BB binding domain and the TAA antigen binding domain is linked to the scaffold using a linker, and the other is directly linked to the scaffold without a linker. In yet another embodiment, the 4-1BB binding domain is linked to the scaffold using a linker, and the TAA antigen binding domain is linked to the 4-1BB binding domain using a linker. In the latter embodiment, the TAA antigen binding domain is considered to be indirectly linked to the scaffold. In an alternative embodiment, the TAA antigen binding domain is linked to the scaffold using a linker, and the 4-1BB binding domain is linked to the TAA antigen binding domain using a linker. In the latter embodiment, the 4-1BB binding domain is considered to be indirectly linked to the scaffold.
[0133] Linkers and Linker Polypeptides As noted above, in some embodiments, indirect linkage of the 4-1BB binding domain and the TAA antigen-binding domain to the scaffold is achieved through the use of a linker. The linker may be a linker peptide, a linker polypeptide, or a non-polypeptide linker. In some embodiments, the antibody constructs described herein comprise a 4-1BB binding domain and a TAA antigen-binding domain, each operably linked to a linker polypeptide, which can form a complex or interface with each other. In some embodiments, the linker polypeptides can form a covalent bond with each other. The spatial conformation of a construct with a linker polypeptide, even in the context of an antibody construct having two antigen-binding domains, is similar to the relative spatial conformation of the paratope of an F(ab')2 fragment generated by papain digestion.
[0134] In one embodiment, the linker polypeptide is selected from an IgG1, IgG2, IgG3, or IgG4 hinge region.
[0135] In some embodiments, linker polypeptides are selected so that they maintain the relative spatial conformation of the paratope of the F(ab') fragment and can form a covalent bond equivalent to the disulfide bond in the core hinge of IgG. Suitable linker polypeptides include those from IgG hinge regions, such as those from IgG1, IgG2, or IgG4. Modified versions of these exemplary linkers can also be used. For example, modifications to improve the stability of the IgG4 hinge are known in the art (see, e.g., Labrijn et al. (2009) Nature Biotechnology 27, 767-771).
[0136] Numerous suitable scaffolds are known in the art, including peptides, polypeptides, polymers, nanoparticles, or other chemicals. In one embodiment, the scaffold is an Fc construct. Numerous scaffolds based on alternative protein or molecular domains are known in the art and can be used to selectively pair two different target-binding polypeptides. Examples of such alternative domains include the cohesin-dockerin scaffold described in International Patent Publication No. WO 2008 / 097817 and the split albumin scaffold described in WO 2012 / 116453 and WO 2014 / 012082. Further examples include leucine zipper domains, such as Fos and Jun, which selectively pair with each other [SA Kostelny et al. J Immunol 1992 148:1547-53; Bernd J. Wranik, et al. J. Biol. Chem. 2012 287:43331-43339]. Alternatively, other selectively paired molecule pairs, such as the barnase-barstar pair [Deyev, et al. (2003). Nat Biotechnol 21, 1486-1492], or split fluorescent protein pairs [WO2011135040], may also be used.
[0137] In other embodiments, the linker polypeptide is operably linked to a scaffold other than Fc. Numerous scaffolds based on alternative protein or molecular domains are known in the art and can be used to selectively pair two different target-binding polypeptides. An example of such an alternative domain is the split albumin scaffold described in WO2012 / 116453 and WO2014 / 012082. Further examples are leucine zipper domains, such as Fos and Jun, which selectively pair with each other [SA Kostelny, MS Cole, and JY Tso. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992 148:1547-53; Bernd J. Wranik, Erin L. Christensen, Gabriele Schaefer, Janet K. Jackman, Andrew C. Vendel, and Dan Eaton. LUZ-Y, a Novel Platform for the Mammalian Cell Production of Full-length IgG-bispecific Antibodies J. Biol. Chem. 2012 287:43331-43339].Alternatively, other selective pairing molecular pairs, such as the barnase-barstar pair [Deyev, SM, Waibel, R., Lebedenko, EN, Schubiger, AP, and Pluckthun, A. (2003). Design of multivalent complexes using the barnase*barstar module. Nat Biotechnol 21, 1486-1492], DNA strand pairs [Zahida N. Chaudri, Michael Bartlet-Jones, George Panayotou, Thomas Klonisch, Ivan M. Roitt, Torben Lund, Peter J. Delves, Dual specificity antibodies using a double-stranded oligonucleotide bridge, FEBS Letters, Volume 450, Issues 1-2, 30 April 1999, Pages 23-26], split fluorescent protein pairs [Ulrich Brinkmann, Alexander Haas. Fluorescent antibody fusion protein, its production and use, WO2011135040A1], etc. may also be used.
[0138] In embodiments where the scaffold is a peptide or polypeptide, the 4-1BB binding domain and / or TAA antigen binding domain of the antibody construct may be linked directly or indirectly to the scaffold by genetic fusion. In other embodiments where the scaffold is a polymer or nanoparticle, the 4-1BB binding domain and / or TAA antigen binding domain of the antibody construct may be linked to the scaffold by chemical bonding.
[0139] In one embodiment, the antibody construct described herein comprises a 4-1BB binding domain and a tumor-associated antigen (TAA) antigen binding domain, wherein the first 4-1BB binding domain and the TAA antigen binding domain are linked directly or indirectly to an Fc construct.
[0140] The term "Fc" or "Fc construct," as used herein, refers to the C-terminal region of an immunoglobulin heavy chain containing at least a portion of the constant region (also referred to as "Fc domain" or "Fc region"), including the CH3 domain. The term includes native sequence Fc regions and variant Fc regions. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also known as the EU index, as described in Edelman, GM et al., Proc. Natl. Acad. USA, 63, 78-85 (1969).
[0141] A "dimeric Fc construct" comprises two Fc polypeptides. The "Fc polypeptide" of a dimeric Fc construct refers to one of the two polypeptides forming the construct, i.e., the polypeptide comprising the C-terminal constant region of an immunoglobulin heavy chain capable of stable self-association. The Fc polypeptide is derived from a heavy chain isotype, including IgG, IgA, IgM, IgD, and IgE. The Fc polypeptide may be derived from a heavy chain subtype IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2. In some embodiments, the Fc construct is a human Fc construct. In some embodiments, the Fc construct is a human IgG Fc construct. In other embodiments, the Fc construct is a human IgG1 Fc construct.
[0142] Each Fc polypeptide comprises a CH3 sequence and optionally a CH2 sequence. In some embodiments, each Fc polypeptide comprises a CH3 sequence with one or more amino acid modifications. In some embodiments, each Fc polypeptide comprises a CH2 sequence with one or more amino acid modifications. In some embodiments, the Fc construct is composed of a single polypeptide, e.g., the Fc polypeptides are linked by a linker. In other embodiments, the Fc construct is a heterodimeric Fc construct, and the Fc polypeptides comprising the Fc construct have different CH3 or CH2 sequences.
[0143] CH3 sequence modification In certain embodiments, the scaffold is a heterodimeric Fc construct comprising CH3 sequence modifications that promote the formation of heterodimeric Fc constructs relative to homodimeric Fcs, as described in International Patent Application No. PCT / CA2011 / 001238 or International Patent Application No. PCT / CA2012 / 050780 (the entire disclosures of each of which are incorporated herein by reference in their entirety for all purposes).
[0144] Table G provides the amino acid sequence of the human IgG1 Fc sequence, which corresponds to amino acids 231 to 447 of the full-length human IgG1 heavy chain. The CH3 sequence includes amino acids 341 to 447 of the full-length human IgG1 heavy chain.
[0145] Typically, an Fc comprises two adjacent heavy chain or Fc polypeptide sequences (A and B) that can dimerize. In some embodiments, one or both of these sequences may comprise one or more mutations or modifications at the following positions using EU numbering: L351, F405, Y407, T366, K392, T394, T350, S400, and / or N390. In some embodiments, an Fc may comprise a variant sequence as shown in Table G. In some embodiments, an Fc may comprise a mutation of variant 1A-B. In some embodiments, an Fc may comprise a mutation of variant 2A-B. In some embodiments, an Fc may comprise a mutation of variant 3A-B. In some embodiments, an Fc may comprise a mutation of variant 4A-B. In some embodiments, an Fc may comprise a mutation of variant 5A-B.
[0146] Table G: IgG1 Fc sequences TIFF0007596263000007.tif100157
[0147] Additional methods for modifying Fc polypeptides of Fc constructs to promote heterodimeric Fc formation are known in the art, including, for example, those described in International Patent Publication No. WO 96 / 027011 (knobs into holes), Gunasekaran et al. (Gunasekaran K. et al. (2010) J Biol Chem. 285, 19637-46, electrostatic design for selective heterodimerization), Davis et al. (Davis, JH. et al. (2010) Prot Eng Des Sel; 23(4):195-202, strand exchange engineered domain (SEED) technology), and Labrijn et al. [Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW. Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5145-50.
[0148] CH2 sequence modification In some embodiments, the scaffold is an Fc construct, and each Fc polypeptide of the Fc construct comprises a CH2 sequence and a CH3 sequence. An example of an Fc CH2 sequence is amino acids 231-340 of the sequence shown in Table B. Some effector functions are mediated by Fc receptors (FcRs), which bind to the Fc of an antibody.
[0149] The terms "Fc receptor" and "FcR" are used to describe receptors that bind to the Fc region of an antibody. For example, an FcR can be a native-sequence human FcR. Generally, FcRs are those that bind IgG antibodies (gamma receptors) and include receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptors") and FcγRIIB ("inhibiting receptors"), which have similar amino acid sequences that differ primarily in their cytoplasmic domains. Immunoglobulins of other isotypes can also be bound by certain FcRs (see, e.g., Janeway et al., ImmunoBiology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999)). Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. The inhibitory receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (reviewed in Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991), Capel et al., Immunomethods 4:25-34 (1994), and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal receptor, FcRn, which is involved in the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976), and Kim et al., J. Immunol. 24:249 (1994)).
[0150] Modification of CH2 sequence can affect FcR binding to Fc constructs. Many amino acid modifications in the Fc region are known in the art for selectively altering the affinity of Fc for different Fc gamma receptors. In some embodiments, Fc comprises one or more modifications to promote selective binding to Fc-gamma receptors.
[0151] Exemplary mutations that alter binding of FcR to Fc are listed below: S298A / E333A / K334A, S298A / E333A / K334A / K326A (Lu Y, Vernes JM, Chiang N, et al.J Immunol Methods.2011 Feb 28;365(1-2):132-41), F243L / R292P / Y300L / V305I / P396L, F243L / R292P / Y300L / L235V / P396L (Stavenhagen JB, Gorlatov S, Tuaillon N, et al. Cancer Res. 2007 Sep 15;67(18):8882-90, Nordstrom JL, Gorlatov S, Zhang W, et al.Breast Cancer Res.2011 Nov 30;13(6):R123), F243L(Stewart R,Thom G,Levens M,et al.Protein Eng Des Sel.2011 Sep;24(9):671-8.) S298A / E333A / K334A (Shields RL, Namenuk AK, Hong K, et al. J Biol Chem. 2001 Mar 2;276(9):6591-604), S239D / I332E / A330L, S239D / I332E (Lazar GA, Dang W, Karki S, et al. Proc Natl Acad Sci US A.2006 Mar 14;103(11):4005-10), S239D / S267E, S267E / L328F (Chu SY, Vostiar I, Karki S, et al.Mol Immunol.2008 Sep;45(15):3926-33), S239D / D265S / S298A / I332E, S239E / S298A / K326A / A327H, G237F / S298A / A330L / I332, S239D / I332E / S298A, S239D / K326E / A330L / I332E / S298A, G236A / S239D / D270L / I332E, S239E / S267E / H268D, L234F / S267E / N325L, G237F / V266L / S267D and other mutations listed in WO2011 / 120134 and WO2011 / 120135, which are incorporated herein by reference.
[0152] Therapeutic Antibody Engineering (by William R. Strohl and Lila M. Strohl, Woodhead Publishing series in Biomedicine No. 11, ISBN 1 907568 37 9, Oct 2012) lists the mutations on page 283.
[0153] In some embodiments, the heterodimeric Fc comprises an Fc polypeptide having a CH2 sequence comprising one or more asymmetric amino acid modifications. Exemplary asymmetric amino acid modifications are described in International Patent Application No. PCT / CA2014 / 050507. In one embodiment, the heterodimeric Fc comprises an Fc polypeptide having amino acid substitutions L234A, L235A, and D265S that reduce FcγR binding.
[0154] Additional modifications to improve effector function In some embodiments, the Fc construct comprises amino acid modifications that improve its ability to mediate effector function. Such modifications are known in the art and include afucosylation or engineering the affinity of the Fc for activating receptors, primarily FcγRIIIa for ADCC and C1q for CDC.
[0155] Methods for producing antibody Fc regions with little or no fucose at the Fc glycosylation site (Asn 297 EU numbering) without altering the amino acid sequence are well known in the art. GlymaX® technology (ProBioGen AG) is based on the genetic introduction of an enzyme that alters the cellular pathway of fucose biosynthesis in the cells used to produce the antibody Fc region. This prevents the cells from adding the sugar "fucose" to the carbohydrate moiety of N-linked antibodies (von Horsten et al. (2010) Glycobiology. 20(12):1607-18). Another approach to obtaining antibody constructs with Fc constructs with reduced levels of fucosylation can be found in U.S. Pat. No. 8,409,572, which teaches selecting cell lines for antibody production based on their ability to reduce the level of fucosylation on antibodies. In some embodiments, the Fc of the antibody construct or antibody construct may be fully afucosylated (meaning that they contain no detectable fucose) or they may be partially afucosylated, meaning that the TAA presentation inducer in the bispecific antibody format contains less than 95%, less than 85%, less than 75%, less than 65%, less than 55%, less than 45%, less than 35%, less than 25%, less than 15%, or less than 5% of the amount of fucose typically found in a similar antibody produced in a mammalian expression system.
[0156] Thus, in some embodiments, the antibody constructs described herein may comprise a dimeric Fc comprising one or more amino acid modifications described in Table H that confer improved effector function. In some embodiments, the constructs may be afucosylated to improve effector function.
[0157] Table H: CH2 domain and effector function engineering TIFF0007596263000008.tif83159
[0158] Fc modifications that reduce FcγR and / or complement binding and / or effector function are known in the art. Various publications describe strategies that have been used to engineer antibodies with reduced or abolished effector activity (see Strohl, WR (2009), Curr Opin Biotech 20:685-691, and Strohl, WR and Strohl LM, "Antibody Fc engineering for optimal antibody performance," In Therapeutic Antibody Engineering, Cambridge: Woodhead Publishing (2012), pp. 225-249). These strategies include reducing effector function by modifying glycosylation, using an IgG2 / IgG4 scaffold, or introducing mutations into the hinge or CH2 region of the Fc. For example, U.S. Patent Publication No. 2011 / 0212087 (Strohl), International Patent Publication No. WO2006 / 105338 (Xencor), U.S. Patent Publication No. 2012 / 0225058 (Xencor), U.S. Patent Publication No. 2012 / 0251531 (Genentech), and Strop et al ((2012) J. Mol. Biol. 420:204-219) describe specific modifications to reduce FcγR or complement binding to Fc.
[0159] Specific, non-limiting examples of known amino acid modifications to reduce FcγR or complement binding to Fc include those identified in Table I.
[0160] Table I: Modifications to Fc to reduce FcγR or complement binding TIFF0007596263000009.tif115128
[0161] In some embodiments, the Fc comprises at least one amino acid modification identified in Table I. In some embodiments, the Fc comprises at least one amino acid modification of L234, L235, or D265. In some embodiments, the Fc comprises amino acid modifications at L234, L235, and D265. In some embodiments, the Fc comprises amino acid modifications L234A, L235A, and D265S.
[0162] In embodiments where the scaffold is Fc, the 4-1BB binding domain may be linked to the N-terminus of one of the Fc polypeptides. In other embodiments, the 4-1BB binding domain may be linked to the C-terminus of one of the Fc polypeptides. In certain embodiments, a 4-1BB x TAA antibody construct may comprise a 4-1BB binding domain linked to the N-terminus of one of the Fc polypeptides and another 4-1BB binding domain linked to the N-terminus of the other Fc polypeptide. In still other embodiments, a 4-1BB x TAA antibody construct may comprise a 4-1BB binding domain linked to the C-terminus of one of the Fc polypeptides. In certain embodiments, a 4-1BB x TAA antibody construct may comprise a 4-1BB binding domain linked to the C-terminus of one of the Fc polypeptides and another 4-1BB binding domain linked to the C-terminus of the other Fc polypeptide.
[0163] In additional embodiments where the scaffold is Fc, the TAA antigen binding domain may be linked to the N-terminus of one of the Fc polypeptides. In other embodiments, the TAA antigen binding domain may be linked to the C-terminus of one of the Fc polypeptides. In certain embodiments, the 4-1BB×TAA antibody construct may comprise a TAA antigen binding domain linked to the N-terminus of one of the Fc polypeptides and another TAA antigen binding domain linked to the N-terminus of the other Fc polypeptide. In yet other embodiments, the 4-1BB×TAA may comprise a TAA antigen binding domain linked to the C-terminus of one of the Fc polypeptides. In certain embodiments, the 4-1BB×TAA antibody construct may comprise a TAA antigen binding domain linked to the C-terminus of one of the Fc polypeptides and another TAA antigen binding domain linked to the C-terminus of the other Fc polypeptide.
[0164] As will be appreciated by one of skill in the art, in some embodiments, combinations of the above combinations are also possible. Certain exemplary combinations are set forth as follows:
[0165] Antibody construct formats 4-1BB×TAA antibody construct The 4-1BBxTAA antibody constructs described herein comprise a 4-1BB binding domain and a TAA antigen binding domain, which are linked directly or indirectly to a scaffold. As is known in the art, these 4-1BBxTAA antibody constructs may be constructed in many formats, and exemplary, non-limiting formats are described below.
[0166] In embodiments in which the 4-1BB binding domain of the 4-1BB x TAA antibody construct is a 4-1BB antigen binding domain, the 4-1BB antigen binding domain may be in Fab, scFv, or sdAb format. In one embodiment, the antibody construct comprises a 4-1BB antigen binding domain and a TAA antigen binding domain in Fab format, and the 4-1BB antigen binding domain and the TAA antigen binding domain are directly or indirectly linked to a scaffold. In another embodiment, the antibody construct comprises a 4-1BB antigen binding domain and a TAA antigen binding domain in scFv format, and the 4-1BB antigen binding domain and the TAA antigen binding domain are directly or indirectly linked to a scaffold. In one embodiment, the antibody construct comprises a 4-1BB antigen binding domain and a TAA antigen binding domain in sdAb format, and the 4-1BB antigen binding domain and the TAA antigen binding domain are directly or indirectly linked to a scaffold. In some of these embodiments, the 4-1BB antigen binding domain is linked to the N-terminus of the scaffold and the TAA antigen binding domain is linked to the C-terminus of the scaffold. In other embodiments, both the 4-1BB antigen binding domain and the TAA antigen binding domain are linked to the N-terminus of the scaffold.
[0167] In some embodiments, the scaffold is an Fc construct. In one such embodiment, the 4-1BB x TAA antibody construct comprises a first 4-1BB antigen-binding domain linked to the N-terminus of a first Fc polypeptide, a second 4-1BB antigen-binding domain linked to the N-terminus of a second Fc polypeptide, and a TAA antigen-binding domain linked to the C-terminus of the first Fc polypeptide. In some embodiments, the first and second 4-1BB antigen-binding domains are both in Fab format, and the TAA antigen-binding domain is in scFv format. Figure 2B provides a diagram of an exemplary construct related to these embodiments.
[0168] In other embodiments where the scaffold is an Fc construct, the 4-1BB x TAA antibody construct comprises a first 4-1BB antigen-binding domain linked to the N-terminus of a first Fc polypeptide, a second 4-1BB antigen-binding domain linked to the N-terminus of a second Fc polypeptide, a first TAA antigen-binding domain linked to the C-terminus of the first Fc polypeptide, and a second TAA antigen-binding domain linked to the C-terminus of the second Fc polypeptide. In some embodiments, the first and second 4-1BB antigen-binding domains are both in Fab format, and the first and second TAA antigen-binding domains are both in scFv format. Figure 2C provides a diagram of an exemplary construct related to these embodiments.
[0169] In other embodiments where the scaffold is an Fc construct, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain linked to the N-terminus of one of the Fc polypeptides of the Fc construct and a first TAA antigen binding domain linked to the C-terminus of the same Fc polypeptide. In some embodiments, the 4-1BB antigen binding domain is in Fab format and the TAA antigen binding domain is in scFv format. Figure 2D provides a diagram of an exemplary construct related to these embodiments.
[0170] In yet other embodiments, in which the scaffold is an Fc construct, the 4-1BB x TAA antibody construct comprises a first 4-1BB antigen-binding domain linked to the N-terminus of a first Fc polypeptide, a second 4-1BB antigen-binding domain linked to the N-terminus of a second Fc polypeptide, and a TAA antigen-binding domain linked to the N-terminus of the VH domain of the first 4-1BB antigen-binding domain. In some embodiments, the first and second 4-1BB antigen-binding domains are both in Fab format, and the TAA antigen-binding domain is in scFv format. Figure 2E provides a diagram of an exemplary construct related to these embodiments.
[0171] In other embodiments where the scaffold is an Fc construct, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain linked to the N-terminus of a first Fc polypeptide and a TAA antigen binding domain linked to the N-terminus of a second Fc polypeptide. In some embodiments, the 4-1BB antigen binding domains are both in Fab format and the TAA antigen binding domain is in scFv format. Figure 2F provides a diagram of an exemplary construct related to these embodiments.
[0172] In other embodiments where the scaffold is an Fc construct, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain linked to the N-terminus of one of the Fc polypeptides of the Fc construct and a TAA antigen binding domain linked to the N-terminus of the VH region of the 4-1BB antigen binding domain. In some embodiments, the 4-1BB antigen binding domain is in Fab format and the TAA antigen binding domain is in scFv format. Figure 2G provides a diagram of an exemplary construct related to these embodiments.
[0173] In further embodiments where the scaffold is an Fc construct, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain linked to the N-terminus of one of the Fc polypeptides of the Fc construct, a TAA antigen binding domain linked to the C-terminus of the same Fc polypeptide, and a TAA antigen binding domain linked to the C-terminus of a second Fc polypeptide. In some embodiments, the 4-1BB antigen binding domain is in Fab format and the TAA antigen binding domain is in scFv format. Figure 2G provides a diagram of an exemplary construct related to these embodiments.
[0174] In still other embodiments where the scaffold is an Fc construct, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain linked to the N-terminus of one of the Fc polypeptides of the Fc construct and a TAA antigen binding domain linked to the C-terminus of a second Fc polypeptide, in some embodiments the 4-1BB antigen binding domain is in Fab format and the TAA antigen binding domain is in scFv format.
[0175] In one embodiment, the 4-1BB x TAA antibody construct comprises a 4-1BB binding domain that is a 4-1BB ligand, the 4-1BB ligand linked to the C-terminus of one of the Fc polypeptides of the Fc construct, and a TAA antigen binding domain in Fab format linked to the N-terminus of the other Fc polypeptide of the Fc construct.
[0176] Functional activity of 4-1BB x TAA antibody constructs The 4-1BB x TAA antibody constructs provided herein can bind to 4-1BB and TAA with varying affinities. The affinity or avidity of an antibody for an antigen can be determined experimentally using methods known in the art (see, e.g., Berzofsky, et al., "Antibody-Antigen Interactions," In Fundamental Immunology, Paul, WE, Ed., Raven Press: New York, NY (1984); Kuby, Janis, Immunology, WH Freeman and Company: New York, NY (1992), and the methods described herein).
[0177] The measured affinity of a particular antibody-antigen interaction may vary when measured under different conditions (e.g., salt concentration, pH). Therefore, measurements of affinity and other antigen binding parameters are preferably made using standard solutions of antibody and antigen, and standard buffers, such as those described herein. Affinity K D is k on / k off Generally, K in the micromolar range is D are considered to have low affinity for monospecific bivalent antibodies. Generally, K values in the picomolar range D are believed to have higher affinity for monospecific bivalent antibodies. As is known in the art, the affinity of antibodies measured as monovalent binders is generally lower than that measured as bivalent binders.
[0178] In some embodiments, the 4-1BB x TAA antibody construct has a K for human 4-1BB, measured as a monovalent binder, of about 15 nM to 100 nM, about 15 nM to 200 nM, or about 15 nM to 500 nM, about 100 pM to 1 μM. D In additional embodiments, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain having a K for human 4-1BB, measured as a monovalent binder, of about 1 nM to about 1000 nM, or about 10 nM to about 500 nM, or about 20 nM to about 400 nM. D In other embodiments, the 4-1BB x TAA antibody construct comprises a 4-1BB antigen binding domain having a K for the TAA of about 0.1 nM to about 50 nM, or about 1 nM to about 20 nM, or about 1 nM to about 10 nM. D The KD may be measured by a number of known methods, for example, SPR, as described elsewhere herein. As used in this section, the term "about" refers to the KD identified in each range. D This means ±10% of the value.
[0179] In some embodiments, the 4-1BB x TAA antibody construct binds to one or more TAA-expressing cell lines, e.g., as determined by ELISA, BiaCore™, and / or flow cytometry, or as described in the Examples. In certain embodiments, the TAA-expressing cell line is an ovarian adenocarcinoma cell line, such as IGROV1, SKOV3, or OVCAR3. In certain embodiments, the TAA-expressing cell line is a lung cancer cell line. In certain embodiments, the lung cancer cell line is a lung squamous cell line, such as H226, or a lung adenocarcinoma cell line, such as H441, HCC827, H1573, H1975, or H1563, or a lung cancer cell line, such as H1299, or a lung large cell carcinoma, such as H661. In some embodiments, the TAA-expressing cell line is a HER2-expressing cell line, such as SKBr3, a FRα-expressing cell line, a LIV-1-expressing cell line, a NaPi2b-expressing cell line, or a mesothelin-expressing cell line.
[0180] In some embodiments, the 4-1BB x TAA antibody construct may be capable of stimulating 4-1BB activity in T cells in the presence of TAA-expressing cells, as measured by cytokine production. In some embodiments, the TAA-expressing cells express the TAA on the cell surface at greater than about 500,000 molecules per cell, as measured by quantitative flow cytometry or other quantification. In some embodiments, the TAA-expressing cells express the TAA on the cell surface at greater than about 100,000 molecules per cell, as measured by quantitative flow cytometry or other quantification. In some embodiments, the TAA-expressing cells express the TAA on the cell surface at about 100,000-500,000 molecules per cell, as measured by quantitative flow cytometry or other quantification. In some embodiments, the TAA-expressing cells express the TAA on the cell surface at about 50,000-500,000 molecules per cell, as measured by quantitative flow cytometry or other quantification.
[0181] In some embodiments, the 4-1BB x TAA antibody construct binds to a 4-1BB-expressing cell as determined by the methods described above. In some embodiments, the 4-1BB-expressing cell is a primary T, NK, or NKT cell, an activated primary T, NK, or NKT cell, a regulatory T cell, or a T, NKT, or NKT cell extracted from a tumor.
[0182] In some embodiments, the 4-1BB×TAA antibody constructs described herein may be capable of stimulating 4-1BB signaling in 4-1BB-expressing cells. Methods for testing 4-1BB activity are known in the art. For example, the NF-κB reporter gene assay described in the Examples may be used to assess the ability of a 4-1BB×TAA antibody construct to promote NF-κB activation and nuclear translocation, followed by induction of reporter gene expression. As another example, primary T cell co-culture assays such as those described in the Examples may be used to measure increased or decreased production of cytokines (e.g., IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-13, IL-15, IL-21, IL-22, IL-35, IFN-γ, TNF-α, TGF-β), increased or decreased expression of chemokine receptors (CXCR3, CXCR5, CXCR6, CCR1, CCR2, CCR4, CCR5, CCR7, CCR8, CCR9, CCR10), increased or decreased expression of key transcription factors (Tbet, GATA3, FOXP3, EOMES, TOX), increased or decreased expression of metabolic activity or proteins regulating metabolic activity, increased or decreased expression of anti- or pro-apoptotic proteins (Bcl2, Bcl-X1), increased or decreased expression of cytokines (e.g., IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-13, IL-15, IL-21, IL-22, IL-35, IFN-γ, TNF-α, TGF-β), increased or decreased expression of cytokines (e.g., IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10), increased or decreased expression of cytokines (e.g., IL-1 ...1, IL-1, , Bim, Mcl1), increased or decreased expression of surface markers (PD1, TIGIT, LAG3, ICOS, CD45RA, CD45RO, CD44, CD69, CD44, KLRG1), increased or decreased ability of T cells to kill tumor cells, or by measuring the phosphorylation, localization, or activity of signaling proteins (Akt / PkB, PI3K, CD3 zeta, LAT, SLP76, IκK, NFκB, TRAF family, MEK, MEKK, NIK, ERK, p38MAPK, c-fos, c-jun, ATF, Foxo) or proteins controlling the cell cycle (cyclin D3, p27kip1). This can be assessed at any available level: protein, mRNA, or chromosome. Activity in primary T cell assays can be assessed by examining an increase or decrease in total cellular DNA content ( 3Cell proliferation can also be assessed by measuring the incorporation of H-thymidine, bromodeoxyuridine, or similar trackers, or by an increase or decrease in the levels of a tracking dye that can determine the number of divisions in assays in which cells are labeled with a dye (CFDA-SE, Cell Tracker Violet, PKH26). These assays are well known to those of skill in the art, and reagents and kits for performing these assays are often commercially available, such as CellTracker™ Violet BMQC Dye (ThermoFisher Scientific) or CellTrace™ Violet Cell proliferation Kit, ThermoFisher Scientific / Invitrogen™.
[0183] 4-1BB antibody construct The present disclosure further provides antibody constructs or antigen-binding fragments thereof (4-1BB antibody constructs) that specifically bind to the 4-1BB ECD. In some embodiments, these 4-1BB antibody constructs comprise the VH and VL sequences set forth in Tables 13 and 14, and the CDR sequences for these VH and VL sequences can be found in Table 18. In certain embodiments, the 4-1BB antibody constructs are capable of stimulating 4-1BB activity as described elsewhere herein. In some embodiments, the 4-1BB antibody constructs bind to any one of CRD1, CRD2, CRD3, or CRD4 of human 4-1BB.
[0184] In one embodiment, the 4-1BB antibody construct or antigen-binding fragment thereof comprises a heavy chain variable sequence comprising three heavy chain CDRs and a light chain variable sequence comprising three light chain CDRs, wherein the heavy chain CDRs and light chain CDRs are derived from any one of antibodies 1G1, 1B2, 1C3, 1C8, 2A7, 2E8, 2H9, 3D7, 3H1, 3E7, 3G4, 4B11, 4E6, 4F9, 4G10, 5E2, 5G8, or 6B3, and the 4-1BB antibody construct binds to human 4-1BB. In some embodiments, the 4-1BB antibody construct or antigen-binding fragment comprises a heavy chain variable (VH) sequence comprising three CDRs and a light chain variable (VL) sequence comprising three CDRs, wherein the heavy chain CDRs and light chain CDRs are derived from any one of antibodies 1G1, 1C3, 1C8, 2E8, 3E7, 4E6, 5G8, or 6B3, and the 4-1BB antibody construct binds to human 4-1BB.
[0185] In certain embodiments, the 4-1BB antibody construct comprises human or humanized VH and VL sequences. In other embodiments, the 4-1BB antibody construct comprises variants v28726, v28727, v28728, v28730, v28700, v28704, v28705, v28706, v28711, v28712, v28713, v28696, v28697, v28698, v28701, v28702, v28703, v28707, v28683, The VH and VL sequences have at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the VH and VL sequences of any one of v28684, v28685, v28686, v28687, v28688, v28689, v28690, v28691, v28692, v28694, or v28695.
[0186] The anti-4-1BB CDR, VH, and VL sequences may be used to construct various formats of antibody constructs, as is known in the art. For example, these sequences may be used to construct Fab fragments or scFvs, which may be linked to scaffolds such as Fc or other scaffolds as described herein. Exemplary formats of antibody constructs comprising these CDR, VH, and VL sequences are illustrated in FIG. 1. The antibody constructs may be monovalent, bivalent, or multivalent. In some embodiments, the antibody constructs are monospecific. In some embodiments, the antibody constructs are monospecific and in a naturally occurring form (FSA).
[0187] The anti-4-1BB VH and VL sequences set forth in Tables 13 and 14 and the anti-4-1BB CDR sequences found in Table 18 may further be used in the construction of bispecific or multispecific antibodies, such as the 4-1BB x TAA antibody constructs described herein, or other antibody constructs comprising at least one antigen-binding domain that binds to the ECD of 4-1BB.
[0188] In some embodiments, the monovalent form of the 4-1BB antibody construct has a K for 4-1BB of about 15 nM to 100 nM, about 15 nM to 200 nM, or about 15 nM to 500 nM, about 100 pM to 1 μM. D In additional embodiments, the monovalent form of the 4-1BB antibody construct binds to human 4-1BB with a K of about 1 nM to about 1000 nM, or about 10 nM to about 500 nM, or about 20 nM to about 400 nM. D As noted above, KD may be measured by a number of known methods, for example, SPR, as described elsewhere herein. As used in this section, the term "about" refers to the KD identified in each range. D In a related embodiment, the term "about" refers to the K as measured by SPR. D This means ±20% of the value.
[0189] The 4-1BB antibody constructs described herein may be prepared, tested and used as described elsewhere herein.
[0190] FRα antibody construct The present disclosure further provides antibody constructs or antigen-binding fragments thereof (FRα antibody constructs) that specifically bind to FRα. These FRα antibody constructs comprise the VH and VL sequences set forth in Tables 17 and 20, and the CDR sequences of these VH and VL sequences can be found in Table 18. In one embodiment, the FRα antibody construct binds to human FRα.
[0191] In some embodiments, the FRα antibody construct comprises a heavy chain variable sequence comprising three heavy chain CDRs and a light chain comprising three light chain CDRs, wherein the heavy chain CDRs and light chain CDRs are derived from antibody 8K22 or antibody 1H06.
[0192] In certain embodiments, the FRα antibody construct comprises VH and VL sequences that are human or humanized. In a related embodiment, the FRα antibody construct comprises VH and VL sequences that have at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the VH and VL sequences of any one of variants 23794, 23795, 23796, 23797, 23798, 23799, 23800, 23801, 23802, 23803, 23804, 23805, 23806, 23807, 23808, 23809, 23810, 23811, 23812, 23813, 23814, 23815, 23816, 23817, or 23818 derived from the 8K22 antibody.
[0193] In other embodiments, the FRα antibody construct comprises humanized VH and VL sequences comprising the heavy and light chain CDRs of antibody 1H06.
[0194] In some embodiments, the humanized FRα antibody construct comprises a humanized FRα Fab domain that is more stable than the parent Fab domain from which it is derived. In related embodiments, the humanized FRα Fab domain may exhibit a Tm that is up to 10° C. higher than that of the parent Fab. In some embodiments, the humanized FRα Fab domain may exhibit a Tm that is up to 5° C. higher than that of the parent Fab.
[0195] In certain embodiments, the FRα antibody construct has a binding affinity or K for human FRα in the range of 100 pM to 100 nM. D In some embodiments, the FRα antibody construct has a binding affinity or K for human FRα in the range of 10 pM to 100 nM. D In a related embodiment, the FRα antibody construct has a K for human FRα in the range of 1 nM to 50 nM. D In additional related embodiments, the affinity of the FRα antibody construct for human FRα is measured by biolayer interferometry (BLI).
[0196] These anti-FRα CDR, VH, and VL sequences listed in Tables 17, 18, and 20 may be used to construct various formats of antibody constructs, as known in the art. For example, these sequences may be used to construct Fab fragments or scFvs, which may be linked to scaffolds such as Fc or other scaffolds described herein. Exemplary formats of antibody constructs comprising these CDR, VH, and VL sequences are illustrated in FIG. 1. The antibody constructs may be monovalent, bivalent, or multivalent. In some embodiments, the antibody constructs are monospecific. In some embodiments, the antibody constructs are monospecific and in their naturally occurring form (FSA).
[0197] The anti-FRα VH and VL sequences set forth in Tables 17 and 20 and the anti-FRα CDR sequences found in Table 18 may further be used in the construction of bispecific or multispecific antibodies, such as the 4-1BB×FRα antibody constructs described herein, or other antibody constructs that include at least one antigen-binding domain that binds to FRα.
[0198] The FRα antibody constructs described herein may be prepared, tested and used as described elsewhere herein.
[0199] Methods for preparing antibody constructs The 4-1BBxTAA antibody constructs, FRα antibody constructs, and 4-1BB antibody constructs described herein may be made using recombinant methods and compositions, for example, as described in U.S. Patent No. 4,816,567. This method and other methods for making these constructs are described as follows.
[0200] Accordingly, certain embodiments relate to one or more nucleic acids encoding the antibody constructs described herein. Such nucleic acids may encode an amino acid sequence corresponding to a 4-1BBxTAA antibody construct or a 4-1BB antibody construct.
[0201] Certain embodiments relate to one or more vectors (e.g., expression vectors) comprising nucleic acids encoding the antibody constructs described herein. In some embodiments, the nucleic acids encoding the antibody constructs are contained in a multicistronic vector. In other embodiments, each polypeptide chain of the antibody construct is encoded by a separate vector. It is further contemplated that a combination of vectors may comprise nucleic acids encoding a single antibody construct.
[0202] Certain embodiments relate to host cells comprising such nucleic acids or one or more vectors comprising nucleic acids. In some embodiments, for example, when the antibody construct is a multispecific or bispecific antibody, the host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antigen-binding domain and an amino acid sequence comprising the VH of the antigen-binding domain, or (2) a first vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antigen-binding domain and a second vector comprising a nucleic acid encoding an amino acid sequence comprising the VH of the antigen-binding domain. In some embodiments, the host cell is a eukaryotic cell, for example, a Chinese hamster ovary (CHO) cell, or a human embryonic kidney (HEK) cell, or a lymphoid cell (e.g., a YO, NS, or Sp20 cell).
[0203] Certain embodiments relate to methods of making an antibody construct, the methods comprising culturing a host cell comprising nucleic acid encoding the antibody construct, as described above, under conditions suitable for expression of the antibody construct, and optionally recovering the antibody construct from the host cell (or host cell culture medium).
[0204] For recombinant production of antibody constructs, for example, nucleic acids encoding the antibody constructs described above are isolated and inserted into one or more vectors for further cloning and / or expression in host cells. Such nucleic acids may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding the heavy and light chains of the antibody construct).
[0205] The term "substantially purified" refers to a construct described herein, or variants thereof, which may be substantially or essentially free from components that normally accompany or interact with the protein as found in its naturally occurring environment, i.e., in native cells, or, in the case of recombinantly produced constructs, in host cells. In certain embodiments, a construct that is substantially free of cellular material includes preparations of the protein having less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% (by dry weight) of contaminating protein. When the construct is recombinantly produced by a host cell, the protein in certain embodiments is present at no more than about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 4%, about 3%, about 2%, or about 1% by dry weight of the cells. When the construct is recombinantly produced by a host cell, the protein in certain embodiments is present in the culture medium at about 5 g / L, about 4 g / L, about 3 g / L, about 2 g / L, about 1 g / L, about 750 mg / L, about 500 mg / L, about 250 mg / L, about 100 mg / L, about 50 mg / L, about 10 mg / L, or about 1 mg / L or less dry weight of cells.
[0206] In certain embodiments, the term "substantially purified," when applied to constructs produced by the methods described herein that comprise a heteromultimeric Fc, has a purity level of at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, particularly at least about 75%, 80%, 85%, more particularly at least about 90%, at least about 95%, at least about 99% or greater, as determined by appropriate methods such as, for example, SDS / PAGE analysis, RP-HPLC, SEC, and capillary electrophoresis.
[0207] Suitable host cells for cloning or expressing vectors encoding the antibody constructs include prokaryotic or eukaryotic cells described herein.
[0208] A "recombinant host cell" or "host cell" refers to a cell that contains an exogenous polynucleotide, regardless of the method used for insertion, e.g., direct uptake, transduction, f-mating, or other methods known in the art for producing recombinant host cells. The exogenous polynucleotide may be maintained as a non-integrated vector, e.g., a plasmid, or alternatively, may be integrated into the host genome.
[0209] As used herein, the term "eukaryote" refers to organisms belonging to the phylogenetic domain Eucarya, such as animals (including but not limited to mammals, insects, reptiles, birds, etc.), ciliates, plants (including but not limited to monocotyledons, dicotyledons, algae, etc.), fungi, yeasts, flagellates, microsporidia, protists, etc.
[0210] As used herein, the term "prokaryote" refers to a prokaryotic organism. For example, non-eukaryotic organisms may belong to the Eubacteria (including, but not limited to, Escherichia coli, Thermus thermophilus, Bacillus stearothermophilus, Pseudomonas fluorescens, Pseudomonas aeruginosa, Pseudomonas putida, etc.) phylogenetic domain, or the Archaea (including, but not limited to, Methanococcus jannaschii, Methanobacterium thermoautotrophicum, Halobacteria (e.g., Haloferax volcanii and Halobacterium species NRC-1, Archaeoglobus fulgidus, Pyrococcus furiosus, Pyrococcus horikoshii, Aeuropyrum pernix, etc.) phylogenetic domain.
[0211] For example, antibody constructs may be produced in bacteria, particularly if glycosylation and Fc effector functions are not required. For expression of antigen-binding construct fragments and polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in E. coli.) After expression, the antigen-binding construct may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
[0212] In addition to prokaryotes, eukaryotic microbes, such as filamentous fungi or yeast, are suitable cloning or expression hosts for vectors encoding antibody constructs, including fungal and yeast strains in which the glycosylation pathway has been "humanized," resulting in the production of antigen-binding constructs with partially or fully human glycosylation patterns. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).
[0213] Suitable host cells for the expression of glycosylated antigen-binding constructs are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. Numerous baculovirus strains have been identified that may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.
[0214] Plant cell cultures can also be used as hosts. See, e.g., U.S. Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (which describe PLANTIBODIES™ technology for producing antigen-binding constructs in transgenic plants).
[0215] Vertebrate cells may also be used as hosts, for example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are SV40-transformed monkey kidney CV1 (COS-7), human embryonic kidney lines (e.g., 293 or 293 cells described in Graham et al., J. Gen Virol. 36:59 (1977)), baby hamster kidney cells (BHK), mouse Sertoli cells (e.g., TM4 cells described in Mather, Biol. Reprod. 23:243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), buffalo rat liver cells (BRL3A), human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor (MMT 060562), e.g., TRI cells described in Mather et al., Annals NYAcad. Sci. 383:44-68 (1982), MRC Other useful mammalian host cell lines include DHFR 5 cells, and FS4 cells. - Examples include Chinese hamster ovary (CHO) cells, including CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)), and myeloma cell lines such as Y0, NS0, and Sp2 / 0. For a review of certain mammalian host cell lines suitable for producing antigen-binding constructs, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).
[0216] In some embodiments, the antibody constructs described herein are produced in stable mammalian cells by a method comprising transfecting at least one stable mammalian cell with nucleic acids encoding the antibody constructs in a predetermined ratio, and expressing the nucleic acids in the at least one mammalian cell. In some embodiments, the predetermined ratio of nucleic acids is determined in transient transfection experiments to determine the relative ratio of introduced nucleic acids that results in the highest percentage of antigen-binding constructs in the expression product.
[0217] In some embodiments, in the methods of producing antibody constructs in stable mammalian cells, the expression product of the stable mammalian cells comprises a higher percentage of the desired glycosylated antigen-binding construct when compared to monomeric heavy or light chain polypeptides or other antibodies.
[0218] If necessary, antibody constructs can be purified or isolated after expression. Proteins can be isolated or purified by a variety of methods known to those skilled in the art. Standard purification methods include chromatographic techniques, including ion exchange, hydrophobic interaction, affinity, size or gel filtration, and reversed phase, performed at atmospheric or elevated pressure using systems such as FPLC and HPLC. Purification methods also include electrophoretic, immunological, precipitation, dialysis, and chromatofocusing techniques. Ultrafiltration and diafiltration techniques combined with protein concentration are also useful. As is well known in the art, various natural proteins bind to Fc and antibodies, and these proteins can be used to purify antigen-binding constructs. For example, bacterial proteins A and G bind to the Fc region. Similarly, bacterial protein L binds to the Fab region of some antibodies. In many cases, purification can be achieved by specific fusion partners. For example, antibodies can be purified by binding to glutathione resins when GST fusions are used, or Ni-based resins when His tags are used. +2Purification may be accomplished using affinity chromatography or, if a flag tag is used, immobilized anti-flag antibodies. For general guidance on suitable purification techniques, see, for example, Protein Purification: Principles and Practice, 3, incorporated by reference in its entirety. rd Ed., Scopes, Springer-Verlag, NY, 1994, which is incorporated by reference in its entirety. The degree of purification required will vary depending on the use of the antigen-binding construct. In some cases, no purification is necessary.
[0219] In certain embodiments, antibody constructs may be purified using anion exchange chromatography, including but not limited to, chromatography on Q-sepharose, DEAE sepharose, poros HQ, poros DEAF, Toyopearl Q, Toyopearl QAE, Toyopearl DEAE, Resource / Source Q and DEAE, Fractogel Q and DEAE columns.
[0220] In some embodiments, the antibody construct is purified using cation exchange chromatography, such as, but not limited to, SP-sepharose, CM sepharose, poros HS, poros CM, Toyopearl SP, Toyopearl CM, Resource / Source S and CM, Fractogel S and CM columns and their equivalents and derivatives.
[0221] In some embodiments, the antibody construct is expressed using a cell-free translation or expression system. Suitable systems are known in the art, such as the method described by Stech et al. in Nature Scientific Reports 7:12030 or the method described by Gregorio et al. in Methods Protoc. 2019 2:24.
[0222] Additionally, antibody constructs can be chemically synthesized using techniques known in the art (see, e.g., Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., NY, and Hunkapiller et al., Nature, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, D-isomers of common amino acids, 2,4-diaminobutyric acid, alpha-aminoisobutyric acid, 4-aminobutyric acid, Abu, 2-aminobutyric acid, g-Abu, eAhx, 6-aminohexanoic acid, Aib, 2-aminoisobutyric acid, 3-aminopropionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β-alanine, fluoro-amino acids, designer amino acids such as α-methylamino acids, C α-methylamino acids, N α-methylamino acids, and common amino acid analogs. Furthermore, amino acids can be D (dextrorotatory) or L (levorotatory).
[0223] Post-translational modifications In certain embodiments, the antibody constructs described herein are differentially modified co- or post-translationally.
[0224] The term "modified," as used herein, refers to any alteration made to a given polypeptide, such as changes to the length, amino acid sequence, chemical structure of the polypeptide, co-translational modifications, or post-translational modifications of the polypeptide.
[0225] The term "post-translationally modified" refers to any modification of a natural or unnatural amino acid that occurs to such an amino acid after it is incorporated into a polypeptide chain. This term encompasses, by way of example only, co-translational in vivo modifications, co-translational in vitro modifications (such as in a cell-free translation system), post-translational in vivo modifications, and post-translational in vitro modifications.
[0226] In some embodiments, antibody constructs may include modifications that are glycosylation, acetylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage or conjugation to an antibody molecule or antigen-binding construct or other cellular ligand, or a combination of these modifications. In some embodiments, antibody constructs are chemically modified by known techniques, including, but not limited to, specific chemical cleavage with cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4, acetylation, formylation, oxidation, reduction, and metabolic synthesis in the presence of tunicamycin.
[0227] Additional optional post-translational modifications of the antigen-binding construct include, for example, N- or O-linked carbohydrate chains, N- or C-terminal processing, conjugation of chemical moieties to the amino acid backbone, chemical modification of N- or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. The antigen-binding constructs described herein are modified with a detectable label, such as an enzymatic, fluorescent, isotopic, or affinity label, to allow for detection and isolation of the protein. In certain embodiments, examples of suitable enzyme labels include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin biotin and avidin / biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, or phycoerythrin; examples of luminescent materials include luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive materials include iodine, carbon, sulfur, tritium, indium, technetium, thallium, gallium, palladium, molybdenum, xenon, and fluorine.
[0228] In some embodiments, the antigen-binding constructs described herein may be conjugated to a macrocyclic chelate that associates with a radioactive metal ion.
[0229] In some embodiments, the antibody constructs described herein may be modified by natural processes, such as post-translational processing, or by any of the chemical modification techniques known in the art. In certain embodiments, the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. In certain embodiments, polypeptides from the antigen-binding constructs described herein are branched, for example, as a result of ubiquitination, and in some embodiments, are cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides are the result of post-translational natural processes or are made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA-mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, e.g., PROTEINS--STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., TECreighton, W.H. Freeman and Company, New York (1993); POST-TRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B.C. Johnson, Ed., Academic Press, New York, pp. 1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. NY Acad. Sci. 663:48-62 (1992)).
[0230] In certain embodiments, the antigen-binding constructs described herein may be attached to a solid support, which is particularly useful for immunoassays or purification of polypeptides that are bound by, bind to, or associate with the proteins described herein. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride, or polypropylene.
[0231] Additional optional modifications In one embodiment, the antibody constructs described herein can be further modified (i.e., by the covalent attachment of various types of molecules) so that the covalent attachment does not interfere with or affect the ability of the 4-1BB x TAA antibody construct to bind to 4-1BB or to a TAA, or does not affect the ability of the 4-1BB antibody construct to bind to 4-1BB, or does not adversely affect the stability of these antibody constructs. Similarly, the 4-1BB antibody construct and the FRα antibody construct can be covalently modified so that their stability or ability to bind to their target is not significantly affected. Such modifications include, but are not limited to, glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, conjugation to cellular ligands or other proteins, and the like. Any of a number of chemical modifications can be performed by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, and the like.
[0232] Certain embodiments contemplate conjugating the antibody construct to a drug moiety, such as a toxin, a chemotherapeutic agent, an immunomodulator, or a radioisotope. Numerous methods for preparing antibody-drug conjugates (ADCs) are known in the art. Examples include the methods described in U.S. Patent No. 8,624,003 (the Pott method), U.S. Patent No. 8,163,888 (one-step method), and U.S. Patent No. 5,208,020 (two-step method). See also Antibody-Drug Conjugates, Series: Methods in Molecular Biology, Laurent Ducry (Ed.), Humana Press, 2013.
[0233] The drug moiety of an ADC is typically a compound or moiety that has a cytostatic or cytotoxic effect. In some embodiments, the drug included in an ADC is a cytotoxic agent. The term "cytotoxic agent," as used herein, refers to a substance that inhibits or prevents the function of cells and / or causes destruction of cells. The term also includes radioisotopes (e.g., 211 At, 131 I, 125 I, 90 Y, 186 Re, 188 Re, 153 Sm, 212 Bi, 32 P and 177The term "ADC" is intended to include chemotherapeutic agents, such as thrombin (Lu), chemotherapeutic agents, and toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant, or animal origin, including fragments and / or variants thereof. Those skilled in the art will understand that some of these drug categories overlap and are therefore not intended to be mutually exclusive. For example, toxins may also be considered chemotherapeutic agents, in the sense that they are chemical compounds that may be used to treat cancer. In some embodiments, the drug included in the ADC is an analog or derivative of a naturally occurring toxin. Examples of such naturally occurring toxins include, but are not limited to, maytansine, auristatin, dolastatin, tubulysin, hemiasterin, calicheamicin, duocarmycin, pyrrolobenzodiazapenes, amatoxin, camptothecin, pseudomonas exotoxin (PE), diphtheria toxin (DT), deglycosylated ricin A (dgA), and gelonin.
[0234] In certain embodiments, the drug included in the ADC is a microtubule-disrupting agent or a DNA-modifying agent. Examples of toxins that are microtubule-disrupting agents include, but are not limited to, maytansine, auristatin, dolastatin, tubulysin, hemiasterlin, and analogs and derivatives thereof. Examples of toxins that are DNA-modifying agents include, but are not limited to, calicheamicin and other enediyne antibiotics, duocarmycins, pyrrolobenzodiazapenes, amatoxins, camptothecin, and analogs and derivatives thereof.
[0235] Exemplary maytansinoids include DM1 (mertansine, emtansine, N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine), DM3 (N2'-deacetyl-N2'-(4-mercapto-1-oxopentyl)maytansine), and DM4 (ravtansine, soravtansine, N2'-deacetyl-N2'-(4-methyl-4-mercapto-1-oxopentyl)maytansine) (see U.S. Patent Application Publication No. US2009 / 0202536). Other examples of naturally occurring, synthetic, and semi-synthetic maytansinoids are described in Cassady et al., 2004, Chem. Pharm. Bull., 52(1):1-26, and in U.S. Pat. Nos. 4,256,746, 4,361,650, 4,307,016, 4,294,757, 4,424,219, 4,331,598, 4,364,866, 4,313,946, 4,315,929, 4,362,663, 4,322,348, and 4,371,533.
[0236] Exemplary dolastatins and auristatins include auristatin E (also known in the art as a derivative of dolastatin-10) and auristatin F, as well as analogs and derivatives thereof. Auristatin analogs include, for example, esters formed between auristatin E and a keto acid. For example, auristatin E can react with paraacetylbenzoic acid or benzoylvaleric acid to produce auristatin EB (AEB) and auristatin EVB (AEVB), respectively. Other exemplary auristatins include auristatin F phenylenediamine (AFP), monomethyl auristatin F (MMAF), and monomethyl auristatin E (MMAE). The synthesis and structures of exemplary auristatins are described in U.S. Patent Nos. 6,884,869, 7,098,308, 7,256,257, 7,423,116, 7,498,298, and 7,745,394. Other examples of auristatin analogs, particularly analogs suitable for attachment via the C-terminus of a drug molecule, include those described in International Publication Nos. WO2002 / 088172 and WO2016 / 041082.
[0237] Exemplary hemiasterlin and hemiasterlin analogs and derivatives include those described in International Publication Nos. WO1996 / 33211 and WO2004 / 026293, U.S. Pat. No. 7,579,323 (which describes a hemiasterlin analog, HTI-286), and International Publication No. WO2014 / 144871.
[0238] Exemplary calicheamicin and calicheamicin analogs and derivatives include those described in International Publication No. WO2015 / 063680, and U.S. Patent Nos. 5,773,001, 5,714,586, and 5,770,701.
[0239] Exemplary duocarmycins and duocarmycin analogs and derivatives include naturally occurring duocarmycins, such as duocarmycins A, B1, B2, C1, C2, D, and SA, as well as CC-1065, and analogs and derivatives, such as adozelesin, bizelesin, and centanamycin. Other calicheamicin analogs and derivatives are described in U.S. Patent Nos. 4,912,227, 5,070,092, 5,084,468, 5,332,837, 5,641,780, 5,739,350, and 8,889,868.
[0240] Exemplary pyrrolobenzodiazapenes (PBDs) include various PBD dimers, such as those described in U.S. Pat. Nos. 6,884,799, 7,049,311, 7,511,032, 7,528,126, 7,557,099, and 9,056,914, and in International Publication Nos. WO2007 / 085930, WO2009 / 016516, WO2011 / 130598, WO2011 / 130613, and WO2011 / 130616, and U.S. Patent Application Publication No. US2011 / 0256157.
[0241] Exemplary amatoxins include a-amanitin, b-amanitin, g-amanitin, and e-amanitin, as well as analogs and derivatives thereof. A variety of amatoxins and amatoxin analogs have been described (see, e.g., European Patent No. EP 1859811, U.S. Patent No. 9,233,173, and International Publication No. WO 2014 / 043403).
[0242] Exemplary camptothecins (CPTs) include irinotecan (CPT-11), SN-38 (7-ethyl-10-hydroxycamptothecin), 10-hydroxycamptothecin, topotecan, lurtotecan, 9-aminocamptothecin, and 9-nitrocamptothecin. Other examples of CPT analogs and derivatives include 7-butyl-10-aminocamptothecin and 7-butyl-9-amino-10,11-methylenedioxycamptothecin (see U.S. Patent Application Publication No. US2005 / 0209263), as well as the aniline-containing derivatives of these compounds described in Burke et al., 2009, Bioconj. Chem. 20(6):1242-1250 and Sharkey et al., 2012, Mol. Cancer Ther. 11:224-234.
[0243] In certain embodiments, the drug included in the ADC is a chemotherapeutic agent. In some embodiments, the drug included in the ADC is an anthracycline, such as doxorubicin, epirubicin, idarubicin, daunorubicin (also known as daunomycin), nemorubicin, or an analog or derivative thereof. Derivatization of daunorubicin and doxorubicin for conjugation to antibodies has been described (see, e.g., Kratz et al., 2006, Current Med. Chem. 13:477-523, and U.S. Patent No. 6,630,579).
[0244] Additional examples of drugs for use in ADCs include mTOR inhibitors, such as rapamycin (sirolimus) and its analogs ("rapalogs"). Rapalogs are considered to be compounds structurally related to rapamycin that retain mTOR inhibitory activity, including, for example, esters, ethers, oximes, hydrazones, and hydroxylamines of rapamycin, as well as compounds in which functional groups on the rapamycin core structure have been modified, for example, by reduction or oxidation. Exemplary rapalogs include, but are not limited to, temsirolimus (CC1779), tacrolimus (FK-506), everolimus (RAD001), deforolimus (AP23573), AZD8055 (AstraZeneca), and OSI-027 (OSI).
[0245] The selected drug may be conjugated to the antibody construct with or without a linker by any of a variety of methods known in the art. Typically, the drug is conjugated to a cysteine or lysine residue in the antibody construct by a linker, which may be cleavable or non-cleavable. Exemplary methods and linkers are provided in Antibody-Drug Conjugates, Series: Methods in Molecular Biology, Laurent Ducry (Ed.), Humana Press, 2013.
[0246] In some embodiments, antibody constructs may be expressed as fusion proteins containing tags to facilitate purification and / or testing, etc. As referred to herein, a "tag" is any series of additional amino acids provided at the C-terminus, N-terminus, or internally in a protein that contributes to the identification or purification of the protein. Suitable tags include, but are not limited to, tags known to those skilled in the art to be useful for purification and / or testing, such as albumin binding domain (ABD), His tag, FLAG tag, glutathione-S-transferase, hemagglutinin (HA), and maltose binding protein. Such tagged proteins may also be engineered to contain cleavage sites, such as thrombin, enterokinase, or factor X cleavage sites, to facilitate tag removal before, during, or after purification.
[0247] Methods for generating antibodies If desired, antibodies against a specific antigen of interest may be generated by standard techniques and used as a basis for preparing the antigen-binding domain of a 4-1BB x TAA antibody construct, e.g., for preparing a 4-1BB, FRα, NaPi2B, HER2, mesothelin, or LIV1 antigen-binding domain. Briefly, antibodies against an antigen may be prepared by immunizing rabbits with purified antigen, preparing serum from the rabbit's blood, and absorbing the serum into a normal plasma fraction to produce antibodies specific to the antigen. Monoclonal antibody preparations against the antigen may be prepared by injecting purified protein into mice, harvesting spleen and lymph node cells, fusing these cells with mouse myeloma cells, and using the resulting hybridoma cells to produce monoclonal antibodies. Both of these methods are well known in the art. In some embodiments, antibodies obtained from these methods may be humanized as described elsewhere herein.
[0248] As an alternative to humanization, human antibodies can be generated. For example, transgenic animals (e.g., mice) can be used that, upon immunization, are capable of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. See, for example, Jakobovits et al., 1993, Proc. Natl. Acad. Sci. USA 90:2551; Jakobovits et al., 1993, Nature 362:255-258; Bruggermann et al., 1993, Year in Immuno. 7:33; and U.S. Patent Nos. 5,591,669, 5,589,369, 5,545,807, 6,075,181, 6,150,584, 6,657,103, and 6,713,610.
[0249] Alternatively, phage display technology (see, e.g., McCafferty et al., 1990, Nature 348:552-553) can be used to produce human antibodies and antibody fragments in vitro from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. Phage display can be performed in a variety of formats, for reviews of which see, e.g., Johnson and Chiswell, 1993, Current Opinion in Structural Biology 3:564-571. Human antibodies can also be generated by in vitro activated B cells (see U.S. Pat. Nos. 5,567,610 and 5,229,275). Novel antibody sequences can also be generated de novo using platforms such as the HuTarg™ platform (Innovative Targeting Solutions Inc., Vancouver, Canada).
[0250] The affinity of an antibody for an antigen may be altered according to methods known in the art.
[0251] Testing of antibody constructs The ability of a 4-1BB×TAA antibody construct to bind to 4-1BB and TAA can be tested according to methods known in the art, including antigen binding assays or cell binding assays. Antigen binding assays are performed by incubating the antibody construct with either purified or mixed antigen (4-1BB or TAA) and assessing the amount of 4-1BB×TAA antibody construct bound to the antigen compared to a control. The amount of 4-1BB×TAA antibody construct bound to the antigen can be assessed, for example, by ELISA or SPR (surface plasmon resonance). Cell binding assays are performed by incubating the antibody construct with cells expressing the 4-1BB or TAA of interest (such cells are commercially available). The amount of 4-1BB×TAA antibody construct bound to the cells can be assessed, for example, by flow cytometry and compared to the binding observed in the presence of a control. Methods for performing these types of assays are well known in the art. Similar methods can be used to assess the ability of a 4-1BB antibody construct to bind to 4-1BB. Similarly, the ability of the FRα antibody construct to bind to purified FRα or FRα expressed on cells can be determined.
[0252] 4-1BB×TAA antibody constructs or 4-1BB antibody constructs may also be tested to determine whether they promote the activation of cells expressing 4-1BB. Suitable assays include the coculture assays described in the Examples, such as the NF-κB-luciferase / 4-1BB-expressing Jurkat cell assay or primary T cell coculture assay. Suitable TAA-expressing cell lines for use in these assays are readily identified by those skilled in the art. For example, to evaluate the ability of a 4-1BB×FRα antibody construct to promote 4-1BB activation in the presence of cells expressing FRα, a number of cell lines, including but not limited to, IGROV1, OVCAR3, OVKATE, NCI-H441, NCI-H661, NCI-H1975, or HCC827, may be used. These FRα-expressing cell lines are identified as FRα-expressing based on the number of receptors expressed in these cells, as measured, for example, by binding of a reference antibody to these cells in quantitative flow cytometry experiments. high , FRα mid and FRα low In some embodiments, FRα high Cells express more than approximately 500,000 FRα molecules per cell, and FRα mid expresses approximately 200,000 to 500,000 FRα molecules per cell, and low In some embodiments, the FRα gene expresses less than about 200,000 FRα molecules per cell. neg Cells where binding of the reference antibody to FRα is not detectable by flow cytometry.
[0253] The in vivo efficacy of the 4-1BB×TAA antibody construct, 4-1BB antibody construct, or FRα antibody construct may also be evaluated by standard techniques. For example, the effect of the antibody construct on tumor growth can be examined in various tumor models. Several suitable animal models are known in the art for testing the ability of candidate therapies to treat cancer, such as breast cancer or gastric cancer. Some models are commercially available. Suitable models include syngeneic or xenograft models (see below). The construct to be tested is generally administered after the tumor has established in the animal, although in some cases the construct may be administered together with a cell line. Responses, which may correlate with tumor volume, animal survival, and / or function, are monitored to determine whether the construct can treat the tumor. The construct may be administered intravenously (iv), intraperitoneally (ip), or subcutaneously (sc). Dosing schedules and amounts vary but can be easily determined by one of skill in the art. An exemplary dosage would be 10 mg / kg once weekly. Tumor growth can be monitored by standard procedures. For example, if labeled tumor cells are used, tumor growth may be monitored by appropriate imaging techniques. In the case of solid tumors, tumor size may be measured by calipers. Other responses that may indicate the efficacy of the construct may include an increase or decrease in systemic or local cytokine or chemokine responses (such as, but not limited to, IFNγ, IL-2, TNFα, CXCL8, IP-10, and RANTES); an increase or decrease in the number of immune cells (such as T, NK, NKT, B, DC, macrophages, and neutrophils); and an increase or decrease in the expression of key surface, intracellular, or nuclear proteins either on or in immune cells (such as, but not limited to, PD1, Tim3, Lag3, 4-1BB, CD163, EOMES, and TOX) or on the surface of the tumor (PDL1). It is further contemplated that these responses may also be assessed in in vitro assays, such as the immune cell co-culture assays described herein and in the Examples, to test the activity of candidate 4-1BB×TAA antibody constructs.
[0254] In vivo mouse tumor models can be syngeneic or xenograft. Syngeneic models involve transplanting a tumor from one mouse to another, provided the genetic backgrounds of the two mice are sufficiently similar that the recipient's immune system will not reject the tumor (Teicher, BA Tumor models in cancer research, Springer 2011). This can be done either directly from mouse to mouse or via stable cell lines in culture. Cell lines can be engineered using standard molecular biology techniques to express TAAs even if they are not naturally expressed, allowing for control of expression levels.
[0255] Xenograft tumor models involve the transplantation of tumors from another species (usually human) into mice. The mice are usually engineered to lack a functional adaptive immune system through a series of mutations that prevent the development of T, B, and NK cells and impair myeloid cell function, resulting in the rejection of the tumor as non-self. Common strains of mice suitable for engraftment of human tumor cells are NSG™, NOG™, and NRG mice, which express Prkdc scid or Rag1 - / - or IL2rg mutation on a NOD background (Morton et al, Cancer Research 2016;76:21 pp6153-6158). These mice can be implanted with human tumors but lack an adaptive immune system. Human tumor cells can be derived from cells that are stable in cell culture (such as OVCAR3, HCC827, IGROV1, or H1975) or from the patient from whom the tumor was removed. The immune system is then mobilized with PBMCs, T cells, or CD34 + These immune cells can then reconstitute the host with T cells to function as effectors during the experiment.
[0256] Competitive binding analysis and epitope mapping of antibody sequences The 4-1BB epitope bound by the 4-1BB antibody construct or the epitope bound by the FRα antibody construct described herein can be determined by standard competitive binding analysis (Fendly et al., Cancer Research 50:1550-1558 (1990)). For example, in the case of 4-1BB, a cross-blocking test can be performed on the antibody by direct fluorescence on intact cells engineered to express 4-1BB, using a suitable method to quantify fluorescence. Each test antibody is conjugated to fluorescein isothiocyanate (FITC) using established procedures (Wofsy et al., Selected Methods in Cellular Immunology, p. 287, Mishel and Schiigi (eds.), San Francisco: WJ Freeman Co. (1980)). Antibodies are considered to share an epitope if they each block the binding of the other by 40% or more at the same antibody concentration, compared to an irrelevant antibody control. Using this assay, one skilled in the art can identify other antibodies that bind to the same epitope as those described herein. Deletion analysis can be performed to identify the approximate location of the antigenic epitope in the 4-1BB polypeptide sequence. In a similar manner, the epitope bound by the TAA antigen-binding domain of the 4-1BB x TAA antibody construct or the FRα antibody construct can also be identified.
[0257] Pharmaceutical Composition Certain embodiments relate to pharmaceutical compositions comprising an antibody construct described herein and a pharmaceutically acceptable carrier.
[0258] The term "pharmaceutically acceptable" means approved by a federal or state regulatory agency or listed in the United States Pharmacopoeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
[0259] The term "carrier" refers to a diluent, adjuvant, excipient, vehicle, or combination thereof, with which the construct is administered. Such pharmaceutical carriers are sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. In some embodiments, the carrier is an artificial carrier not found in nature. Water can be used as a carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, nonfat dry milk, glycerol, propylene, glycol, water, ethanol, and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EW Martin.
[0260] The pharmaceutical compositions may be in the form of a solution, suspension, emulsion, tablet, pill, capsule, powder, sustained-release formulation, etc. The compositions may also be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulations may include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, etc.
[0261] The pharmaceutical composition will contain a therapeutically effective amount of the antibody construct, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.
[0262] In certain embodiments, a composition comprising an antibody construct is formulated according to routine procedures as a pharmaceutical composition suitable for intravenous administration to humans. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also contain a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the injection site. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a sealed, sealed container such as an ampoule or sachet indicating the quantity of active ingredient. When the composition is administered by infusion, it can be dispensed using an infusion bottle containing pharmaceutical-grade sterile water or saline. When the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
[0263] In certain embodiments, the compositions described herein are formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, procaine, etc.
[0264] Methods of using antibody constructs In certain embodiments, methods of treating cancer are provided, comprising administering to a subject in whom such treatment, prevention, or amelioration is desired a 4-1BBxTAA antibody construct described herein in an amount effective to treat or ameliorate the cancer. In other embodiments, methods are provided for using a 4-1BBxTAA antibody construct in the preparation of a medicament for treating, preventing, or ameliorating cancer in a subject. In additional embodiments, the 4-1BBxTAA antibody construct may be used to treat cancer in a subject in need of such treatment. The 4-1BB antibody construct and the FRα antibody construct may also be used to treat cancer, as described below.
[0265] In some embodiments, the 4-1BBxTAA antibody construct, 4-1BB antibody construct, or FRα antibody construct may be used in a subject to treat, prevent, or ameliorate a cancer selected from breast cancer, bladder cancer, colorectal cancer, head and neck cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, skin cancer, prostate cancer, kidney cancer, or thyroid cancer. In certain embodiments, the 4-1BBxTAA antibody construct may be used to treat, prevent, or ameliorate lung cancer or ovarian cancer in a subject. In certain embodiments, the 4-1BBxTAA antibody construct may be used to treat solid tumors. In embodiments where the 4-1BBxTAA is a 4-1BBxFRα antibody construct, the construct may be used to treat, prevent, or ameliorate lung cancer or ovarian cancer in a subject. In embodiments where the 4-1BBxTAA is a 4-1BBxNaPi2b antibody construct, the construct may be used to treat, prevent, or ameliorate lung cancer in a subject.
[0266] The term "subject" refers to an animal, in some embodiments a mammal, that has been the object of treatment, observation, or experiment. The animal may be a human, a non-human primate, a companion animal (e.g., dog, cat, etc.), a livestock animal (e.g., cow, sheep, pig, horse, etc.), or a laboratory animal (e.g., rat, mouse, guinea pig, etc.).
[0267] The term "mammal" as used herein includes, but is not limited to, humans, non-human primates, canines, felines, murines, bovines, equines, and porcines.
[0268] "Treatment" or "treating" refers to a clinical intervention that attempts to alter the natural course of the individual or cell being treated and may be performed during the course of clinical pathology. Desirable effects of treatment include preventing disease recurrence, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or mitigating the disease state, and achieving remission or improved prognosis. In some embodiments, the 4-1BBxTAA antibody constructs described herein are used to delay the onset of a disease or disorder in a subject. In one embodiment, the 4-1BBxTAA antibody constructs and methods described herein result in tumor regression in a subject. In one embodiment, the 4-1BBxTAA antibody constructs and methods described herein result in inhibition of tumor / cancer growth in a subject.
[0269] The term "effective amount," as used herein, refers to that amount of antibody construct administered that achieves the recited method goal, e.g., alleviates to some extent one or more of the symptoms of the disease, condition, or disorder being treated. The amount of the compositions described herein that is effective in treating, inhibiting, and preventing diseases or disorders associated with aberrant expression and / or activity of a therapeutic protein can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration and the severity of the disease or disorder, and should be determined according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
[0270] As used herein, a "therapeutically effective amount" refers to an amount that produces a desired effect when administered. In some embodiments, the term refers to an amount sufficient to treat a disease, disorder, and / or condition when administered to a population suffering from or susceptible to the disease, disorder, and / or condition according to a therapeutic dosing regimen. In some embodiments, a therapeutically effective amount is an amount that reduces the incidence and / or severity of, and / or delays the onset of, one or more symptoms of the disease, disorder, and / or condition. Those skilled in the art will understand that the term "therapeutically effective amount" does not actually require successful treatment to be achieved in a particular individual. Rather, a therapeutically effective amount may be that amount that, when administered to patients in need of such treatment, provides a specific, desired pharmacological response in a significant number of subjects. In some embodiments, reference to a therapeutically effective amount may be a reference to the amount as measured in one or more specific tissues (e.g., tissues affected by a disease, disorder, or condition) or bodily fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc.). Those skilled in the art will understand that in some embodiments, a therapeutically effective amount of a particular agent or therapy may be formulated and / or administered in a single dose, hi some embodiments, a therapeutically effective agent may be formulated and / or administered in multiple doses, for example, as part of a dosing regimen.
[0271] The 4-1BB×TAA antibody construct may be administered to a subject. Various delivery systems are known and can be used to administer the antibody construct formulations described herein, such as encapsulation in liposomes, microparticles, or microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), or construction of a nucleic acid as part of a retrovirus or other vector. Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compound or composition may be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal, and intestinal mucosa), or may be administered together with other biologically active agents. Administration may be systemic or local. Additionally, in certain embodiments, it may be desirable to introduce the antibody construct compositions described herein into the central nervous system by any suitable route, including intraventricular and intrathecal injection, which may be facilitated, for example, by an intraventricular catheter attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration may also be employed, for example, by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
[0272] In certain embodiments, it may be desirable to administer an antibody construct or composition described herein locally to the area requiring treatment, which may be achieved, for example, but not limited to, by local infusion during surgery, topical application, e.g., in combination with a wound dressing after surgery, by injection, by catheter, by suppository, or by implant, which may be a porous, non-porous, or gelatinous material, including a membrane such as a silastic membrane, or a fiber. Preferably, when administering proteins, including the antibody constructs described herein, care must be taken to use materials to which the protein does not absorb.
[0273] In another embodiment, the antibody construct or composition may be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.).
[0274] In yet another embodiment, the antibody construct or composition can be delivered in a controlled release system, in one embodiment, a pump can be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)). In another embodiment, polymeric materials may be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard et al., J. Neurosurg. 71:105 (1989)). In yet another embodiment, a controlled release system can be placed near the therapeutic target, e.g., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, In Medical Applications of Controlled Release, vol. 2, pp. 115-138 (1984)).
[0275] In certain embodiments, including nucleic acids encoding the antibody constructs described herein, the nucleic acid can be administered in vivo by constructing the nucleic acid as part of an appropriate nucleic acid expression vector to promote expression of its encoded protein and administering the vector so that it is intracellular, using means such as, for example, by use of a retroviral vector (see U.S. Pat. No. 4,980,286), by direct injection, by use of microparticle bombardment (e.g., gene gun, Biolistic, Dupont), by coating with lipids or cell surface receptors or transfection agents, or by administering the nucleic acid bound to a homeobox-like peptide known to enter the nucleus (see, e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)). Alternatively, the nucleic acid can be introduced intracellularly and incorporated into host cell DNA for expression by homologous recombination.
[0276] The amount of an antibody construct that is effective in treating, inhibiting, or preventing a disease or disorder can be determined by standard clinical techniques. In addition, in vitro assays may optionally be used to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration and the severity of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
[0277] The antibody constructs described herein may be administered alone or in combination with other alternative forms of treatment or anti-cancer therapy (e.g., radiation therapy, chemotherapy, hormone therapy, immunotherapy, bispecific antibodies, and anti-tumor agents). Generally, administration of products of species origin or species reactivity (in the case of antibodies) that is allogeneic to that of the patient's species is preferred.
[0278] In some embodiments, the antibody constructs may be used to treat patients who have received one or more alternative forms of anti-cancer therapy. In some embodiments, the patient has relapsed or failed to respond to one or more alternative forms of anti-cancer therapy. In other embodiments, the antibody constructs are administered to patients in combination with one or more alternative forms of anti-cancer therapy. In other embodiments, the antibody constructs are administered to patients who have become resistant to treatment with one or more alternative forms of anti-cancer therapy.
[0279] Kits and Products Also described herein is a kit containing one or more antibody constructs.The individual components of the kit are packaged in separate containers, and such containers may be accompanied by a notice in the form prescribed by a government agency that regulates the manufacture, use, or sale of pharmaceuticals or biological products, indicating that the notice has been approved by the agency for manufacture, use, or sale.The kit may optionally contain instructions or instructions outlining the use or administration regimen of the antibody construct.
[0280] Where one or more components of the kit are provided as a liquid solution, for example, an aqueous solution, or a sterile aqueous solution, the container means may itself be an inhaler, syringe, pipette, eye dropper, or other similar device, with which the solution may be administered to a subject or applied to and mixed with the other components of the kit.
[0281] The components of the kit may also be provided in a dried or lyophilized form, and the kit may further contain a suitable solvent for reconstituting the lyophilized components. Regardless of the number or type of container, the kits described herein may also include a device to assist in administering the composition to a patient. Such a device may be an inhaler, a nasal spray device, a syringe, a pipette, forceps, a measuring spoon, an eye dropper, or a similar medically approved delivery vehicle.
[0282] Certain embodiments relate to articles of manufacture containing materials useful for treating a patient as described herein. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, intravenous infusion bags, etc. The container may be formed from a variety of materials, such as glass or plastic. The container holds a composition comprising an antibody construct, alone or in combination with another composition effective for treating a patient, and may have a sterile access port (e.g., the container may be an intravenous infusion bag or a vial with a stopper pierceable by a hypodermic needle). The label or package insert indicates that the composition is used to treat a condition suitable for use of the composition. In some embodiments, the article of manufacture may include (a) a first container containing a composition contained in a container, the composition comprising an antibody construct described herein, and (b) a second container containing a composition contained in a container, the composition in the second container comprising an additional cytotoxic or otherwise therapeutic agent. In such embodiments, the article of manufacture may further comprise a package insert indicating that the composition can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, dextrose solution, etc. The article of manufacture may optionally further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
[0283] Polypeptides and Polynucleotides As described herein, the antibody construct comprises at least one polypeptide. Certain embodiments relate to polynucleotides encoding such polypeptides as described herein.
[0284] The antibody constructs, polypeptides, and polynucleotides described herein are typically isolated. As used herein, "isolated" refers to an agent (e.g., a polypeptide or polynucleotide) that has been identified and separated and / or recovered from components of its natural cell culture environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the antibody construct, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. Isolated also refers to an agent that has been produced synthetically, for example, by human intervention.
[0285] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. That is, a description directed to a polypeptide applies equally to a description of a peptide and a description of a protein, and vice versa. The term applies to naturally occurring amino acid polymers as well as to amino acid polymers in which one or more amino acid residues are non-naturally encoded amino acids. As used herein, the term encompasses amino acid chains of any length, including full-length proteins, in which the amino acid residues are linked by covalent peptide bonds.
[0286] The term "amino acid" refers to naturally occurring and non-naturally occurring amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally encoded amino acids are the 20 common amino acids (alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine), as well as pyrrolysine and selenocysteine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids, i.e., a carbon bonded to a hydrogen, a carboxyl group, an amino group, and an R group, such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Reference to amino acids includes, for example, naturally occurring proteinogenic L-amino acids, D-amino acids, chemically modified amino acids, such as amino acid variants and derivatives, naturally occurring non-proteinogenic amino acids, e.g., β-alanine, ornithine, and the like, as well as chemically synthesized compounds having properties characteristic of amino acids known in the art. Examples of non-naturally occurring amino acids include, but are not limited to, α-methyl amino acids (e.g., α-methylalanine), D-amino acids, histidine-like amino acids (e.g., 2-amino-histidine, β-hydroxy-histidine, homohistidine), amino acids with an additional methylene in the side chain ("homo" amino acids), and amino acids in which the carboxylic acid functionality in the side chain is replaced with a sulfonic acid group (e.g., cysteic acid). The incorporation of non-natural amino acids, including synthetic non-natural amino acids, substituted amino acids, or one or more D-amino acids, into the antibody constructs described herein can be advantageous in a number of different ways. D-amino acid-containing peptides and the like exhibit increased stability in vitro or in vivo compared to their L-amino acid-containing counterparts.Therefore, constructing peptides and the like incorporating D-amino acids can be particularly useful when greater intracellular stability is desired or required. More specifically, D-peptides and the like are resistant to endogenous peptidases and proteases, thereby improving the bioavailability of the molecule and providing a longer in vivo efficacy period when such properties are desirable. Furthermore, D-peptides and the like are less likely to induce a humoral immune response in the whole organism because they cannot be efficiently processed for major histocompatibility complex class II-restricted presentation to T helper cells.
[0287] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Similarly, nucleotides may be referred to by their commonly accepted single-letter codes.
[0288] Polynucleotides encoding the polypeptides of the antibody constructs are also included herein. The term "polynucleotide" or "nucleotide sequence" is intended to refer to a contiguous stretch of two or more nucleotide molecules. The nucleotide sequence may be of genomic, cDNA, RNA, semisynthetic or synthetic origin, or any combination thereof.
[0289] The term "nucleotide sequence" or "nucleic acid sequence" is intended to denote a contiguous stretch of two or more nucleotide molecules. The nucleotide sequence may be of genomic, cDNA, RNA, semisynthetic or synthetic origin, or any combination thereof.
[0290] "Cell," "host cell," "cell line," and "cell culture" are used interchangeably herein, and all such terms should be understood to include progeny resulting from the growth or cultivation of a cell. "Transformation" and "transfection" are used interchangeably to refer to the process of introducing a nucleic acid sequence into a cell.
[0291] The term "nucleic acid" refers to deoxyribonucleotides, deoxyribonucleosides, ribonucleosides, or ribonucleotides and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless specifically limited otherwise, the term also refers to oligonucleotide analogs, including PNAs (peptide nucleic acids), DNA analogs used in antisense technology (phosphorothioates, phosphoramidates, etc.). Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses the sequence explicitly indicated, as well as conservatively modified variants thereof (including, but not limited to, degenerate codon substitutions) and complementary sequences. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0292] "Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to a particular nucleic acid sequence, "conservatively modified variants" refers to those nucleic acids that encode the same or essentially the same amino acid sequence, or, if the nucleic acid does not encode an amino acid sequence, to essentially the same sequence. Due to the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For example, the codons GCA, GCC, GCG, and GCU all encode the amino acid alanine. Thus, at every position where alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are a type of conservatively modified variation. All nucleic acid sequences herein that encode polypeptides also encompass all possible silent variations of the nucleic acid. Those skilled in the art will understand that each codon in a nucleic acid (except AUG, which is normally the only codon for methionine, and TGG, which is normally the only codon for tryptophan) can be modified to produce a functionally identical molecule. Accordingly, each silent variation of a nucleic acid that encodes a polypeptide is implicit in each described sequence.
[0293] With respect to amino acid sequences, those skilled in the art will understand that individual substitutions, deletions, or additions to a nucleic acid, peptide, polypeptide, or protein sequence that alter, add, or delete a single amino acid or a small percentage of amino acids in the encoded sequence are "conservatively modified variants," where the alteration results in the deletion of an amino acid, the addition of an amino acid, or the substitution of an amino acid with a chemically similar amino acid.
[0294] Conservative substitution tables providing functionally similar amino acids are known to those of skill in the art. Such conservatively modified variants are in addition to, and do not exclude, polymorphic variants, interspecies homologs, and alleles described herein. The following eight groups each contain amino acids that are conservative substitutions for one another: 1) alanine (A), glycine (G), 2) aspartic acid (D), glutamic acid (E), 3) asparagine (N), glutamine (Q), 4) arginine (R), lysine (K), 5) isoleucine (I), leucine (L), methionine (M), valine (V), 6) phenylalanine (F), tyrosine (Y), tryptophan (W), 7) serine (S), threonine (T), and 8) cysteine (C), methionine (M) (see, e.g., Creighton, Proteins: Structures and Molecular Properties (W.H. Freeman & Co.; 2nd edition (December 1993)).
[0295] The term "identical" in the context of two or more nucleic acid or polypeptide sequences refers to two or more sequences or subsequences that are the same. Sequences are "substantially identical" if, when compared and aligned for closest correspondence over a comparison window, or designated region, the sequences have the same percentage of amino acid residues or nucleotides (i.e., about 60% identity, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% identity over a designated region) as measured using one of the following sequence comparison algorithms (or other algorithms available to those of skill in the art) or by manual alignment and visual inspection. This definition also refers to the complement of a test sequence. Identity can exist over a region that is at least about 50 amino acids or nucleotides in length, or over a region that is 75-100 amino acids or nucleotides in length, or, if not specified, over the entire polynucleotide or polypeptide sequence. Polynucleotides encoding the polypeptides described herein, including homologs from species other than human, may be obtained by a process comprising screening libraries under stringent hybridization conditions with a labeled probe having a polynucleotide sequence described herein, or a fragment thereof, and isolating full-length cDNA and genomic clones containing the polynucleotide sequence. Such hybridization techniques are well known to those skilled in the art.
[0296] For sequence comparison, typically, one sequence serves as a reference sequence, and this sequence is compared with test sequence.When using sequence comparison algorithm, test sequence and reference sequence are input into computer, and if necessary, partial sequence coordinates are designated, and sequence algorithm program parameters are designated.Default program parameters can be used, or alternative parameters can be designated.Then, sequence comparison algorithm calculates the percent sequence identity of test sequence compared with reference sequence based on program parameters.
[0297] A "comparison window," as used herein, includes reference to any segment of a number of contiguous positions selected from the group consisting of 20 to 600, usually about 50 to about 200, and more usually about 100 to about 150, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods for aligning sequences for comparison purposes are known to those of skill in the art. Optimal sequence alignment for comparison can be performed by means including, but not limited to, for example, the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Ausubel et al., Current Protocols in Molecular Biology (1995 supplement)).
[0298] Examples of suitable algorithms for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1997) Nuc. Acids Res. 25:3389-3402 and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available from the National Center for Biotechnology Information and available on the World Wide Web at ncbi.nlm.nih.gov. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89:10915) with alignments (B) of 50, an expectation (E) of 10, M=5, N=4, and a comparison of both strands. The BLAST algorithm is typically run with the "low complexity" filter turned off.
[0299] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, for example, Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the minimum sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences will occur by chance. For example, a nucleic acid is considered to be similar to a reference sequence if the minimum sum probability in the comparison between the test nucleic acid and the reference nucleic acid is less than about 0.2, or less than about 0.01, or less than about 0.001.
[0300] As used herein, the term "engineer," and grammatical variations thereof, is considered to include any manipulation of the peptide backbone or post-translational modification of a naturally occurring or recombinant polypeptide or fragment thereof. Engineering includes modifications of the amino acid sequence, glycosylation pattern, or individual amino acid side groups, as well as combinations of these approaches. Engineered proteins are expressed and produced by standard molecular biology techniques.
[0301] A derivative or variant of a polypeptide is said to share "homology" with, or be "homologous to," a polypeptide if the amino acid sequence of the derivative or variant has at least 50% identity with a 100-amino acid sequence from the original polypeptide. In certain embodiments, a derivative or variant is at least 75% identical to either a polypeptide or a fragment of a polypeptide having the same number of amino acid residues as the derivative. In various embodiments, a derivative or variant is at least 85%, 90%, 95%, or 99% identical to either a polypeptide or a fragment of a polypeptide having the same number of amino acid residues as the derivative.
[0302] In some embodiments, the antibody construct comprises an amino acid sequence that is at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical to the relevant amino acid sequence, or a fragment thereof, set forth in the tables or accession numbers disclosed herein. In some embodiments, the isolated antibody construct comprises an amino acid sequence encoded by a polynucleotide that is at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical to the relevant nucleotide sequence, or a fragment thereof, set forth in the tables or accession numbers disclosed herein.
[0303] Embodiment A1. An antibody construct comprising: a) a first 4-1BB binding domain that binds to the 4-1BB extracellular domain (4-1BB ECD); b) a tumor-associated antigen (TAA) antigen-binding domain that binds to a tumor-associated antigen (TAA antigen-binding domain), The antibody construct, wherein the first 4-1BB binding domain and the TAA antigen binding domain are directly or indirectly linked to a scaffold.
[0304] A2. The antibody construct of embodiment A1, wherein said first 4-1BB binding domain is a first 4-1BB antigen binding domain or a 4-1BB ligand.
[0305] A3. The antibody construct of embodiment A2, wherein the first 4-1BB antigen-binding domain binds to a first epitope of the 4-1BB ECD.
[0306] A4. The antibody construct of any one of embodiments A1 to A3, further comprising a second 4-1BB binding domain.
[0307] A5. The antibody construct of embodiment A4, wherein said second 4-1BB binding domain is a second 4-1BB antigen binding domain.
[0308] A6. The antibody construct of embodiment A5, wherein the second 4-1BB antigen binding domain binds to a second epitope of the 4-1BB ECD.
[0309] A7. The antibody construct of embodiment A5 or A6, wherein the first epitope of said 4-1BB ECD is the same as the second epitope of said 4-1BB ECD.
[0310] A8. The antibody construct of embodiment A5 or A6, wherein the first epitope of said 4-1BB ECD is different from the second epitope of said 4-1BB ECD.
[0311] A9. The antibody construct of any one of embodiments A4 to A8, wherein the first or second 4-1BB antigen binding domain binds to human and cynomolgus monkey 4-1BB.
[0312] A10. The antibody construct of any one of embodiments A4 to A9, wherein the 4-1BB antigen binding domain binds to Domain 1 or Domain 2 of 4-1BB.
[0313] A11. The antibody construct of any one of embodiments A4 to A9, wherein the 4-1BB antigen-binding domain binds to domains other than 3 and 4 of 4-1BB.
[0314] A12. The first 4-1BB binding domain is a first 4-1BB antigen binding domain comprising a heavy chain variable sequence comprising three CDRs and a light chain variable sequence comprising three CDRs, wherein the heavy chain variable sequence and the light chain variable sequence are selected from the group consisting of variants v28726, v28727, v28728, v28730, v20022, v28700, v28704, v28705, v28706, v28711, v28712, v28713, v28714, v28715, v28716, v28717, v28718, v28719, v28729, v28730, v20022, v28700, v28704, v28705, v28706, v28711, v28712, v28713, v28714, v28715, v28716, v28717, v28718, v28719, v28720, v28721, v28722, v28723, v28724, v28725, v28726, v28727, v28728, v28730, v28728, v28730, v20022, v28700, v28704, v28705, v28706, v28711, v28712, v28713, v28714, v28715, v28716, v28717, v28718, v28719, v28721, v28722, v28723, v2 0036, v28696, v28697, v28698, v28701, v28702, v28703, v28707, v20023, v28683, v28684, v28685, v28686, v28687, v28688, v28689, v28690, v28691, v28692, v28694, or v28995.
[0315] A13. The antibody construct of any one of embodiments A4 to A12, wherein the first 4-1BB antigen-binding domain and / or the second 4-1BB antigen-binding domain is in Fab format.
[0316] A14. The antibody construct of any one of embodiments A4 to A12, wherein one of the first 4-1BB antigen binding domain or the second 4-1BB antigen binding domain is in scFv format.
[0317] A15. The antibody construct of any one of embodiments A1 to A14, wherein the TAA antigen binding domain is a folate receptor-alpha (FRα) antigen binding domain, a solute carrier family 34 member 2 (NaPi2b) antigen binding domain, a HER2 antigen binding domain, a mesothelin antigen binding domain, or a solute carrier family 39 member 6 (LIV-1) antigen binding domain.
[0318] A16. The antibody construct of any one of embodiments A1 to A15, wherein the TAA antigen-binding domain is an FRα antigen-binding domain.
[0319] A17. The antibody construct of embodiment A16, wherein the FRα antigen-binding domain comprises the three heavy chain CDRs and three light chain CDRs of antibody 8K22 or 1H06.
[0320] A18. The antibody construct of embodiment A17, wherein the FRα antigen-binding domain is a human or humanized antigen-binding domain.
[0321] A19. The antibody construct of any one of embodiments A1 to A18, wherein the TAA antigen binding domain is in scFv format.
[0322] A20. The antibody construct of any one of embodiments A1 to A18, wherein said TAA antigen binding domain is in Fab format.
[0323] A21. The antibody construct of any one of embodiments A1-A20, wherein the scaffold is a dimeric Fc construct having a first Fc polypeptide and a second Fc polypeptide, each Fc polypeptide comprising a CH3 sequence, or the scaffold is a linker or albumin polypeptide.
[0324] A22. The antibody construct of embodiment A21, wherein the scaffold is a heterodimeric Fc construct having a first Fc polypeptide that is different from the second Fc polypeptide, and the CH3 sequences of the first Fc polypeptide and the second Fc polypeptide comprise amino acid substitutions that promote the formation of a heterodimeric Fc.
[0325] A23.a) one Fc polypeptide comprises the amino acid substitutions T350V_L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T350V_T366L_K392L_T394W; or b) one Fc polypeptide comprises the amino acid substitutions T350V_T366L_K392M_T394W and the other Fc polypeptide comprises the amino acid substitutions T350V_L351Y_F405A_Y407V; or c) one Fc polypeptide comprises the amino acid substitutions L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T366L_K392M_T394W; or d) one Fc polypeptide comprises the amino acid substitution L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitution T366L_K392L_T394W; or e) one Fc polypeptide comprises the amino acid substitutions L351Y_S400E_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T366I_N390R_K392M_T394W; The antibody construct of embodiment A22, wherein residue numbering is according to the EU numbering system.
[0326] A24. The antibody construct of any one of embodiments A21-A23, further comprising one or more amino acid modifications that reduce effector function.
[0327] A25. The antibody construct of any one of embodiments A21-A24, wherein the first 4-1BB antigen binding domain is linked to the N-terminus of the first Fc polypeptide and the TAA antigen binding domain is linked to the C-terminus of the first Fc polypeptide.
[0328] A26. The antibody construct of embodiment A25, further comprising a second 4-1BB antigen binding domain linked to the N-terminus of the second Fc polypeptide.
[0329] 1. An antibody construct or antigen-binding fragment thereof that specifically binds to A27.4-1BB, comprising a heavy chain variable sequence comprising three CDRs and a light chain variable sequence comprising three CDRs, wherein the heavy chain variable sequence and the light chain variable sequence are selected from the group consisting of variants v28726, v28727, v28728, v28730, v20022, v28700, v28704, v28705, v28706, v28711, v28712, v28713, The antibody construct or the antigen-binding fragment thereof is derived from any one of v20036, v28696, v28697, v28698, v28701, v28702, v28703, v28707, v20023, v28683, v28684, v28685, v28686, v28687, v28688, v28689, v28690, v28691, v28692, v28694, or v28995.
[0330] A28. Variants v28726, v28727, v28728, v28730, v20022, v28700, v28704, v28705, v28706, v28711, v28712, v28713, v20036, v28696, v28697, v28698, v28701, v28702, v28703, v28707, v20023, v28 The antibody construct of embodiment A27, comprising a VH sequence and a VL sequence that have at least 85% sequence identity to the VH sequence and the VL sequence of any one of v28683, v28684, v28685, v28686, v28687, v28688, v28689, v28690, v28691, v28692, v28694, or v28995.
[0331] A29. The antibody construct of any one of embodiments A1 to A28, which is conjugated to a drug.
[0332] A30. A pharmaceutical composition comprising an antibody construct according to any one of embodiments A1 to A29.
[0333] A31. One or more nucleic acids encoding the antibody construct of any one of embodiments A1-A28.
[0334] A32. One or more vectors comprising one or more nucleic acids of embodiment A31.
[0335] A33. An isolated cell comprising one or more nucleic acids of embodiment A31 or one or more vectors of embodiment A32.
[0336] A34. A method for preparing an antibody construct described in any one of embodiments A1 to A29, comprising culturing the isolated cell described in embodiment A33 under conditions suitable for expressing the antibody construct, and purifying the antibody construct.
[0337] A35. A method of treating a subject with cancer, comprising administering to said subject an effective amount of an antibody construct of any one of embodiments A1 to A29.
[0338] A36. Use of an effective amount of the antibody construct of any one of embodiments A1 to A29 to treat cancer in a subject in need thereof.
[0339] A37. Use of an antibody construct according to any one of embodiments A1 to A29 in the preparation of a medicament for treating cancer.
[0340] A38. The antibody construct of any one of embodiments A1 to A29 for use in treating cancer in a subject.
[0341] B1. An antibody construct comprising: a) a first 4-1BB binding domain that binds to the 4-1BB extracellular domain (4-1BB ECD); b) a first tumor-associated antigen (TAA) antigen-binding domain that binds to a tumor-associated antigen (TAA antigen-binding domain); The antibody construct, wherein the first 4-1BB binding domain and the first TAA antigen binding domain are directly or indirectly linked to a scaffold.
[0342] B2. The antibody construct of embodiment B1, wherein said first 4-1BB binding domain is a first 4-1BB antigen binding domain.
[0343] B3. The construct of embodiment B1 or B2, wherein said first 4-1BB antigen binding domain is derived from an anti-4-1BB agonist antibody.
[0344] B4.a) the first 4-1BB antigen-binding domain in monovalent form has a KD for human 4-1BB of about 1 μM to 100 pM, and / or b) the 4-1BB x TAA antibody construct binds to one or more TAA-expressing cell lines as determined by flow cytometry, and / or c) the 4-1BB x TAA antibody construct binds to human 4-1BB as measured by SPR and to the TAA as measured by SPR; and / or d) the 4-1BB x TAA antibody construct stimulates 4-1BB activity in T cells as measured by cytokine production in the presence of TAA-expressing cells, and / or e) the 4-1BB x TAA antibody construct binds to 4-1BB-expressing cells and binds to TAA-expressing cells as measured by flow cytometry, and / or f) A construct according to any one of embodiments B1 to B3, wherein the 4-1BB x TAA antibody construct is capable of stimulating 4-1BB signaling in 4-1BB-expressing cells in the presence of TAA-expressing cells.
[0345] B5. The first 4-1BB antigen-binding domain comprises: a) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 1C3 and a light chain variable domain comprising the three light chain CDRs of antibody 1C3; b) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 1C8 and a light chain variable domain comprising the three light chain CDRs of antibody 1C8; c) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 1G1 and a light chain variable domain comprising the three light chain CDRs of antibody 1G1; d) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 2E8 and a light chain variable domain comprising the three light chain CDRs of antibody 2E8; e) an antibody The antibody construct of any one of embodiments B1 to B4, comprising: a heavy chain variable domain comprising the three heavy chain CDRs of antibody 3E7, and a light chain variable domain comprising the three light chain CDRs of antibody 3E7; f) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 4E6, and a light chain variable domain comprising the three light chain CDRs of antibody 4E6; g) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 5G8, and a light chain variable domain comprising the three light chain CDRs of antibody 5G8; or h) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 6B3, and a light chain variable domain comprising the three light chain CDRs of antibody 6B3.
[0346] B6. The antibody construct of any one of embodiments B1-B5, wherein the first 4-1BB antigen-binding domain is a human or humanized antigen-binding domain.
[0347] B7. The first 4-1BB antigen binding domain is: a) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28726 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28726; b) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28727 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28727; c) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28728 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28728; d) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28730 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28730; e) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28700 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28700; f) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28704 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28704; g) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28705 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28705; h) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28706 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28706; i) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28711 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28711; j) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28712 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28712; k) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28713 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28713; l) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28696 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28696; m) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28697 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28697; n) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28698 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28698; o) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28701 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28701; p) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28702 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28702; q) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28703 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28703; r) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28707 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28707; s) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28683 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28683; t) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28684 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28684; u) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28685 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28685; v) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28686 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28686; w) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28687 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28687; x) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28688 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28688; y) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28689 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28689; z) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28690 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28690; aa) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28691 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28691; ab) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28692 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28692; ac) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28694 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28694; or ad) An antibody construct according to embodiment B6, comprising a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v28695 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v28695.
[0348] B8. The antibody construct of any one of embodiments B1 to B7, further comprising a second 4-1BB binding domain.
[0349] B9. The antibody construct of any one of embodiments B1 to B8, wherein said second 4-1BB binding domain is a second 4-1BB antigen binding domain.
[0350] B10. The antibody construct of embodiment B9, wherein the second 4-1BB antigen binding domain is the same as the first 4-1BB antigen binding domain.
[0351] B11. The antibody construct of embodiment B10, wherein the first 4-1BB antigen binding domain and / or the second 4-1BB antigen binding domain is in Fab format.
[0352] B12. The antibody construct of any one of embodiments B1-B11, wherein the TAA antigen binding domain is a folate receptor-alpha (FRα) antigen binding domain, a solute carrier family 34 member 2 (NaPi2b) antigen binding domain, a HER2 antigen binding domain, a mesothelin antigen binding domain, or a solute carrier family 39 member 6 (LIV-1) antigen binding domain.
[0353] B13. The antibody construct of any one of embodiments B1-B12, comprising a second TAA antigen binding domain.
[0354] B14. The antibody construct of embodiment B13, wherein the first and second TAA antigen binding domains bind to the same TAA.
[0355] B15. The antibody construct of any one of embodiments B1-B14, wherein said first TAA antigen binding domain is a FRα antigen binding domain.
[0356] B16. The antibody construct of embodiment B15, wherein the FRα antigen-binding domain comprises: a) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 8K22 and a light chain variable domain comprising the three light chain CDRs of antibody 8K22; or b) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 1H06 and a light chain variable domain comprising the three light chain CDRs of antibody 1H06.
[0357] B17. The antibody construct of embodiment B16, wherein the FRα antigen-binding domain is a human or humanized antigen-binding domain.
[0358] B18. The FRα antigen-binding domain is: a) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23794 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23794; b) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23795 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23795; c) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23796 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23796; d) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23797 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23797; e) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23798 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23798; f) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23799 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23799; g) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23800 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23800; h) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23801 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23801; i) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23802 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23802; j) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23803 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23803; k) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23804 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23804; l) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23805 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23805; m) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23806 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23806; n) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23807 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23807; o) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23808 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23808; p) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23809 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23809; q) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23810 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23810; r) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23811 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23811; s) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23812 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23812; t) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23813 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23813; u) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23814 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23814; v) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23815 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23815; w) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23816 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23816; x) a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23817 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23817; or y) An antibody construct according to embodiment B17, comprising a heavy chain variable domain (VH) sequence that is at least 85% identical to the VH sequence of v23818 and a light chain variable domain (VL) sequence that is at least 85% identical to the VL sequence of v23818.
[0359] B19. The antibody construct of any one of embodiments B1-B18, wherein said TAA antigen binding domain is in scFv format.
[0360] B20. The antibody construct of any one of embodiments B1-B18, wherein said TAA antigen binding domain is in Fab format.
[0361] B21. The antibody construct of any one of embodiments B1-B20, wherein the scaffold is a dimeric Fc construct having a first Fc polypeptide and a second Fc polypeptide, each Fc polypeptide comprising a CH3 sequence, or the scaffold is a linker or albumin polypeptide.
[0362] B22. The antibody construct of embodiment B21, wherein the scaffold is a heterodimeric Fc construct having a first Fc polypeptide that is different from the second Fc polypeptide, and the CH3 sequences of the first Fc polypeptide and the second Fc polypeptide comprise amino acid substitutions that promote heterodimeric Fc formation.
[0363] B23.a) one Fc polypeptide comprises the amino acid substitution T350V_L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitution T350V_T366L_K392L_T394W, or b) one Fc polypeptide comprises the amino acid substitutions T350V_T366L_K392M_T394W and the other Fc polypeptide comprises the amino acid substitutions T350V_L351Y_F405A_Y407V; or c) one Fc polypeptide comprises the amino acid substitutions L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T366L_K392M_T394W; or d) one Fc polypeptide comprises the amino acid substitution L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitution T366L_K392L_T394W; or e) one Fc polypeptide comprises the amino acid substitutions L351Y_S400E_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T366I_N390R_K392M_T394W; The antibody construct of embodiment B22, wherein residue numbering is according to the EU numbering system.
[0364] B24. The antibody construct of any one of embodiments B21 or B23, further comprising one or more amino acid modifications that reduce effector function.
[0365] B25. The antibody construct of embodiment B24, wherein the one or more amino acid modifications are L234A, L235A and D265S, and wherein residue numbering is according to the EU numbering system.
[0366] B26. The antibody construct of any one of embodiments B1-B25, wherein the first 4-1BB antigen binding domain is linked to the N-terminus of the first Fc polypeptide and the first TAA antigen binding domain is linked to the C-terminus of the first Fc polypeptide.
[0367] B27. The antibody construct of any one of embodiments B1-B25, wherein the first 4-1BB antigen binding domain is linked to the N-terminus of a first Fc polypeptide and the first TAA antigen binding domain is linked to the C-terminus of a second Fc polypeptide.
[0368] B28. The antibody construct of embodiment B26 or B27, further comprising a second 4-1BB antigen binding domain linked to the N-terminus of said second Fc polypeptide.
[0369] B29. The antibody construct of any one of embodiments B1-B25, comprising a first 4-1BB antigen binding domain linked to the N-terminus of the first Fc polypeptide, a second 4-1BB antigen binding domain linked to the N-terminus of the second Fc polypeptide, a first TAA antigen binding domain linked to the C-terminus of the first Fc polypeptide, and a second TAA antigen binding domain linked to the C-terminus of the second Fc polypeptide.
[0370] B30. The antibody construct of any one of embodiments B1-B25, comprising a first 4-1BB antigen binding domain linked to the N-terminus of the first Fc polypeptide or to the N-terminus of the second Fc polypeptide, a first TAA antigen binding domain linked to the C-terminus of the first Fc polypeptide, and a second TAA antigen binding domain linked to the C-terminus of the second Fc polypeptide.
[0371] B31. The antibody construct of any one of embodiments B1 to B30, wherein the first and / or second 4-1BB antigen-binding domain comprises a heavy chain variable domain comprising the three heavy chain CDRs of antibody 1G1 and a light chain variable domain comprising the three light chain CDRs of antibody 1G1, and the first and / or second FRα antigen-binding domain comprises a heavy chain variable domain comprising the three heavy chain CDRs of antibody 8K22 and a light chain variable domain comprising the three light chain CDRs of antibody 8K22.
[0372] B32. The antibody construct of embodiment B31, wherein the first and second 4-1BB antigen-binding domains comprise a heavy chain variable domain (VH) sequence at least 85% identical to the VH sequence of v28614 and a light chain variable domain (VL) sequence at least 85% identical to the VL sequence of v28614, and the first and / or second FRα antigen-binding domain comprises a VH sequence at least 85% identical to the heavy chain variable domain (VH) sequence of v23807 and a VL sequence at least 85% identical to the VL sequence of v23807.
[0373] B33. The antibody construct of embodiment B32, comprising a first heavy chain polypeptide sequence set forth in SEQ ID NO:353, a second heavy chain polypeptide sequence set forth in SEQ ID NO:349, and a light chain polypeptide sequence set forth in SEQ ID NO:346.
[0374] B34. The antibody construct of any one of embodiments B1-B33, which is conjugated to a drug.
[0375] B35. A pharmaceutical composition comprising an antibody construct according to any one of embodiments B1 to B33.
[0376] B36. One or more nucleic acids encoding the antibody construct of any one of embodiments B1-B34.
[0377] B37. One or more vectors comprising one or more nucleic acids of embodiment B36.
[0378] B38. An isolated cell comprising one or more nucleic acids of embodiment B36 or one or more vectors of embodiment B37.
[0379] B39. A method for preparing an antibody construct according to any one of embodiments B1 to B34, comprising culturing the isolated cell according to embodiment B38 under conditions suitable for expressing the antibody construct, and purifying the antibody construct.
[0380] B40. A method of treating a subject with cancer, comprising administering to said subject an effective amount of an antibody construct of any one of embodiments B1 to B34.
[0381] B41. Use of an effective amount of the antibody construct of any one of embodiments B1 to B34 for treating cancer in a subject in need thereof.
[0382] B42. Use of an antibody construct according to any one of embodiments B1 to B34 in the preparation of a medicament for treating cancer.
[0383] B43. The antibody construct of any one of embodiments B1 to B34 for use in treating cancer in a subject.
[0384] An antibody construct or antigen-binding fragment thereof that specifically binds to C1.4-1BB, comprising a heavy chain variable sequence comprising three heavy chain CDRs and a light chain variable sequence comprising three light chain CDRs, wherein the heavy chain CDRs and the light chain CDRs are derived from any one of antibodies 1G1, 1B2, 1C3, 1C8, 2A7, 2E8, 2H9, 3D7, 3H1, 3E7, 3G4, 4B11, 4E6, 4F9, 4G10, 5E2, 5G8, or 6B3.
[0385] The antibody construct of embodiment C1, which stimulates C2.4-1BB.
[0386] C3. The antibody construct of embodiment C2, wherein the antibody construct comprises a heavy chain variable (VH) sequence comprising three CDRs and a light chain variable (VL) sequence comprising three CDRs, and the heavy chain CDRs and the light chain CDRs are derived from any one of antibodies 1G1, 1C3, 1C8, 2E8, 3E7, 4E6, 5G8, or 6B3.
[0387] C4. The antibody construct of any one of embodiments C1-C3, wherein the antibody or antigen-binding fragment is or comprises a humanized antibody.
[0388] C5. Variants v28726, v28727, v28728, v28730, v28700, v28704, v28705, v28706, v28711, v28712, v28713, v28696, v28697, v28698, v28701, v28702, v28703, v28707, v28683, v28684, An antibody construct described in embodiment C1 or C2, comprising VH and VL sequences that have at least 85% sequence identity to the VH and VL sequences of any one of v28685, v28686, v28687, v28688, v28689, v28690, v28691, v28692, v28694, or v28695.
[0389] C6. The antibody or antigen-binding fragment has a binding affinity (K) for human 4-1BB molecules of about 10 nM to about 500 nM. D The antibody construct of any one of embodiments C1 to C5, having the following structure:
[0390] C7. The antibody construct of any one of embodiments C1-C6, wherein the antibody or antigen-binding fragment binds to an epitope within the extracellular domain of human 4-1BB polypeptide.
[0391] C8. The antibody construct of any one of embodiments C1-C7, wherein the antibody construct comprises an immunoglobulin constant domain, wherein the constant domain is derived from an IgG1 or variant thereof, an IgG2 or variant thereof, an IgG4 or variant thereof, an IgA or variant thereof, an IgE or variant thereof, an IgM or variant thereof, or an IgD or variant thereof.
[0392] C9. The antibody construct of any one of embodiments C1-C8, wherein the antibody is or comprises a human IgG1.
[0393] C10. The antibody construct of any one of embodiments C1-C9, wherein the antibody or antigen-binding fragment is a monoclonal antibody.
[0394] C11. The antibody construct of any one of embodiments C1 to C7, wherein the antibody fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an Fv fragment, an scFv fragment, a single domain antibody, or a diabody.
[0395] C12. The antibody construct of any one of embodiments C1-C11, which is conjugated to a drug.
[0396] C13. A pharmaceutical composition comprising the antibody construct of any one of embodiments C1 to C12.
[0397] C14. One or more nucleic acids encoding the antibody construct of any one of embodiments C1-C11.
[0398] C15. One or more vectors comprising one or more nucleic acids of embodiment C14.
[0399] C16. An isolated cell comprising one or more nucleic acids of embodiment C14, or one or more vectors of embodiment C15.
[0400] C17. A method for preparing an antibody construct described in any one of embodiments C1 to C12, comprising culturing the isolated cell described in embodiment C16 under conditions suitable for expressing the antibody construct, and purifying the antibody construct.
[0401] C18. A method of treating a subject having cancer, comprising administering to said subject an effective amount of the antibody construct of any one of embodiments C1 to C12.
[0402] C19. Use of an effective amount of the antibody construct of any one of embodiments C1 to C12 to treat cancer in a subject in need thereof.
[0403] C20. Use of an antibody construct of any one of embodiments C1 to C12 in the preparation of a medicament for treating cancer.
[0404] C21. The antibody construct of any one of embodiments C1-C12 for use in treating cancer in a subject.
[0405] An antibody construct or its antigen-binding fragment that specifically binds to D1.FRα, comprising a heavy chain variable (VH) sequence comprising three CDRs and a light chain variable (VL) sequence comprising three CDRs, wherein the heavy chain CDRs and the light chain CDRs are derived from antibody 8K22 or 1H06.
[0406] D2. The anti-FRα antibody or antigen-binding fragment of embodiment D1, wherein the antibody or antigen-binding fragment thereof is or comprises a humanized antibody.
[0407] D3. The anti-FRα antibody or antigen-binding fragment of embodiment D1 or D2, comprising VH and VL sequences that have at least 85% sequence identity to the VH and VL sequences of any one of variants 23794, 23795, 23796, 23797, 23798, 23799, 23800, 23801, 23802, 23803, 23804, 23805, 23806, 23807, 23808, 23809, 23810, 23811, 23812, 23813, 23814, 23815, 23816, 23817, or 23818.
[0408] D4. An anti-FRα antibody or antigen-binding fragment of embodiment D1 or D2, comprising a VH sequence having at least 85% sequence identity to the VH sequence set forth in SEQ ID NO:300, and a VL sequence having at least 85% sequence identity to the VL sequence set forth in SEQ ID NO:301.
[0409] D5. Binding affinity (K) for human FRα molecules of approximately 100 pM to approximately 100 nM D The anti-FRα antibody or antigen-binding fragment of any one of embodiments D1 to D4, having the following structure:
[0410] D6. The anti-FRα antibody or antigen-binding fragment of any one of embodiments D1-D5, wherein the antibody comprises an immunoglobulin constant domain, and the constant domain is selected from IgG1 or a variant thereof, IgG2 or a variant thereof, IgG4 or a variant thereof, IgA or a variant thereof, IgE or a variant thereof, IgM or a variant thereof, and IgD or a variant thereof.
[0411] D7. The anti-FRα antibody or antigen-binding fragment of any one of embodiments D1-D6, wherein the antibody is or comprises a human IgG1.
[0412] D8. The anti-FRα antibody or antigen-binding fragment of any one of embodiments D1-D7, which is a monoclonal antibody.
[0413] D9. The anti-FRα antibody or antigen-binding fragment of any one of embodiments D1 to D8, wherein the antibody fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an Fv fragment, an scFv fragment, a single domain antibody, or a diabody.
[0414] D10. The antibody construct of any one of embodiments D1-D9, which is conjugated to a drug.
[0415] D11. A pharmaceutical composition comprising an antibody construct according to any one of embodiments D1 to D10.
[0416] D12. One or more nucleic acids encoding the antibody construct of any one of embodiments D1-D9.
[0417] D13. One or more vectors comprising one or more nucleic acids of embodiment D12.
[0418] D14. An isolated cell comprising one or more nucleic acids of embodiment D12, or one or more vectors of embodiment D13.
[0419] D15. A method for preparing an antibody construct according to any one of embodiments D1 to D10, comprising culturing the isolated cell according to embodiment D14 under conditions suitable for expressing the antibody construct, and purifying the antibody construct.
[0420] D16. A method of treating a subject with cancer, comprising administering to said subject an effective amount of an antibody construct of any one of embodiments D1 to D10.
[0421] D17. Use of an effective amount of the antibody construct of any one of embodiments D1 to D10 for treating cancer in a subject in need thereof.
[0422] D18. Use of an antibody construct according to any one of embodiments D1 to D10 in the preparation of a medicament for treating cancer.
[0423] D19. The antibody construct of any one of embodiments D1-D10 for use in treating cancer in a subject. [Example]
[0424] The following are examples of specific embodiments related to the antibody constructs described herein. The examples are provided for illustrative purposes only and are not intended to limit the scope of the present disclosure in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.
[0425] The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA technology, and pharmacology, within the skill of one of ordinary skill in the art. Such techniques are explained fully in the literature, e.g., T.E. Creighton, Proteins: Structures and Molecular Properties (W.H. Freeman and Company, 1993); A.L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990); Carey and Sundberg Advanced Organic Chemistry 3 rd Ed. (Plenum Press) Vols A and B (1992).
[0426] Example 1: Design and preparation of an exemplary 4-1BB x HER2 bispecific antibody construct A number of exemplary bispecific antibody constructs (or bispecific antibodies) targeting 4-1BB and TAA HER2, as well as controls, were constructed as described below. The antibodies and controls were prepared in different exemplary formats, as shown in Figure 2. These antibody constructs were prepared to test the potential for conditional agonism of 4-1BB and the optimal format for the activity of the 4-1BB x HER2 construct.
[0427] Design of an exemplary bispecific antibody construct targeting 4-1BB and HER2 Bispecific antibody constructs were prepared in a format in which the HER2 antigen-binding domain was an scFv and the 4-1BB antigen-binding domain was a Fab. Constructs, including controls, contained an IgG1 Fc unless otherwise indicated (see Table 1). These bispecific antibody constructs contained a human IgG1 heterodimeric Fc with a set of CH3 domain amino acid substitutions that promote heterodimeric Fc formation. These sets of amino acid substitutions are referred to herein as Het FcA (with amino acid substitutions T350V / L351Y / F405A / Y407V) and Het FcB (with amino acid substitutions T350V / T366L / K392L / T394W). Variants with these sets of amino acid substitutions are referred to in Table 1 as having "Het Fc" modifications. Variants in Table 1 noted as having "FcKO" have the following CH2 amino acid substitutions that knock out FcγR binding: L234A, L235A, and D265S. The amino acid residues of the Fc region are identified according to the EU index.
[0428] Bivalent, trivalent, and tetravalent antibody constructs were generated, all having three polypeptide chains: one heavy chain containing a Het FcA mutation, a second heavy chain containing a Het FcB mutation, and one light chain. The heavy chains were constructed in a series of formats, all consisting of one or two anti-4-1BB antigen-binding domains in Fab format and a single anti-HER2 antigen-binding domain in scFv format. These heavy chain formats are listed below, from N- to C-terminus: - VL-VH-VH-CH1-hinge-CH2-CH3 - VH-CH1-hinge-CH2-CH3-VL-VH - VH-CH1-hinge-CH2-CH3 - VL-VH-hinge-CH2-CH3
[0429] Table 1 provides a description of the 4-1BB x HER2 bispecific antibody constructs that were prepared. The number of 4-1BB targeting domains and HER2 targeting domains is indicated in the "Format" column. For example, in Table 1, 1 x 1 indicates that the bispecific antibody construct has one 4-1BB binding domain and one HER2 binding domain, 2 x 1 indicates that the bispecific antibody construct has two 4-1BB binding domains and one HER2 binding domain, etc. The formats of certain bispecific antibody constructs described below are also shown in Figure 3.
[0430] Table 1: Exemplary bispecific antibody constructs targeting 4-1BB and HER2 TIFF0007596263000010.tif167166
[0431] The VH and VL sequences used to construct the 4-1BB antigen-binding domain of the constructs are provided in Table 15, as are the scFv sequences used to construct the HER2 scFv-containing constructs. Table X identifies the clones that make up each of the antibody constructs. The polypeptide sequence of each clone can be found in Table Y.
[0432] Production of 4-1BB×HER2 bispecific antibodies To enable the production of bispecific antibodies, a heavy chain vector containing a 5'-EcoRI restriction site-signal peptide-heavy chain clone ending at G446 (EU numbering) of CH3-TGA stop-BamH1 cleavage site-3' was ligated into the pTT5 vector to generate a heavy chain expression vector. A light chain vector containing a 5'-EcoRI cleavage site-signal peptide-light chain-TGA stop-BamH1 cleavage site-3' was ligated into the pTT5 vector (Durocher Y et al., Nucl. Acids Res. 2002;30, No.2 e9) to generate a light chain expression vector. The resulting heavy and light chain expression vectors were sequenced to confirm the correct reading frame and sequence of the coding DNA. Two signal peptides, i.e., artificially designed sequences, were inserted. TIFF0007596263000011.tif4128 (Barash S et al., Biochem and Biophys Res. Comm. 2002;294,835-842) or HLA-A signal peptide One of the following files was used: TIFF0007596263000012.tif4128.
[0433] The variant heavy and light chains were expressed in 200 ml CHO-3E7 cell cultures. CHO-3E7 cells were cultured at 1.7–2 × 10 6Cells were grown at a density of 100 cells / ml in FreeStyle™ F17 medium (Thermo Fisher, Watham, MA) supplemented with 4 mM glutamine (GE Life Sciences, Marlborough, MA) and 0.1% Kolliphor P188 (Sigma-Aldrich, St. Louis, MO) at 37°C. A total volume of 200 ml was transfected with a total of 200 μg of DNA (100 μg of variant DNA and 100 μg of GFP / AKT / stuffer DNA) using PEI-max (Polyscience, Philadelphia, PA) at a DNA:PEI ratio of 1:4 (w / w). Twenty-four hours after addition of the DNA-PEI mixture, 0.5 mM valproic acid (final concentration) + 1% w / v tryptone (final concentration) + 1x antibiotic / antimycotic (GE Life Sciences, Marlborough, MA) was added to the cells, and the cells were then transferred to 32°C and incubated for 7 days before harvesting.
[0434] Clarified supernatant samples were incubated in batch with NaOH-washed MabSelect™ SuRe™ resin (GE Healthcare, Chicago, IL) and equilibrated in DPBS. The resin was poured into a washed column, the column was washed with DPBS, and the protein was eluted with 100 mM sodium citrate buffer (pH 3.0). The eluted antibody was pH-adjusted by adding 10% (v / v) 1 M HEPES (pH 8) to a final pH of 6–7. The sample was buffer-exchanged into PBS and sterile-filtered. Protein was quantified based on A280 nm (NanoDrop™). Endotoxin levels were determined using the Endosafe® Portable system (Charles River, Wilmington, MA). For samples exceeding 0.1 EU / mg, endotoxin removal was performed using a Proteus NoEndo™ spin column (Charles River, Wilmington, MA).
[0435] After Protein A purification, samples were either buffer exchanged into DPBS and sterile filtered or subjected to SEC purification depending on their homogeneity as assessed by UPLC-SEC. Samples were loaded onto a Superdex200 10 / 30 Increase column (GE Healthcare Life Sciences, Marlborough, MA) on an Akta Avant 25 chromatography system (GE Healthcare Life Sciences, Marlborough, MA) at a flow rate of 0.5 mL / min in DBPS. Eluted protein fractions were collected based on A280 nm, and fractions were evaluated by non-reduced and reduced High Throughput Protein Express assays using a Caliper LabChip GXII (Perkin Elmer, Waltham, MA). The procedure was performed according to the LabChip GXII user manual in the HT Protein Express LabChip User Guide Version 2, with the following modifications. Antibody samples were added in either 2 μl or 5 μl (concentration range 5-2000 ng / μl) to separate wells of a 96-well plate (BioRad, Hercules, CA) along with 7 μl of HT Protein Express Sample Buffer (Perkin Elmer #760328). Antibody samples were then denatured at 70°C for 15 minutes. The LabChip instrument was operated using the HT Protein Express Chip (Perkin Elmer, Waltham, MA) and the Ab-200 assay setup.
[0436] Endotoxin levels were determined by LAL (limulus amebocyte lysate) assay using the Endosafe® Portable Test System (PTS, Charles River, Wilmington, MA). Protein was quantified based on protein A and A280nm (Nanodrop) after SEC.
[0437] UPLC-SEC was performed using a Waters Acquity BEH200 SEC column (2.5 mL, 4.6 × 150 mm, stainless steel, 1.7 μm particles) (Waters LTD, Mississauga, ON) mounted on a Waters Acquity UPLC H-Class Bio system set at 30 °C with a PDA detector. The run time was 7 min, with a total volume of 2.8 mL per injection, using a running buffer of DPBS or DPBS containing 0.02% Tween 20 (pH 7.4) at 0.4 mL / min. Elution was monitored by UV absorbance in the range of 210–500 nm, and chromatograms were extracted at 280 nm. Peak integration was performed using Empower3 software.
[0438] Bispecific antibody purity assessment by LC / MS The apparent purity of the variants was assessed using mass spectrometry after purification and native deglycosylation as described below.
[0439] Because the antibody contained only Fc N-linked glycans, the sample was treated with only one enzyme, N-glycosidase F (PNGase-F). The purified sample was deglycosylated with PNGase-F as follows: 0.1 U PNGase-F / μg antibody in 50 mM Tris-HCl (pH 7.0), overnight incubation at 37°C, and a final protein concentration of 0.48 mg / mL. After deglycosylation, the sample was stored at 4°C before LC-MS analysis.
[0440] Deglycosylated protein samples were analyzed by intact LC-MS using an Agilent 1100 HPLC system coupled to an LTQ-Orbitrap XL mass spectrometer (ThermoFisher, Waltham, MA) with an Ion Max electrospray source. Samples (5 μg) were injected onto a 2.1 × 30 mm Poros R2 reverse-phase column (Applied Biosystems) and resolved using the following gradient conditions: 0–3 min: 20% solvent B; 3–6 min: 20–90% solvent B; 6–7 min: 90–20% solvent B; 7–9 min: 20% solvent B. Solvent A was degassed with 0.1% aqueous formic acid, and solvent B was degassed with acetonitrile. The flow rate was 3 mL / min. The flow rate was split post-column, with 100 μL / mL directed to the electrospray interface. The column was heated to 82.5 °C, and the solvent was preheated to 80 °C to improve protein peak shape. Prior to analysis, the LTQ-Orbitrap XL was calibrated using LTQ Positive Ion ESI calibration solution (caffeine, MRFA, and Ultramark 1621) from ThermoFisher Scientific and adjusted for optimal detection of larger proteins (>50 kDa) using a 1 mg / mL lactalbumin solution. The cone voltage (source fragmentation setting) was approximately 40 V, the FT resolution was 7,500, and the scan range was m / z 400–4,000. The LC-MS system was evaluated for IgG sample analysis using a deglycosylated antibody standard mixture (25:75 half antibody:full antibody) in addition to a deglycosylated IgG standard (Waters IgG standard).
[0441] For each LC-MS analysis, mass spectra acquired across the entire antibody peak (typically 3.6–4.1 min) were summed, and the entire multiply charged ion envelope (m / z 1,400–4,000) was deconvoluted into molecular weight profiles using the MaxEnt 1 module of MassLynx™ (Waters LTD, Mississauga, ON), an instrument control and data analysis software. Briefly, raw protein LC-MS data were first opened in QualBrowser (Thermo Fisher, Waltham, MA), the spectral display module of Xcalibur™, and then converted to MassLynx™ compatibility using Databridge™, a file conversion program provided by Waters. The converted protein spectra were displayed in the MassLynx™ spectral module and deconvoluted using MaxEnt 1. The apparent abundance of each antibody species in each sample was determined from their peak heights in the resulting molecular weight profile. In most cases, the antibodies contained more than 95% of the desired construct and were free of major glycovariants.
[0442] Example 2: Ability of 4-1BB x HER2 bispecific antibody constructs to bind 4-1BB and HER2 as assessed by surface plasmon resonance (SPR) To confirm the production and characterization of the 4-1BB×HER2 bispecific antibodies described in Example 1, the ability of these antibodies to bind to human 4-1BB and HER2 was assessed by SPR. In addition to the 4-1BB×HER2 bispecific variants 16601, 16605, 16675, and 16679, a control antibody variant 19353 (with two anticalin domains at the C-terminus of both heavy chains that bind trastuzumab, 4-1BB) was evaluated.
[0443] 4-1BB binding to antibody by SPR Surface plasmon resonance (SPR) binding assays to determine 4-1BB binding affinity for 4-1BB antibody variants were performed on a Biacore™ T200 instrument (GE Healthcare, Mississauga, ON, Canada) at 25°C using a PBS-T (PBS + 0.05% (v / v) Tween 20) running buffer (0.5 M EDTA stock solution was added to a final concentration of 3.0 mM). CM5 Series S sensor chips, Biacore™ amine coupling kit (NHS, EDC, and 1 M ethanolamine), and 10 mM sodium acetate buffer were all purchased from GE Healthcare. PBS running buffer containing 0.05% Tween 20 (PBS-T) was purchased from Teknova Inc. (Hollister, CA). Goat polyclonal anti-human Fc antibody was purchased from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA).
[0444] SPR binding of the antibody to the 4-1BB antigen was performed in two steps: indirect capture of the antibody onto an anti-human Fc-specific polyclonal antibody surface, followed by injection of five concentrations of purified human monomeric 4-1BB (SEQ ID NO:70). Monomeric 4-1BB protein was generated by cleaving a 4-1BB-Fc fusion protein (v16730). 4-1BB-Fc was expressed similarly to the antibody in Example 1 above and purified with Protein A. The construct contained a factor Xa cleavage site between 4-1BB and Fc, and was generated with a 10xHis tag at the c-terminus of Fc.
[0445] v16730 in dPBS was buffer exchanged into factor Xa cleavage buffer (20 mM Tris, 100 mM NaCl, 2 mM CaCl2 (pH 8)) using a 5 mL Zeba spin column (ThermoFisher) and cleaved overnight at room temperature with 0.45% (w / w) factor Xa (New England Biolabs, Whitby, ON, Canada). The cleavage reaction was stopped by adding 1,5-dansyl-Glu-Gly-Arg-chloromethylketone (Calbiochem, San Diego, California, USA) as an inhibitor at a final concentration of 0.372 μM. Successful cleavage was verified by NR+R SDS-PAGE. The cleavage reaction mixture was then loaded onto a 1 mL HiTrap Ni Sepharose Excel (GE Healthcare) column equilibrated with dPBS, and the column was washed with 5 CV dPBS. The cleaved 41BB protein was collected in the flow-through fraction. Residual Fc was removed using Protein A purification by applying the protein sample to mAb Select SuRe by gravity. The flow-through was loaded onto a Superdex 200 10 / 30 column equilibrated with dPBS. Fractions corresponding to the major 41BB product were collected and used for SPR.
[0446] Anti-human Fc surfaces were prepared on CM5 Series S sensor chips by standard amine coupling methods as described by the manufacturer (GE Healthcare). Briefly, immediately after EDC / NHS activation, a 25 μg / mL solution of anti-human Fc in 10 mM NaOAc (pH 4.5) was injected for 420 seconds at a flow rate of 10 μL / min until approximately 2000 resonance units (RU) were immobilized on all four flow cells. Remaining active groups were quenched by injecting 1 M ethanolamine at 10 μL / min for 420 seconds.
[0447] The antibody for analysis was captured onto the anti-Fc surface by injecting a 5 μg / mL solution at a flow rate of 10 μL / min for 60 seconds. Using single-cycle kinetics, a two-fold dilution series of five concentrations of 4-1BB (for both supernatant and purified antibody runs) starting at 40 nM, including a blank buffer control, was injected sequentially at 40 μL / min for 180 seconds with a 600-second dissociation phase, resulting in a series of sensorgrams including a buffer blank reference. Experiments were performed at a constant temperature of 25°C. The anti-human Fc surface was regenerated and prepared for the next injection cycle by a single injection of 10 mM glycine / HCl (pH 1.5) at 40 μL / min for 120 seconds. Blank-subtracted sensorgrams were analyzed using Biacore™ T200 Evaluation Software v3.0. The blank-subtracted sensorgrams were then fitted to a 1:1 Langmuir binding model.
[0448] HER2 binding to antibodies by SPR Anti-Fc capture chips were prepared as described above, and then 50 μg / ml of analytical antibody was injected over the chip for 60 seconds at a flow rate of 10 μL / min. Using single-cycle kinetics, five 2-fold dilution series (for both supernatant and purified antibody runs) of HER2 (recombinant human Her-2, containing amino acids 23-652, eBioscience) starting at 40 nM, including a blank buffer control, were injected sequentially at 50 μL / min for 180 seconds with a dissociation phase of 1800 seconds, resulting in a series of sensorgrams including a buffer blank reference. Experiments were performed at a constant temperature of 25°C. The anti-human Fc surface was regenerated and prepared for the next injection cycle by a single injection of 10 mM glycine / HCl (pH 1.5) at 40 μL / min for 120 seconds. Blank-subtracted sensorgrams were analyzed using Biacore™ T200 Evaluation Software v3.0. The blank-subtracted sensorgrams were then fitted to a 1:1 Langmuir binding model to obtain the ka, kd and KD values shown in Table 2 below.
[0449] Table 2: Ability of bispecific antibody constructs to bind to targets TIFF0007596263000013.tif32157
[0450] Table 2 shows that antibodies of different formats can still bind to their targets with similar affinity, regardless of format. Variants v16605 and v16679, which have a C-terminal trastuzumab scFv, showed approximately a two- to three-fold decrease in KD compared to antibodies with an N-terminal scFv; however, this was deemed a minor change and was not expected to affect function. All 4-1BB antibodies showed similar KD values, with the anti-4-1BB anticalin v19353 demonstrating lower affinity for 4-1BB compared to the antibody.
[0451] Example 3: Ability of 4-1BB x HER2 bispecific antibody constructs to stimulate 4-1BB activity in an NF-kB-luciferase reporter assay To test the ability of bispecific 4-1BB x HER2 antibodies to stimulate 4-1BB activity in the presence of HER2-expressing tumor cells, a reporter gene assay was used as a measure of signaling downstream of 4-1BB to a luciferase-inducing NF-kB reporter. The 4-1BB x HER2 bispecific antibodies tested included variants 16675, 16679, 15534, 16601, and 16605. Control constructs 19353, 1040, 16992, and 12952 were also tested.
[0452] The ability of the bispecific antibody to activate 4-1BB in the context of HER2+ tumor cells was measured using a coculture assay. This assay used Jurkat cells engineered to express 4-1BB and a luciferase reporter gene driven by an NF-kB site. This assay measures signaling from 4-1BB on the cell surface to the nucleus. Two different tumor lines, SKOV3, which expresses high levels of HER2, and MDA-MB-468, which expresses low levels of HER2, were used. If 4-1BB activation is HER2-dependent, activation should be observed in coculture with SKOV3 cells but not in MDA-MB-468 cells.
[0453] The day before the assay, TC-treated, white polystyrene 384-well plates (Corning) were treated with 40 μL / well of mouse anti-human CD3 antibody OKT3 (Biolegend) at 5 μg / mL in phosphate-buffered saline (PBS) (Gibco). The plates were sealed with a plate lid by wrapping in parafilm. The plates were incubated overnight at 4°C. The following day, the plate contents were aspirated and the plates were washed with three changes of distilled water (120 μL / well) using a 405HT ELISA plate washer (Biotek). The plates were then ready for use in the assay.
[0454] Bispecific antibodies were diluted to 400 nM (final assay concentration 100 nM) in assay buffer (RPMI (Gibco) / 1% FBS (Gibco)). 15 μL volumes were pipetted into wells of a 384-well plate treated with OKT3 as described above to obtain the highest concentration of variant. A 5 μL volume was pipetted into the next well's 10 μL volume of assay buffer for the second-highest concentration well and mixed to obtain a 3-fold dilution. This was repeated, moving from the second-highest well to the third-highest well until the lowest concentration well was reached, and the remaining 5 μL volume was removed. Then, 10 μL of either SKOV3 or MDA-MB-468 tumor cells were added at a concentration of 2 × 10 6 Add at a density of 2 x 10 cells / mL 4 Cells / well were obtained. NFκB luc2P / 4-1BB Thaw-and-Use Jurkat cells (Promega) were thawed at 37°C according to the manufacturer's instructions and diluted with 5.8 mL of assay buffer. A 20 μL volume of reporter cell suspension was added to approximately 1 × 10 6 cells / mL (approximately 2×10 4 cells) was added to each well containing the variant / effector cell mixture.
[0455] The co-cultured cells with the variants were then incubated at 37°C in a 5% CO2 atmosphere for 5 hours, then equilibrated to room temperature on the bench for 10 minutes. A 40 μL volume of Bio-Glo™ (Promega) luciferase substrate reagent was added to each well of the plate and incubated at room temperature for 10 minutes. The plate was scanned in luminescence mode on a Synergy™ H1 (Biotek) multimode plate reader. Data were analyzed using Prism7 (GraphPad) and a four-parameter variable slope nonlinear fitting.
[0456] result All variants containing the 4-1BB-binding arm induced dose-dependent NF-kB signaling downstream of 4-1BB, as measured by luciferase production in this assay when cocultured with SKOV-3 cells (Figures 4A-4I). In comparison, active variants showed lower activity against MDA-MD-468 cells, suggesting that the presence of HER2 on the surface of SKOV-3 cells induced antibody cross-linking and enhanced 4-1BB signaling. The lowest activation of 4-1BB was observed with the v16601 variant. v16605 and v16675 showed higher activity. v16679 showed the highest activity, as determined by maximum potency (EC50) and activity (maximum RLU). The positive control 4-1BB x HER2 bispecific antibody v19353 showed moderate potency, higher than v16601 and v16605 but lower than v16675 and v16679. However, v19353 (containing the lipocalin 4-1BB-binding domain) showed lower activity as determined by maximum RLU compared to antibody-based 4-1BB agonists. The 4-1...
Claims
1. 1. An antibody construct comprising: a) a first 4-1BB antigen binding domain and a second 4-1BB antigen binding domain, each binding to a 4-1BB extracellular domain (4-1BB ECD), wherein the first 4-1BB antigen binding domain is the same as the second 4-1BB antigen binding domain, and the first 4-1BB antigen binding domain and the second 4-1BB antigen binding domain are in a Fab format; b) a first folate receptor alpha (FRα) antigen binding domain (FRα antigen binding domain) in scFv format that binds to the folate receptor alpha; the first 4-1BB antigen-binding domain, the second 4-1BB antigen-binding domain, and the first FRα antigen-binding domain are directly or indirectly linked to a scaffold; the first 4-1BB antigen-binding domain comprises: a) a heavy chain variable domain (VH) comprising a complementarity determining region (CDR) 1 (HCDR1) comprising the sequence set forth in SEQ ID NO: 624, a HCDR2 comprising the sequence set forth in SEQ ID NO: 766, and a HCDR3 comprising the sequence set forth in SEQ ID NO: 618, and a light chain variable domain (VL) comprising a LCDR1 comprising the sequence set forth in SEQ ID NO: 510, a LCDR2 comprising the sequence set forth in SEQ ID NO: 511, and a LCDR3 comprising the sequence set forth in SEQ ID NO: 512; b) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 545, an HCDR2 comprising the sequence set forth in SEQ ID NO: 777, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 773; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 734, an LCDR2 comprising the sequence set forth in SEQ ID NO: 735, and an LCDR3 comprising the sequence set forth in SEQ ID NO: 749; c) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 758, an HCDR2 comprising the sequence set forth in SEQ ID NO: 759, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 753; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 665, an LCDR2 comprising the sequence set forth in SEQ ID NO: 746, and an LCDR3 comprising the sequence set forth in SEQ ID NO: 770; d) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 545, an HCDR2 comprising the sequence set forth in SEQ ID NO: 546, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 539; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 550, an LCDR2 comprising the sequence set forth in SEQ ID NO: 551, and an LCDR3 comprising the sequence set forth in SEQ ID NO: 552; e) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 624, an HCDR2 comprising the sequence set forth in SEQ ID NO: 625, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 618; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 510, an LCDR2 comprising the sequence set forth in SEQ ID NO: 511, and an LCDR3 comprising the sequence set forth in SEQ ID NO: 512; f) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 660, an HCDR2 comprising the sequence set forth in SEQ ID NO: 661, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 655; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 665, an LCDR2 comprising the sequence set forth in SEQ ID NO: 666, and an LCDR3 comprising the sequence set forth in SEQ ID NO: 667; or g) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 742, an HCDR2 comprising the sequence set forth in SEQ ID NO: 546, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 539; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 550, an LCDR2 comprising the sequence set forth in SEQ ID NO: 744, and an LCDR3 comprising the sequence set forth in SEQ ID NO:
552. Including, the scaffold is a dimeric Fc construct having a first Fc polypeptide and a second Fc polypeptide, each Fc polypeptide comprising a CH3 sequence; and the first 4-1BB antigen binding domain is linked to the N-terminus of the first Fc polypeptide, the first FRα antigen binding domain is linked to the C-terminus of the first Fc polypeptide, and the second 4-1BB antigen binding domain is linked to the N-terminus of the second Fc polypeptide. The antibody construct.
2. The antibody construct of claim 1, wherein the first and second 4-1BB antigen binding domains are human or humanized antigen binding domains.
3. The first and second 4-1BB antigen-binding domains each comprise: a) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 46 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 58; b) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 52 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 55; c) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 53 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 48; d) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 53 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 54; e) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 53 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 55; f) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 61 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 64; g) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 62 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 64; h) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 62 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 65; i) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 62 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 66; j) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 63 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 64; k) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 63 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 65; l) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 63 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 66; m) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 47 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 64; n) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 47 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 65; o) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 47 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 66; p) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 61 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 65; q) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 61 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 66; r) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 62 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 50; s) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 63 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 50; t) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 46 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 49; u) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 46 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 59; v) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 46 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 60; w) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 56 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 49; x) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 56 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 58; y) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 56 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 59; z) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 56 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 60; aa) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 57 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 49; ab) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 57 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 58; ac) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 57 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 60; or a) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 47 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO:
50. The antibody construct of claim 2, comprising:
4. the first FRα antigen-binding domain comprises: a) a heavy chain variable domain (VH) comprising a complementarity determining region (CDR) 1 (HCDR1) comprising the sequence set forth in SEQ ID NO: 498, a HCDR2 comprising the sequence set forth in SEQ ID NO: 499, and a HCDR3 comprising the sequence set forth in SEQ ID NO: 492; and b) a light chain variable domain (VL) comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 503, an LCDR2 comprising the sequence set forth in SEQ ID NO: 504, and an LCDR3 comprising the sequence set forth in SEQ ID NO:
505. The antibody construct according to any one of claims 1 to 3, comprising:
5. The antibody construct of claim 4, further comprising a second FRα antigen binding domain in scFv format, the second FRα antigen binding domain being linked to the C-terminus of the second Fc polypeptide.
6. The second FRα antigen-binding domain comprises a complementarity determining region (CDR) 1 (HCDR1), a HCDR2, and a HCDR3 having the same sequences as those of the first FRα antigen-binding domain. a heavy chain variable domain (VH) comprising HCDR2, and HCDR3, and an LCDR1 having the same sequence as each of LCDR1, LCDR2, and LCDR3 of the first FRα antigen-binding domain; The antibody construct of claim 5, comprising a light chain variable domain (VL) comprising LCDR2 and LCDR3.
7. The antibody construct of claim 6 , wherein the first and / or second FRα antigen-binding domain is a human or humanized antigen-binding domain.
8. the first and / or second FRα antigen binding domain comprises: a) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 310 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 315; b) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 307 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 313; c) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 308 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 313; d) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 309 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 313; e) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 310 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 313; f) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 311 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 313; g) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 307 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 314; h) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 308 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 314; i) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 309 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 314; j) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 310 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 314; k) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 311 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 314; l) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 307 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 315; m) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 308 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 315; n) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 309 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 315; o) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 311 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 315; p) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 307 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 316; q) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 308 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 316; r) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 309 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 316; s) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 310 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 316; t) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 311 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 316; u) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 307 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 317; v) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 308 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 317; w) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 309 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 317; x) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 310 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 317; or y) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 311 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO:
317. The antibody construct of claim 6, comprising:
9. 9. The antibody construct of any one of claims 1 to 8, wherein the scaffold is a heterodimeric Fc construct having a first Fc polypeptide that is different from the second Fc polypeptide, and the CH3 sequences of the first Fc polypeptide and the second Fc polypeptide comprise amino acid substitutions that promote the formation of a heterodimeric Fc.
10. a) one Fc polypeptide comprises the amino acid substitution T350V_L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitution T350V_T366L_K392L_T394W; or b) one Fc polypeptide comprises the amino acid substitution T350V_T366L_K392M_T394W and the other Fc polypeptide comprises the amino acid substitution T350V_L351Y_F405A_Y407V; or c) one Fc polypeptide comprises the amino acid substitution L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitution T366L_K392M_T394W; or d) one Fc polypeptide comprises the amino acid substitution L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitution T366L_K392L_T394W; or e) one Fc polypeptide comprises the amino acid substitution L351Y_S400E_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitution T366I_N390R_K392M_T394W; The antibody construct of claim 9, wherein residue numbering is according to the EU numbering system.
11. 11. The antibody construct of claim 9 or 10, further comprising one or more amino acid modifications that reduce effector function.
12. The antibody construct of claim 11, wherein the one or more amino acid modifications are L234A, L235A and D265S, and the residue numbering is according to the EU numbering system.
13. the first and second 4-1BB antigen binding domains each comprise a heavy chain variable domain (VH) comprising a complementarity determining region (CDR) 1 (HCDR1) comprising the sequence set forth in SEQ ID NO: 624, a HCDR2 comprising the sequence set forth in SEQ ID NO: 766, and a HCDR3 comprising the sequence set forth in SEQ ID NO: 618, and a light chain variable domain (VL) comprising a LCDR1 comprising the sequence set forth in SEQ ID NO: 510, a LCDR2 comprising the sequence set forth in SEQ ID NO: 511, and a LCDR3 comprising the sequence set forth in SEQ ID NO: 512; the first and / or second FRα antigen binding domain comprises a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 498, an HCDR2 comprising the sequence set forth in SEQ ID NO: 499, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 492, and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 503, an LCDR2 comprising the sequence set forth in SEQ ID NO: 504, and an LCDR3 comprising the sequence set forth in SEQ ID NO: 505; An antibody construct according to any one of claims 6 to 12.
14. the first and second 4-1BB antigen binding domains respectively comprise a heavy chain variable domain (VH) sequence at least 90% identical to the VH sequence set forth in SEQ ID NO: 46 and a light chain variable domain (VL) sequence at least 90% identical to the VL sequence set forth in SEQ ID NO: 58; the first and / or second FRα antigen binding domain comprises a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 310 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 315; The antibody construct of claim 13.
15. 15. The antibody construct of claim 14, comprising a first heavy chain polypeptide sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 353, a second heavy chain polypeptide sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 349, and two light chain polypeptide sequences having at least 95% sequence identity to the sequence set forth in SEQ ID NO:
346.
16. 16. The antibody construct of claim 15, comprising a first heavy chain polypeptide sequence as set forth in SEQ ID NO: 353, a second heavy chain polypeptide sequence as set forth in SEQ ID NO: 349, and two light chain polypeptide sequences as set forth in SEQ ID NO:
346.
17. An antibody construct according to any one of claims 1 to 16, conjugated to a drug.
18. A pharmaceutical composition comprising an antibody construct according to any one of claims 1 to 17.
19. One or more nucleic acids encoding an antibody construct according to any one of claims 1 to 16.
20. 20. One or more vectors comprising one or more nucleic acids of claim 19.
21. 21. An isolated cell comprising one or more nucleic acids of claim 19 or one or more vectors of claim 20.
22. A method for preparing an antibody construct according to any one of claims 1 to 16, comprising culturing an isolated cell according to claim 21 under conditions suitable for expressing said antibody construct, and purifying said antibody construct.
23. A pharmaceutical composition for treating cancer comprising an antibody construct according to any one of claims 1 to 17.
24. Use of an antibody construct according to any one of claims 1 to 17 in the preparation of a medicament for treating cancer.
25. 1. An antibody construct or antigen-binding fragment thereof that specifically binds to 4-1BB, comprising: a) a heavy chain variable domain (VH) comprising a complementarity determining region (CDR) 1 (HCDR1) comprising the sequence set forth in SEQ ID NO: 624, a HCDR2 comprising the sequence set forth in SEQ ID NO: 766, and a HCDR3 comprising the sequence set forth in SEQ ID NO: 618, and a light chain variable domain (VL) comprising a LCDR1 comprising the sequence set forth in SEQ ID NO: 510, a LCDR2 comprising the sequence set forth in SEQ ID NO: 511, and a LCDR3 comprising the sequence set forth in SEQ ID NO: 512; b) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 545, an HCDR2 comprising the sequence set forth in SEQ ID NO: 777, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 773; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 734, an LCDR2 comprising the sequence set forth in SEQ ID NO: 735, and an LCDR3 comprising the sequence set forth in SEQ ID NO: 749; c) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 758, an HCDR2 comprising the sequence set forth in SEQ ID NO: 759, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 753; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 665, an LCDR2 comprising the sequence set forth in SEQ ID NO: 746, and an LCDR3 comprising the sequence set forth in SEQ ID NO: 770; d) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 545, an HCDR2 comprising the sequence set forth in SEQ ID NO: 546, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 539; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 550, an LCDR2 comprising the sequence set forth in SEQ ID NO: 551, and an LCDR3 comprising the sequence set forth in SEQ ID NO: 552; e) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 624, an HCDR2 comprising the sequence set forth in SEQ ID NO: 625, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 618; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 510, an LCDR2 comprising the sequence set forth in SEQ ID NO: 511, and an LCDR3 comprising the sequence set forth in SEQ ID NO: 512; f) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 660, an HCDR2 comprising the sequence set forth in SEQ ID NO: 661, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 655; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 665, an LCDR2 comprising the sequence set forth in SEQ ID NO: 666, and an LCDR3 comprising the sequence set forth in SEQ ID NO: 667; or g) a VH comprising an HCDR1 comprising the sequence set forth in SEQ ID NO: 742, an HCDR2 comprising the sequence set forth in SEQ ID NO: 546, and an HCDR3 comprising the sequence set forth in SEQ ID NO: 539; and a VL comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 550, an LCDR2 comprising the sequence set forth in SEQ ID NO: 744, and an LCDR3 comprising the sequence set forth in SEQ ID NO:
552.
26. 26. The antibody construct of claim 25, wherein the antibody or antigen-binding fragment is or comprises a humanized antibody.
27. a) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 46 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 58; b) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 52 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 55; c) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 53 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 48; d) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 53 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 54; e) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 53 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 55; f) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 61 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 64; g) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 62 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 64; h) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 62 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 65; i) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 62 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 66; j) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 63 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 64; k) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 63 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 65; l) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 63 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 66; m) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 47 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 64; n) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 47 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 65; o) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 47 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 66; p) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 61 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 65; q) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 61 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 66; r) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 62 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 50; s) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 63 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 50; t) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 46 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 49; u) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 46 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 59; v) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 46 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 60; w) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 56 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 49; x) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 56 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 58; y) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 56 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 59; z) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 56 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 60; aa) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 57 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 49; ab) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 57 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 58; ac) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 57 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 60; or a) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 47 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO:
50.
27. The antibody construct of claim 25 or 26, comprising:
28. 28. The antibody construct of any one of claims 25 to 27, wherein the antibody construct comprises an immunoglobulin constant domain, said constant domain being derived from IgG1 or a variant thereof, IgG2 or a variant thereof, IgG4 or a variant thereof, IgA or a variant thereof, IgE or a variant thereof, IgM or a variant thereof, or IgD or a variant thereof.
29. The antibody construct of any one of claims 25 to 28, wherein the antibody is a monoclonal antibody or the antigen-binding fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an Fv fragment, a scFv fragment, a single domain antibody, or a diabody.
30. An antibody construct according to any one of claims 25 to 29, conjugated to a drug.
31. A pharmaceutical composition comprising an antibody construct according to any one of claims 25 to 30.
32. One or more nucleic acids encoding an antibody construct according to any one of claims 25 to 29.
33. 33. One or more vectors comprising one or more nucleic acids of claim 32.
34. 34. An isolated cell comprising one or more nucleic acids of claim 32 or one or more vectors of claim 33.
35. A method for preparing an antibody construct according to any one of claims 25 to 29, comprising culturing an isolated cell according to claim 34 under conditions suitable for expressing said antibody construct, and purifying said antibody construct.
36. A pharmaceutical composition for treating cancer comprising an antibody construct according to any one of claims 25 to 30.
37. Use of an antibody construct according to any one of claims 25 to 30 in the preparation of a medicament for treating cancer.
38. a heavy chain variable domain (VH) comprising a complementarity determining region (CDR) 1 (HCDR1) comprising the sequence set forth in SEQ ID NO: 498, a HCDR2 comprising the sequence set forth in SEQ ID NO: 499, and a HCDR3 comprising the sequence set forth in SEQ ID NO: 492; and A light chain variable domain (VL) comprising an LCDR1 comprising the sequence set forth in SEQ ID NO: 503, an LCDR2 comprising the sequence set forth in SEQ ID NO: 504, and an LCDR3 comprising the sequence set forth in SEQ ID NO:
505. An antibody construct or antigen-binding fragment thereof that specifically binds to FRα, comprising:
39. 39. The antibody construct or antigen-binding fragment of claim 38, wherein the antibody or antigen-binding fragment is or comprises a humanized antibody.
40. a) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 310 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 315; b) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 307 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 313; c) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 308 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 313; d) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 309 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 313; e) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 310 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 313; f) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 311 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 313; g) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 307 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 314; h) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 308 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 314; i) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 309 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 314; j) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 310 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 314; k) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 311 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 314; l) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 307 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 315; m) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 308 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 315; n) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 309 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 315; o) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 311 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 315; p) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 307 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 316; q) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 308 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 316; r) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 309 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 316; s) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 310 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 316; t) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 311 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 316; u) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 307 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 317; v) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 308 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 317; w) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 309 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 317; x) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 310 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO: 317; or y) a heavy chain variable domain (VH) sequence that is at least 90% identical to the VH sequence set forth in SEQ ID NO: 311 and a light chain variable domain (VL) sequence that is at least 90% identical to the VL sequence set forth in SEQ ID NO:
317.
40. The antibody construct or antigen-binding fragment of claim 38 or 39, comprising:
41. 41. The antibody construct or antigen-binding fragment of any one of claims 38 to 40, wherein the antibody comprises an immunoglobulin constant domain, the constant domain being selected from IgG1 or a variant thereof, IgG2 or a variant thereof, IgG4 or a variant thereof, IgA or a variant thereof, IgE or a variant thereof, IgM or a variant thereof, and IgD or a variant thereof.
42. The antibody construct or antigen-binding fragment of any one of claims 38 to 41, wherein said antibody is a monoclonal antibody or said antigen-binding fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an Fv fragment, a scFv fragment, a single domain antibody, or a diabody.
43. An antibody construct according to any one of claims 38 to 42, conjugated to a drug.
44. A pharmaceutical composition comprising an antibody construct according to any one of claims 38 to 43.
45. One or more nucleic acids encoding an antibody construct according to any one of claims 38 to 42.
46. 46. One or more vectors comprising one or more nucleic acids of claim 45.
47. 47. An isolated cell comprising one or more nucleic acids of claim 45 or one or more vectors of claim 46.
48. A method for preparing an antibody construct according to any one of claims 38 to 42, comprising culturing an isolated cell according to claim 47 under conditions suitable for expressing said antibody construct, and purifying said antibody construct.
49. A pharmaceutical composition for treating cancer comprising an antibody construct according to any one of claims 38 to 43.
50. Use of an antibody construct according to any one of claims 38 to 43 in the preparation of a medicament for treating cancer.
51. A kit comprising an antibody construct according to any one of claims 1 to 17, 25 to 30 and 38 to 43, and instructions for using same.
Citation Information
Patent Citations
Compositions and methods for treating cancer
JP2014509841A
Novel bispecific polypeptides against CD137
WO2017182672A1
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
WO2018156740A1
